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Abstract 
Necrotising enterocolitis (NEC) is a devastating disease that can affect pre-term infants and if 
survived can lead to long term intestinal damage. Currently a variety of antibiotics and in extreme 
cases surgery is required to manage the disease. However, no treatment exists that attenuates the 
widespread cell death and suppresses the innate pro-inflammatory response whilst promoting 
regeneration in the intestine thus reducing long term damage and the need for surgery. The 
discovery of stem cells, in particular multipotent stem cells (MSCs) has shown them to have potent 
regenerative therapeutic properties. In particular, C-kit+ foetal derived MSCs from amniotic fluid 
(amniotic fluid stem cells - AFSCs) when introduced into a rat model of NEC increased the survival of 
animals affected whilst also promoting the repair of damaged epithelial layers. Nevertheless, the 
ability of stem cells to promote regeneration was independent of transplanted cell engraftment. This 
led to a paradigm shift in which it was proposed that regeneration was via the secretion of factors 
acting in a paracrine manner with target cells. This was proven by the introduction of stem cell 
conditioned media (CM), which mimicked the beneficial effect seen when whole MSCs were 
introduced. However, much of the MSC CM is produced from non-stressed MSCs. Stressing MSCs has 
been shown to increase the secretion of paracrine factors and the extracellular vesicles that contain 
them. Creation of an AFSC CM (AF-CM) under conditions of stress using a protocol created by 
industrial partners was therefore hypothesised to produce a more potent AF-CM beneficial for 
regeneration and in particular for the treatment of NEC. Here we characterise the AF-CM under 
conditions of stress but also in a clinically compliant manner. The AF-CM was characterised for 
protein and RNA content, which elucidated to a multitude of proteins present but interestingly 
showed that the majority of RNA present was miRNA. In vitro investigation into AF-CM treatment 
also showed significant improvements in cellular proliferation and migration capacity whilst 
protecting from senescence. Furthermore, I showed that AF-CM treatment accelerated the 
regeneration of skeletal muscle fibres following an established mouse model of acute cardiotoxin 
damage in vivo, of which could be partly attributed to increased blood vasculature.  
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Necrotising Enterocolitis  
Necrotising enterocolitis (NEC) is an intestinal disorder thought to result from extensive and 
substantial inflammation. Occurring in premature infants it is defined by variable stages of damage to 
the intestinal tract as often demarcated by the Bell staging criteria (Table 1.1.)  (Zani and Pierro, 
2015). NEC affects 0.5-5/ 1000 of all live births and was first described as a clinical syndrome 
consisting of vomiting, perforation, shock, intestinal haemorrhage and abdominal distension (Rees et 
al., 2008, Mizrahi et al., 1965). The prevalence of the disease is known to be directly proportional to 
the number of days born prematurely. Pathology ranges from mucosal injury presenting with 
increased gastric residuals, mild abdominal distension and occult blood in the stool to full-thickness 
necrosis and perforation coupled with local and systemic sepsis (Zani and Pierro, 2015). Although 
NEC affects around 5% of pre-term neonates its exact aetiology is still unclear (Zani and Pierro, 2015). 
The occurrence of NEC in preterm infants has been suggested to derive from the immaturity of a 
multitude of the bodies systems such as the cardiovascular, respiratory, intestinal and also the 
immune system (Zani et al., 2016, Zani and Pierro, 2015, Chen et al., 2016). As a general consensus it 
is accepted that the immaturity of these systems lead to hypoxia within the intestine, which causes 
cell death and inflammation. This in turn activates the innate immune system leading to extensive 
infiltrations of innate immune cells such as macrophages. However, the immaturity of the immune 
system lends to the over activation of macrophages thus producing a pro-inflammatory response 
which causes further cell death in the form of necrosis. Cell death via necrosis is essentially an 
explosion of the cell and release of its contents in an unregulated manner into the environment. 
Often this leads to inflammation, potential regeneration of tissue and scar formation (Zhang et al., 
2014). However as in the case of NEC, inflammation proceeding necrosis can be so widespread that 
phagocytes cannot locate necrotic bodies efficiently enough to clear the debris. Surgery is therefore 
often necessary to remove necrotic tissue before further damage due to inflammation is caused 
(Proskuryakov et al., 2003). Although necrosis may be initially instigated by combinations of 
cytokines (IL-1β, TNF-α and INF-γ) released as part of the inflammatory response, dysbiosis of the 
guts microbiota following inflammation can produce high levels of lipopolysaccharide (LPS), a 
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bacterial toxin which contributes further to necrosis (Saldeen, 2000, Emami et al., 2009). 
Interestingly, genes upregulated within NEC such as TLR4 and Lysozyme are also detected at high 
levels in inflammatory diseases of the intestine often associated with adults, for example Crohns 
disease (Tremblay et al., 2016, Haberman et al., 2014). In total 22% of the differentially expressed 
genes (DEG) and 25% of DEGs in NEC were also found to be modulated in Crohns disease and 
paediatric Crohns disease respectively (Tremblay et al., 2016). This suggests that similar therapies 
could be used to manage both conditions as long as the treatment affects similar signalling 
pathways. 
Stage I IIA IIB IIIA IIIB 
Description Suspected 
NEC 
Mild NEC Moderate 
NEC 
Severe 
NEC 
Severe NEC 
Systemic  
signs 
Temperature  
instability, 
apnea,  
bradycardia 
Similar to 
stage I 
Mild acidosis,  
thrombocytope
nia 
Respiratory 
and  
metabolic 
acidosis,  
mechanical 
ventilation,  
hypotension, 
oliguria, 
DIC 
Further 
deterioration  
and shock 
Intestinal  
signs 
Increased 
gastric  
residuals, 
mild  
abdominal  
distension, 
occult  
blood in the 
stool 
Marked 
abdominal  
distension ± 
tenderness,  
absent bowel 
sounds,  
grossly 
bloody stools 
Abdominal 
wall edema  
and tenderness 
±  
palpable mass 
Worsening 
wall edema  
with 
erythema 
and  
induration 
Evidence of  
perforation 
Radiographic  
signs 
Normal or 
mild  
ileus 
Ileus, dilated 
bowel  
loops, focal 
pneumatosis 
Extensive 
pneumatosis,  
early ascites ± 
PVG 
Prominent 
ascites, 
fixed  
bowel loop, 
no free air 
Pneumoperitoneum 
DIC, disseminated intravascular coagulopathy; NEC, necrotizing enterocolitis; PVG, portal venous 
gas. 
Table 1.1: Bell staging criteria of NEC as described by Zani and Pierro et al  (Zani and Pierro, 2015). 
Cellular Homeostasis and Regeneration of the Intestine 
Derived from the endoderm, the intestine not only provides a means of nutritional digestion and 
absorption but also hormonal signalling, a barrier against pathogens due to immune function and 
also a means of symbiotically benefiting from the diverse and enormous microbiota which inhabits it.  
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Intestinal function is highly dependent on its tissue architecture allowing for the greatest possible 
surface area enabling tasks such as efficient digestion of food. The most prominent feature is the 
exceptionally large surface area of the lumen derived from its many projections and folds, known as 
villi which on an ultrastructural level is made up of a variety of cell types, the most common being 
epithelial cells. Epithelial cells, enterocytes, lining the intestine exhibit microvilli on the apical surface 
providing a greater surface area for absorption of nutrients.  Due to the constant physical process of 
food moving through the gut, enterocytes are sloughed off and therefore replaced by new cells 
arising from the cells located in the crypts of Lieberkuhn. The new cells originate from stem cells near 
the bottom of the villi crypts, which also provide a means of cells replacement for other cells 
including Paneth, enteroendocrine and goblet cells. Further division and differentiation of cells as 
they move upwards towards the villi and in the case of enterocytes, balance the amount of lost cells 
with new cells. Paneth cells express and secrete a number of factors (EGF, TGFα, Wnt3 and the 
Notch-ligand Dll4) to maintain the stem cell niche and cellular homeostasis (Sato et al., 2011). 
Importantly, Wnt3 signalling initiated by binding to the 7 trans-membrane receptor Frizzled and its 
co-receptor LRP 5/6 and leads to inhibition of GSK3β, Axin and APC complex which would otherwise 
cause β-catenin ubiquitination thus tagging it for degradation by the proteasome (MacDonald et al., 
2009). Lack of β-catenin breakdown allows its levels to build in the cytoplasm so that it may 
translocate into the nucleus to induce β-catenin mediated gene expression providing proliferative 
signalling for cell progenitors (Sato et al., 2011, van de Wetering et al., 2002, MacDonald et al., 2009). 
Labelling of Lgr5 exposes a stem cell population (figure 1.1.), which is mitotically active under normal 
conditions, provides daughter cells to maintain the stem cell population but also balance normal cell 
loss in the stromal population (Cheng and Leblond, 1974, Yan et al., 2012, Tian et al., 2011). 
However, another subset also thought to exist, characterised by Bmi1 expression, activates when 
damage to the gut has occurred but are otherwise quiescent (Kozar et al., 2013, Yan et al., 2012, Tian 
et al., 2011).  Functionally these two populations react differently to canonical Wnt signalling; with 
the Lrg5 and not the Bmi1 population proliferating to retain normal cellular homeostasis (Yan et al., 
2012). Sensitivity of these two populations to damage also varies with Bmi1 positive cells showing 
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resistance to radiation and chemotherapy (Zhu et al., 2013, Shivdasani, 2014). On the other hand, 
once Bmi1 cells activate and awaken from a quiescent state their resistance diminishes (Zhu et al., 
2013). Chronic disease is damaging to this Bmi1 population, which are activated after the initial 
damage to the tissue but are sensitised to further stress. This further stress occurs during the 
ongoing injury in chronic disease. Certainly this aberration of the local stem cell population within 
the intestine would disrupt regeneration. Chronic intestinal diseases such as coeliac disease 
(autoimmune) often present as long-term pro-inflammatory conditions in which cytokine production 
leads to cell death and diminished tissue architecture along with local stem cell reserves (Piscaglia et 
al., 2015). An ideal treatment for such diseases would not only protect the local stem cell population 
but also provide positive growth signalling for stromal cells and the stem cell population. 
Furthermore, acute intestinal conditions such as necrotising enterocolitis in new-borns would benefit 
from treatments that provide regenerative signalling such as growth signalling and modulation of the 
inflammatory response. 
 
Figure 1.1: Intestinal stem cell (ISC) populations expressing Bmi1 or Lgr5 within the crypts of the 
mammalian intestinal lumen. The ISC progeny, the transit-amplifying cells are moved towards the 
tip of the villus as they differentiate. It is the Lgr5 positive ISCs that provide that maintain this 
constant epithelial cell homeostasis. Modified from Karpowicz and Perrimon, 2010 (Karpowicz and 
Perrimon, 2010). 
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Protection from stress is particularly important in the intestine because it serves as a barrier to 
infection. Stresses can originate from pathogenic bacteria infection or an imbalance in the micro-
biota leading to increased endotoxin levels such as LPS exposure. LPS binds to TLR4 on host cell 
surfaces and causes an NF-κb signalling response and consequential inflammation (Shi et al., 2007). 
In Vivo rodent models of NEC 
In vivo rodent models of NEC have been developed (Koike et al., 2017, Chen et al., 2016, Zani et al., 
2016, Zani et al., 2014). Furthermore, a number of different methods have been used to induce the 
pathology and mimic that seen in humans. Such methods include hypoxia, maternal separation, 
gavage feeding, oral LPS administration and hyperosmolar formula feeding. Combinations of these 
methods have been tested to improve on the frequently used mix of gavage feeding with 
hyperosmolar formula and hypoxia (Zani et al., 2016). Hyperosmolar feed is thought to cause a fluid 
shift from the villus vessels to the bowel lumen as well as increasing gut permeability and 
predisposing them to bacterial toxin uptake (Zani et al., 2016, Zani and Pierro, 2015). Although not 
thought to be specific to maternal separation, separation is known to induce barrier dysfunction and 
has been proposed to contribute to endoplasmic reticulum stress and subsequent signalling 
responses (Li et al., 2016). Stress response proteins such as BiP and CHOP are increased along with 
the apoptotic marker, CC3. Moreover, maternal separation leads to decreases in Goblet cell numbers 
thus reducing the capability of mucus production. Arguably of most importance to the induction of 
NEC in vivo is the introduction of bacterial LPS within the neonatal intestine (Zani et al., 2016, Jilling 
et al., 2006).  NEC has been shown not to occur within germ free rodents and does not occur in utero 
(widely believed to be sterile) (Jilling et al., 2006, Rozenfeld et al., 2001). The high expression of TLR4 
in neonates, a receptor of LPS, may explain the high susceptibility of pre-term infants to NEC 
compared to full term born infants who have a lower level of TLR4 expression therefore making them 
more vulnerable to the inflammatory signalling instigated by LPS (Fusunyan et al., 2001, Chan et al., 
2002, Jilling et al., 2006). 
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Current Medical Management 
Managing the severity of NEC in the best way possible is highly debated, however suspected (Bell 
stage 1) or mild to moderate confirmed (Bell stage 2A-B) cases of NEC are often managed without 
surgery (Zani and Pierro, 2015). IV fluid feeding is carried out to reduce aggressive enteral feeding, 
which can exaggerate the hypoxic environment but also risks damaging fluid shifts in the villi 
described later, but also enhance bowel rest (Zani et al., 2016, Zani and Pierro, 2015, Koike et al., 
2017, Chen et al., 2016). Ventilatory and inotropic support help facilitate efficient oxygenation of the 
intestine as well as preventing heart and respiratory failure due to under-development (Zani and 
Pierro, 2015). Additionally, the use of antibiotics are widely utilised clinically although their 
deployment varies greatly between hospital culture and individual clinicians (Zani and Pierro, 2015). 
It is not known whether a specific bacterial species or set of species causes NEC. Furthermore, the 
use of broad spectrum antibiotics may be detrimental to the neonate’s health because of their 
tendency to destroy most if not all of the gut microflora, some of which are believed to be beneficial 
to the normal intestinal homeostasis (Zani and Pierro, 2015, Khailova et al., 2010, Khailova et al., 
2009). Further deterioration or perforation of the gut often calls for the surgical resection of the 
affected region. However, if the infant survives NEC following surgical resection they will often 
present with long term intestinal conditions such as short bowel syndrome (Zani et al., 2014, Zani 
and Pierro, 2015, Rees et al., 2008). It is therefore apparent that there is a need for a treatment for 
NEC without significant adverse effects. However, a better understanding of stem cells and their 
potential as a regenerative therapeutic has led to the option of stem cells potentially being able to 
treat NEC. 
Stem Cells 
A Russian-American histologist, Alexander A. Maximow, coined the term ‘Stem cell’ at a special 
meeting of the Berlin Haematological Society on the 1st of June 1909 as he explained his Unitarian 
theory of haematopoiesis (Konstantinov, 2000). However, it was not until the 1960’s when Ernest A. 
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McCulloch and James E. Till from the University of Toronto led pioneering research that opened the 
scientific community’s eyes to stem cells (Siminovitch et al., 1963, Becker et al., 1963). 
Stem cells can be defined as a cell that has the ability to self-renew and to differentiate into one or 
more cell types. In order to do this, it should be able to divide asymmetrical in order to produce a 
multipotent daughter cell and a further progeny cell which has a more specialized function 
(Weissman, 2000, Weissman et al., 2001). However, this classic approach to defining a stem cell has 
come under scrutiny since the number of studies claiming their use in the field of therapeutics has 
risen (Bianco and Gehron Robey, 2000, Orkin and Zon, 2002). This is particularly true due to the wide 
propensity of stem cells available from different tissues and developmental origins.  Prior to testing 
cells must be isolated and purified so that the population is homogenous and then rigorously 
characterised to determine marker expression, which can alter during population expansion (Orkin 
and Zon, 2002, Bianco and Gehron Robey, 2000, Holden and Vogel, 2002).  Demonstration of tissue 
specific functions and a significant purpose within the host tissue are other factors that have also 
been requested prior to the term ‘Stem cell’ can be applied to a prospective cell (Holden and Vogel, 
2002, Anderson et al., 2001).   
Potency 
The potency of a stem cell describes its potential to differentiate into different cell types. Stem cells 
can be described mainly as being totipotent, pluripotent, multipotent, oligopotent and unipotent. 
Pluripotent cells are described by the National Institutes of Health Guidelines for Research Using 
Human Pluripotent Stem Cells as, "cells that are self-replicating, are derived from embryos or foetal 
tissue, and are known to develop into cells and tissues of the three primary germ layers (ectoderm, 
endoderm, and mesoderm). Although human pluripotent stem cells may be derived from embryos or 
foetal tissue, such stem cells are not considered embryos.” Pluripotent cells are the descendants of 
blastocyst derived totipotent stem cells, that unlike pluripotent stem cells can differentiate into any 
cell within the body with the potential to form a complete and viable organism (Donovan and 
Gearhart, 2001). Multipotent stem cells can differentiate into most cell types, but do not have as 
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large a differentiation capacity as totipotent or pluripotent cells. Oligopotent cells, such as myeloid 
stem cells, only have the potential to differentiate into a few cell types. Lastly, unipotent stem cells 
will differentiate into a single cell type. 
Embryonic stem cells are derived from the inner cell mass of the blastocyst. These pluripotent stem 
cells can provide limitless copies of them-selves and are extremely potent. Therefore pluripotent 
stem cells prove attractive for use in regenerative medicine and as a key in vitro developmental 
model. Foetal stem cells derive from the growing foetus following the embryonic stage. They provide 
the regenerative capacity to not only form new tissues, such as during organogenesis as part of 
normal development, but they also maintain the cellular make up of tissues. This can be part of 
processes such as the turnover of blood or regeneration of tissue following injury.  Adult stem cells, 
which are often multipotent, also provide a bank of cells ready to divide in order to both replenish 
the stem cell niche following injury or normal cell turnover such as the cells lining intestinal villi. 
Lastly, induced pluripotent stem cells (iPSCs) are frequently produced by introducing various factors 
to the culture of a multipotent stem cell whilst in embryonic culture conditions in order to re-
programme them from a multipotent cell to pluripotent, thus creating a more flexible cell for use 
(Takahashi and Yamanaka, 2006). Four transcription factors, known collectively as OSKM (Oct4, Sox2, 
Klf4 and c‐Myc) were found to be the key to pluripotentency induction (Takahashi and Yamanaka, 
2006). All of which are involved in regulating self-renewal and differentiation of undifferentiated 
embryonic stem cells. Unfortunately, the altered signalling involved in creating iPSCs is poorly 
understood and their use for therapy is widely considered to be unsafe until more is known about 
these processes (Ohnuki and Takahashi, 2015). 
Octamer-binding transcription factor 4 (Oct-4) is frequently used as a marker for undifferentiated 
cells (Niwa et al., 2000). This transcription factor must be tightly regulated (Figure 1.2.) within stem 
cells in order to prevent too much or too little expression which can lead to differentiation (Niwa et 
al., 2000). Oct-4 interacts with many other proteins such as WD repeat containing protein 5 (WDR5) 
(Ang et al., 2011). Furthermore, it was found via chromatin immune-precipitation that the WDR5 
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gene (intron 1) is a downstream target of Oct4 and Nanog 1 (another marker of undifferentiated 
cells) (Ang et al., 2011). Research such as this not only shows the complexity of the undifferentiated 
state but also the wide propensity of markers for undifferentiated cells. 
Morphology 
Stem cells can present morphologically as either epithelial or mesenchymal. Epithelial stem cells, 
including those that reside in the crypts of Lieberkühn within the intestinal villi, do not actively 
migrate and so their role is often to replenish the cell population at the site at which they lie 
(Blanpain et al.).In contrast, at the point at which cells lose all their connection to their stroma they 
become mesenchymal. Mesenchymal stem cells, although traditionally found in the bone marrow, 
can be found in many tissues and are often multipotent and thus frequently present a more valuable 
cell than their epithelial counterparts. Classical definitions of MSCs describe them as being both 
adherent and non-haematopoietic whilst expressing CD90, CD73 and CD105 but do not express 
CD45, CD34 and CD14 (Madrigal et al., 2014).  
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Figure 1.2: Regulation of the Nanog genes transcription is tightly controlled by various 
transcription factors. SOX2 and Oct 4 bind to the Nanog gene aiding its expression to promote self-
renewal in the embryonic stem cell. However, too much Oct-4 expression can lead to an autogenic 
inhibition of Nanog and therefore differentiation of the cell. From Qiagen. 
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Use of Stem Cells for Therapy 
Although not fully understood at the time, the use of stem cells for therapy arose with the 
development of bone marrow transplants established through the 1950’s to 1970’s by E. Donnall 
Thomas and his team (Thomas et al., 1957). This work showed that the intravenously injected blood 
cells could repopulate the bone marrow niche in order to restore bone marrow reserves and 
function. In 2011 the stem cell therapeutics market, although mostly made up by the bone marrow 
transplant sector, was estimated to be worth $2.7 billion. Additionally, auxiliary stem cell products 
and stem cell bio-banking sectors were estimated to be worth $2.6 billion. The overall market was 
worth $8.8 billion by 2016 (Visiongain, 2012). This data shows how the promise of stem cell based 
therapeutics entering our health care system in the future has attracted massive funding in a race to 
not only find the best stem cell source for use but also the optimum way to apply them.  
Advantages and Disadvantages of Stem Cells for Therapy 
Ethical concerns over the use of embryonic stem cells make their use an issue, especially in the USA 
due to federal funding restrictions. This comes mainly from the fact that they originate from the 
inner cell mass of a blastocyst, and in order to isolate them the potential future foetus is terminated. 
Much of the time, blastocysts used for this isolation are retrieved from in vitro fertilisation 
procedures where some blastocysts are simply discarded. However, due to the high regenerative 
potential of the ESCs, cell lines can be produced, thus reducing the requirement of freshly isolated 
ESCs. Many stem cell lines were isolated in the 1990’s and are still in use today for research. 
Therefore, the ability to create these cell lines in this way has an advantage over many adult stem 
cells, which must be harvested frequently to provide a primary supply suitable for research. 
Unfortunately there is a risk of teratoma formation due to the high regeneration potential involved 
when using pluripotent cells and they must be rigorously tested before being used clinically (Ohnuki 
and Takahashi, 2015). Furthermore, the ‘stem cellness’ can decline over time with continued 
passaging. Additionally, the current techniques involved in differentiating these cells must be refined 
so that they become more specific as to not form unwanted cell types in vivo. As an example, in the 
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case of a search for stem cell use in creating an unrestricted supply of red blood cells for blood banks, 
much of the research is presently untranslatable from small scale lab work to large scale industrial 
production. The wide use of animal products, such as foetal bovine serum (FBS), creates the issue of 
infection and immune related risks when adapting a lab created product to a clinically used product. 
The Food and Drugs Agency (FDA) set up guidelines to prevent such issues (Halme and Kessler, 2006). 
Efforts have been made to culture cells in serum free medium or autologous derived serum based 
medium (Bhasin et al., 2011, Honmou et al., 2011). Furthermore a huge tissue bank would most 
probably be required in order to receive cells for tissue matching. This is not so much the case for 
iPScs, although they do require more processing in order to attain the pluripotency.  
An important factor to consider when using stem cells is the heterogeneity of the body’s cellular 
population. The programming of cells in the body varies greatly depending on where they reside and 
thus collate stromal signals into a resulting pattern of gene expression. As stem cells are found 
throughout the body and from various sources, gene expression can be highly heterogenic and may 
result in stem cells acting in different ways, something that should be considered prior to their 
clinical use (Ebben et al., 2011, Cahan and Daley, 2013). Essentially the correct stem cell should be 
matched for the disease or use it is required for. There is of course an ongoing debate as to which 
stem cell is best for use. An example of improving the effectiveness of the stem cells is to pre-
condition them. Such processes include pre-treating amniotic fluid stem cells with IL-1β, with the aim 
of inhibiting the activation of T-lymphocytes thus altering the immune response and potentially 
reducing inflammation (Moorefield et al., 2011a). Furthermore, by increasing the lifespan of the stem 
cells once introduced to the patient, their effects are thought to be extended. This was done using a 
ROCK inhibitor, Y-27632, to enhance the life span of human-ESCs (Watanabe et al., 2007). Exposing 
the stem cells to hypoxic conditions prior to use has been shown to improve their therapeutic 
potential, thought to be due to an increased stress response (Hu et al., 2008), as explained later in 
more detail. Unfortunately, once injected into the body the concentrations of stem cell products and 
the stem cell activity is difficult to estimate, making the estimation of how many cells to inject in the 
first place a challenging task (Murphy et al., 2013). Stem cell therapies can use allogeneic or 
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autologous derived stem cells. Their effectiveness may depend on their immunogenicity. Allogeneic 
stem cells, cells from a non-self-donor, may cause an immunological response and therefore be 
destroyed before reaching their therapeutic potential but may also cause a harmful inflammatory 
response to the body. Furthermore, the use of allogeneic stem cells poses a risk of viral trans-
infection from donor to recipient (Ikegame et al., 2014). Autogenic stem cell use may therefore 
overcome the disadvantages presented by allogeneic stem cell use and potentially aid the 
regenerative process and protect from necrosis rather than possibly inducing it further because of 
consequential inflammation.  
Amniotic Fluid 
At the start of the second week of human gestation the amniotic fluid materialises and thus forms a 
protective barrier around the developing embryo and foetus. In humans the volume of AF increases 
from 20ml at week 7 to 1000ml at week 34 and then subsequently reduces in volume to 800ml 
towards term (Beall et al., 2007). AF is known to contain foetal urine and foetal lung fluid, both of 
which increase over time (Brace et al., 1994, Rabinowitz et al., 1989). Post term pregnancies can 
pathologically present as oligohydramnios, where there is too little AF present, due to the 33% 
reduction in AF volume per ongoing week. In contrast, a condition where excessive AF is present, 
polyhydramnios usually occurs following twin-to-twin transfusion syndrome (Beall et al., 2007). Both 
extremes can cause birth complications and foetal defects. Amniocentesis is a procedure commonly 
used to remove a sample of AF whether this is to reduce the volume associated with 
polyhydramnios, sometimes around 4 litres, or often in the second trimester to remove around 2ml 
of AF for analytical processing. AF contains a wide variety of cell types originating from extra-
embryonic structures such as the placenta but also foetal tissue (Gosden, 1983). The morphologies of 
cells found in AF can be characterised into fibroblastic, epithelioid and amniotic fluid in order of 
relative abundance(Hoehn et al., 1975). 
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Amniotic Fluid Stem Cells 
In 2003 a small sub-population (0.1-0.5%) of AF cells were shown to express Oct-4, a transcription 
factor of undifferentiated cells (Prusa et al., 2003). This was later demonstrated to be the case as 
these AF Oct-4 cells were shown to be C-kit (CD117) positive and were able to differentiate into a 
number of lineages including osteogenic, myogenic, hepatic and neural (Tsai et al., 2006, Kim et al., 
2007, De Coppi et al., 2007, Prusa et al., 2003). The surface antigen C-kit is used to characterise and 
isolate this small pluripotent population later called amniotic fluid stem cells, of which over ninety 
percent express Oct-4 (De Coppi et al., 2007). Isolation can be completed through the use of 
magnetic columns and magnetic beads selective for C-kit or a FACS cell sorting machine following the 
marking of the cells with C-kit selective antibodies. Furthermore the culturing of C-kit positive AFSCs 
is carried out in non-tissue treated flasks or dishes in order to provide optimum growing conditions 
for C-kit selected AFSCs, essentially adding a further selective measure. Karyotyping of AFSCs from 
male births showed that the AFSCs contained the Y chromosome and were therefore of foetal origin 
as opposed to maternal (De Coppi et al., 2007, Moschidou et al., 2012). Along with a rapid 36 hour 
doubling time, late passages of AFSCs still maintain a constant telomere length (De Coppi et al., 2007, 
Valli et al., 2010). Their characterisation revealed the presence of markers such as CD90, CD73, 
CD105, CD29, CD44 and MHC-I (De Coppi et al., 2007, Moorefield et al., 2011b). The presence of 
MHC-I may aid the cell with their immune-modulatory properties (Bailo et al., 2004). In contrast, 
markers including CD34, CD14, CD45, CD133, CD31 and MHC-II were not expressed (De Coppi et al., 
2007, Ditadi et al., 2009, Chiavegato et al., 2007, Guan et al., 2011, Rota et al., 2012).  Moreover, 
pluripotency markers such as Oct 4, SSEA3, SSEA4, NANOG, KLF4, Myc, TRA1-60 and TRA1-81 are 
expressed by the AFSCs (Moschidou et al., 2012, Zani et al., 2014, Wolfrum et al., 2010). Although 
AFSCs cannot be considered true pluripotent cells because of their lack of ability to produce tumours 
in immune-deficient mice, such as the SCID model (De Coppi et al., 2007, Moschidou et al., 2012, 
Carraro et al., 2008, Chiavegato et al., 2007, Gekas et al., 2010, Ma et al., 2012). However, 
Moschidou et al. proved that culturing AFSCs on matrigel in ES cell medium along with the histone 
deacetylase inhibitor (HDACi) Valproic acid without the use of ectopic reprogramming factors (AFiPS) 
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could induce their pluripotency (Moschidou et al., 2012). Furthermore, AF iPSCs were shown to 
produce tumours in SCID mice. 
Advantages of Amniotic Fluid Stem Cells for the Use of Therapy 
Advantages over other stem cells currently being researched, such as ESCs, make AFSCs highly 
favourable for stem cell based regenerative therapy. AFSCs can be obtained without ethical concern 
or interference with diagnostic procedures because they are retrieved through amniocentesis, which 
is required for diagnosis anyway, or amnio-drainage, which is often used as a protective measure for 
the baby and mother. Their use is seen to be safe because the AFSCs remain genomically stable and 
lack the ability to form tumours. However, if the need to reprogram them to pluripotency arose, the 
methods required are highly efficient, easy to follow and produce a set of cells whose pluripotent 
phenotype is stable. Furthermore, their use provides a reduced risk of random genetic integration of 
transgenes that could reprogram the host genome (Kaji et al., 2009, Warren et al., 2010). 
Additionally,  AFSCs exhibit a phenotype and multi-lineage differentiation capacity similar to 
postnatal bone marrow (BM) derived mesenchymal stem cells (MSCs) (In 't Anker et al., 2003). 
Promisingly, expansion potentials of amniotic fluid–derived MSCs were also revealed to surpass that 
of BM-derived MSCs (In 't Anker et al., 2003), which therefore makes them an attractive cell source 
for future therapeutic approaches. Their extensive differentiation potential is mirrored by their 
ability to co-stain by over 75% with a minimum of two surface marker proteins such as Sox17 (an 
endodermal marker), SM22α (a mesodermal marker) and Tubb3 (an ectodermal marker), thus 
making them stand out from other cell types (Maguire et al., 2013). The broad differentiation 
potential of AFSCs is reflected through their relatively successful use to treat diseased organs derived 
from all germ layers. Muscle, bone and heart (mesodermal in origin) disease models have been 
treated along with kidney and lung (endoderm in origin) disease models but also nervous system 
(ectoderm in origin) based diseases (Chiavegato et al., 2007, Guan et al., 2011, Carraro et al., 2008, 
Castellani et al., 2013, Perin et al., 2010, Hauser et al., 2010, Peister et al., 2011, Maraldi et al., 2011, 
Riccio et al., 2012, Calzarossa et al., 2013). 
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Conditioned Media 
Studies that have focused on directly treating disease with stem cells have had issues with the 
targeting of the stem cells to the area of interest in order to promote regeneration. One such study 
that looked into treating nerve injuries with AFSCs noticed a large deposition of the cells in the lung 
after intravenous injection and consequently had to increase the expression of homing factors in the 
injured tissue to direct a larger proportion of the cells to the correct area of injury (Yang et al., 2012). 
The use of conditioned medium (CM) would bypass the problem of a lack of target tissue specificity 
by injecting the CM directly to the area without concern for the treatment actively relocating to an 
undesirable location in the body. Conversely, previous studies have shown that although injected 
stem cells did not reach the target tissue, for example were trapped in the muscle following 
intramuscular injection, a regenerative effect was still recorded (Shabbir et al., 2009). The injection of 
BM-MSCs into TO2 cardiomyopathy hamster models was compared to the less invasive 
intramuscular injection of BM-MSC extract, CM, which also significantly improved cardiac repair 
through reduced apoptosis and fibrosis (Shabbir et al., 2009). A paracrine mechanism of stem cell 
action was first hypothesised by Gnecchi et al (Gnecchi et al., 2005), who later provided evidence 
with the use of stem cell CM for the directed functional improvement of ischemic damaged 
cardiocytes in vitro (Gnecchi et al., 2006). Investigations into other disease models including spinal 
injury support a paracrine theory of stem cell action. Human umbilical mesenchymal stem cells were 
implanted into the lesion of pre-transected rat spinal cords (Yang et al., 2008). This resulted in an 
increase in the number of axons and reduced the number of microglia and astrocytes. However, a 
regenerative setting could not be attributed as being the result of stem cell differentiation because 
human MSC antigen did not overlap with the new neurons and oligodendrocytes, suggesting the 
stem cells lay undifferentiated (Yang et al., 2008). Instead large concentrations of cytokines and 
growth factors such as human basic fibroblast growth factor (bFGF), produced by stem cells, were 
believed to be the key to the stem cell transplant success (Yang et al., 2008, Lee et al., 1999, Teng et 
al., 1999). 
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As briefly discussed previously, preconditioning of cells is an important factor to remember when 
preparing to collect CM of stem cells. The belief that stem cells act as repair mechanisms in times of 
injury to tissues suggests that the stem cells are not constitutively producing paracrine factors which 
have the potential to induce regeneration. Instead stress signals from the stromal cells that are 
damaged or that neighbour the damaged cells are thought to reprogram the stem cells to awaken 
from a quiescent state. Such examples include the satellite cells of the skeletal muscle which activate 
following inflammation and damage to muscle fibres thus subsequently migrating to the area of 
damage to replace muscle fibres following myotube formation (Collins et al., 2005). The culture 
conditions of stem cells can vary greatly and therefore stem cell secretomes are highly likely to vary 
because of this. It may prove necessary to alter these conditions in order to retrieve the optimum set 
of trophic factors for the user’s requirement.  
Microvesicle and Exosome Biogenesis and Release 
Small extracellular bodies produced by the stem cells constituting of both microvesicles and 
exosomes mediate the delivery of trophic factors within the conditioned media.. Exosomes are the 
smallest of the two vesicles (30-100nm). Their release (Figure 2a) is mediated through the fusion of 
multivesicular bodies with the cell membrane through exocytosis, thus releasing multiple exosomes 
into the environment (Thery et al., 2002b, Thery et al., 2009). Microvesicles are however larger in 
size (ranging from 100-1000nm) and released directly (Figure1.3.b) from the cells plasma membrane 
(Thery et al., 2009). Both vesicle types are found in various fluids such as blood, plasma, urine, saliva, 
breast milk, cerebral spinal fluid and amniotic fluid (Murakami et al., 2014, Hata et al., 2010, Kafian et 
al., 2014, Keller et al., 2007, Burgos et al., 2014, Xiao and Wong, 2012). 
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Figure 1.3: Mechanisms of exosome release. A depiction of how exosomes are released from the cell 
(a) compared to microvesicles (b). From Camussi, G., et al. (Camussi et al., 2010). 
Although exosome release is thought to be regulated it also takes place constitutively, unlike 
microvesicles, which are mainly believed to be released in a regulated manner (Cocucci et al., 2009). 
Exosome release has been shown to be a p53 controlled process and is therefore thought to be up-
regulated by stress (Yu et al., 2006). The activation of the p-53 pathway is likely to directly interact 
with  tumour suppressor-activated pathway 6 (TSAP6), otherwise known as steap3, thus upregulating 
exosome release (Lespagnol et al., 2008). Exosome release is postulated to transfer stress linked 
receptors from one cell to another so that other cells may intercept signals indicating a hazardous 
environment, therefore inducing a more resilient cell  (Yu et al., 2006). Using the ionophore 
treatment monensin (MON), exosome release was upregulated, providing evidence that this process 
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is partly calcium dependent, further backed up by the chelation of calcium with BAPTA-AM leading to 
reduced exosome release (Savina et al., 2003). 
The endosomal sorting complex required for transport (ESCRT) mediates the inward budding of 
vesicles derived from the membrane of endosomes by weakening the endosomal membrane at 
isolated sites, via protein-protein and protein-lipid interactions. ESCRT I/II/III recognise 
monoubiquitinated cargoes and promote their inclusion in multivesicular bodies (MVBs) via an 
inward budding mechanism (Piper and Katzmann, 2007). ESCRT I/II orchestrates the clustering of 
ubiquitinated cargoes to the endosomal membrane following their binding to hepatocyte growth 
factor – regulated kinase substrate (Hrs), a component of ESCRT 0, on the clathrin coats surrounding 
the endosomal membrane(Hurley, 2008, Williams and Urbe, 2007). The role of ESCRT III proteins is to 
facilitate the removal of ubiquitin from cargo via de-ubiquitylating enzyme employment. Apoptosis 
linked 2 interacting protein X (Alix) is thought to link the various ESCRT complexes thus promoting 
their interactions (Babst, 2005). ESCRT then dissociates from MVB membranes aided by adenosine 
triphosphatase vacuolar protein sorting 4 (Vps 4), also recruited by ESCRT III, and is then recycled 
(Yeo et al., 2003). 
Cholesterol and sphingomyelin rich micro domains, otherwise known as lipid rafts, have been shown 
to be important components of both microvesicle and exosome origins. A reduction in lipid rafts 
have led to reduced microvesicle budding (Del Conde et al., 2005, Lakkaraju and Rodriguez-Boulan, 
2008). Lipid rafts are thought to cluster the proteins required for the release of both exosomes and 
microvesicles from the plasma membrane and are therefore not thought of as being specific to either 
exosome release or microvesicle release mechanisms (Cocucci et al., 2009). On the other hand, 
reducing cholesterol at the membrane or cholesterol synthesis has also been shown to increase 
exosome release, believed to be a result of removing associations between Rab7 and endosomes and 
instead allowing Rab 7 to associate with Rab4, which leads to increased endosomal recycling speed. 
Furthermore this is thought to result from an increase in endosomal migration to the positive pole of 
micro-tubules (Stoeck et al., 2006, Keller et al., 2007, Lebrand et al., 2002, Chen et al., 2008). Rab 
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proteins (small GTPases) promote exosome docking and membrane fusion events, specifically Rab35. 
Their inhibition leads to the accumulation of endosomal vesicles intracellularly and a reduction in 
exosome secretion (Ostrowski et al., 2010, Hsu et al., 2010). 
In order for exosome release to take place the MVB must fuse with the plasma membrane. This is 
mediated by two main types of soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (SNAREs). The first resides on the MVB membrane, vesicular SNAREs (v-SNAREs), whilst the 
other presents itself on the intracellular side of the plasma membrane, a ‘membrane-bridging SNARE 
complex’ known as target SNAREs (t-SNAREs) (Südhof and Rothman, 2009, Urbanelli et al., 2013, 
Chaineau et al., 2009).  Interaction between these two sets of SNARE proteins enables the coming 
together of the MVB membrane and plasma membrane. 
Microvesicles as discussed are released via a blebbing like mechanism. The initiation of their 
formation and release is preceded by the translocation of phosphatidylserines (PS) from the 
intercellular side of the cells plasma membrane to the extracellular side, mediated by floppases 
(Zwaal and Schroit, 1997).  A series of ERK facilitated phosphorylation follows. Conscripted by 
phospholipase-D at the membrane, myosin light chains activate and cytoskeletal organisations 
contract to allow microvesicle release (Muralidharan-Chari et al., 2009, McConnell et al., 2009). 
Microvesicle and Exosome Isolation and Analysis 
There are various techniques to isolate exosomes and microvesicles. Commonly, a two-step 
differential centrifugation is used. Centrifugation of the sample at a lower speed, around 17000g, 
removes cells and debris but not the vesicles, which are of too low a density and therefore remain in 
the supernatant. An ultracentrifugation step at 200,000g follows in order to pellet the vesicles. 
However, stepwise centrifugation is time consuming (Alvarez et al., 2012). Tamm-Horfall protein 
(THP) traps exosomes during initial low speed centrifugation (17000g). THP is reduced using DL-
dithiothreitol to increase exosome yield (Alvarez et al., 2012). Furthermore, a sucrose density 
gradient technique can be used in which fractions of supernatant are formed following 
centrifugation. Each fraction contains specific particle masses and can therefore be collected through 
 General Introduction 
Page | 37  
 
simply pipetting (Thery et al., 2006). The use of immune-magnetic micro beads specific for markers 
(such as HLA-DP) found on exosomes or microvesicles have also been used for vesicle isolation. Light 
microscope based studies cannot confirm the purity of the selection and so an electron microscope is 
often used (Clayton et al., 2001).  Exosomes carry lots of different molecules (Schorey and Bhatnagar, 
2008). The exosomes themselves bring stability to their contents, more so than if they were found 
freely, for example in plasma. However, the correct storage of exosome containing supernatants at -
20°C ensures the constant size of exosomes throughout storage (Yu et al., 2014). ExoQuick (Systems 
Biosciences) is a commercial precipitation reagent for high quality exosome isolation with high 
quality miRNA and mRNA (Beninson et al., 2014).  
CD24, a protein often expressed on haematopoietic subpopulations of B and T lymphocytes, is a 
marker of exosomes in AF and urine (Keller et al., 2007). It is due to CD24’s glycosyl-
phosphatidylinositol (GPI) anchor, which specifically localises the associated protein to lipid rafts that 
largely increases CD24 concentration in exosomal membranes (de Gassart et al., 2003). However, 
other markers such as CD63, a membrane tetraspaning protein on exosomes, can also be used to 
quantitatively assess exosomes using an ELISA assay  (Beninson et al., 2014). Markers such as IL-6, 
which are not expressed on exosomes, may also be used in tandem to act as a control measure 
(Beninson et al., 2014). Microvesicles unlike exosomes have a high concentration of PS and can 
therefore act as a marker to distinguish between the two. 
Shuttle RNA 
The first indication of miRNA detection came from the Ambros and Ruvkun labs who were working 
on C.elegans when a short RNA sequence was found to alter the time of transitions during the 
worm’s development. The mechanism surrounding this outcome was found to be the miRNA 
complementarily binding to the bases of target mRNA (Lee et al., 1993, Wightman et al., 1993). Later 
research elaborated upon this process. Argonaute (AGO) proteins, the catalytic components of the 
RNA induced silencing complex (RISC), associate with miRNA. The miRNA directs AGO to 
complementary mRNAs to endonucleolytically cleave them, thus silencing their expression 
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(Hutvagner and Simard, 2008). A process of mRNA translational suppression is believed to be ensued 
by mRNA degradation. However, miRNAs were found not to be as specific as first thought with 
individual miRNAs targeting numerous mRNAs and the majority of mRNAs being targeted by multiple 
miRNAs (Chi et al., 2009). Both mRNA and miRNA are found in microvesicles and exosomes and may 
therefore be transferred to target cells to influence their behaviour. In the case of mRNA, a direct 
instruction for protein production could be transferred as opposed to miRNAs mechanism of action 
as explained. The selective trafficking of RNA binding proteins to vesicles is thought to play a major 
role in selectively transferring RNA to the exosomes and microvesicles  (Valadi et al., 2007, Skog et 
al., 2008, Taylor and Gercel-Taylor, 2008, Mittelbrunn et al., 2011).  Ribonucleoproteins (RNPs) are 
thought to act in such a manner (Figure 1.4.) as well as Gag proteins found in retroviral vesicle 
biogenesis processes to target larger RNAs to the budding vesicles (Thery et al., 2001, Alcazar et al., 
2009). 
mRNA contained in exosomes has been shown to be translated into protein production (Valadi et al., 
2007). This field of work has become of high interest not only within areas of cancer biology but also 
stem cell biology (Ratajczak et al., 2006, Skog et al., 2008, Lotvall and Valadi, 2007, Valadi et al., 
2007). In the case of stem cells, RNAs are believed to be a major mediator of regenerative potential 
of stem cell exosomes and microvesicles.  The transfer of Oct-4 mRNA in microvesicles could 
handover a direct instruction for pluripotency and increased regenerative potential (Ratajczak et al., 
2006). A point to note when studying miRNAs found in micro-vesicles and exosomes, if any at all, is 
that the miRNAs up-regulated in stressful conditions and times of disease often provide a large 
switch like effect as opposed to fine tuning, as suggested takes place in most cases (van Rooij et al., 
2007). By analysing 47 gene products that derive from mRNA found in exosomes, the mRNA is 
believed to be involved in cellular growth, protein synthesis and the post transcriptional modification 
of RNA (Lotvall and Valadi, 2007). Furthermore, exosomal miRNA analysis shows a variety of 
functions related to stem cell properties such as differentiation, organogenesis (miR-1) and 
development (Let-7) (Alvarez-Garcia and Miska, 2005, Zhao et al., 2005, Eirin et al., 2014). The levels 
of these ‘exosomal shuttle RNAs’ could potentially decrease or increase depending on the 
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environment in which the cell they derive from is kept in. Introducing cells to a hypoxic environment 
is thought to stress cells and therefore modify the RNA which they express (Bussolati et al., 2012, Hu 
et al., 2008). Further research must be carried out to confirm whether the stress related RNAs are 
translocated to the microvesicles or exosomes of the cells following stress exposure. 
 
Figure 1.4: Packaging of miRNA into exosomes. Heterogeneous nuclear ribonucleoprotein A2B1 
(hnRNPA2B1), a RNP, binds specifically to certain miRNA motifs following hnRNPA2B1 sumoylation 
(addition of a small ubiquitin-related modifier) allowing miRNA transportation into exosomes. From 
Villarroya-Beltri, C., et al. (Villarroya-Beltri et al., 2013). 
Microvesicle Proteins 
Targeting of proteins to the vesicles is aided via widely used cellular mechanisms such as 
myristoylation and palmitoylation of the protein thus anchoring them to the vesicle plasma 
membrane (Shen et al., 2011). Stressing cells through hypoxia changes the protein composition of 
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exosomes and microvesicles (Salomon et al., 2013). As discussed, common proteins found in 
exosomes and microvesicles include CD63 and CD24, however upon stress, cells may produce other 
proteins like the heat shock proteins (Hsp72) (Asea et al., 2008), which could provide signals to target 
cells to potentially protect them in a stressful environment. Moreover, the transport of embryonic 
related proteins including Oct-4, detected in embryonic stem cell microvesicles along with Wnt-3, 
may provide a means of inducing regeneration in target tissue (Rolf et al., 2012, Ratajczak et al., 
2006). Furthermore as discussed, the protective coating provided by exosomes and microvesicles 
would allow these regenerative properties to affect wider reaches of the body. Another example of 
how stem cells may potentiate their effects comes from evidence of active Wnt proteins being 
discovered within exosomes derived from Drosphilia cells but also a human Caco-2 colon cancer cell 
line and embryonic stem cells (Gross et al., 2012, Ratajczak et al., 2006). Their secretion via exosomes 
was also proven to be dependent on Ykt-6, a R-SNARE protein, providing further evidence that Wnt 
excretion is in at least partly due to exosome secretion (Gross et al., 2012). Wnt proteins are 
extremely important morphogens and thus play a role in the patterning of tissues during 
development. Although Gross’s research shows that exosomal transfer of Wnt is not the only route 
of transfer, because Wnt secretion was still detected following exosome release was inhibited, it 
provides a possible hypothesis of how Wnt proteins are able to travel over long distances through 
the body to produce an effect without degrading. Insulin like growth factor binding protein (IGFBP) 
are also found to reside in microvesicles of C2C12 myoblast cells, a protein which regulates the 
action of insulin like growth factor (IGF) (Guescini et al., 2010). The transfer of IGFBP to target cells 
would alter the IGF activity acting to significantly alter signal transduction and therefore increase or 
decrease IGF activity, hence increasing or decreasing cell growth (Guescini et al., 2010). 
Understanding the protein content of vesicles excreted by cells would allow their use in regenerative 
medicine.   
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Cell Targeting 
In order to specifically target cells, exosomes and microvesicles are thought to possess specific 
surface proteins which bind to complementary proteins on the target cell. Dendritic cell originating 
exosomes have been shown to express MHC proteins on their surface, which can present pathogen 
derived peptide fragments. This allows for specific binding of these exosomes to complementary T 
cell receptors on T cells leading to modulation of T cell activity (Nolte-'t Hoen et al., 2009, Admyre et 
al., 2006, Thery et al., 2002a).  
Another potential mechanism of cell specificity may lie with the production of enzymes by the target 
cells. These enzymes could cleave a specific protein on the exosome or microvesicle membrane thus 
allowing the cleaved product to interact with the target cells surface receptors. Pro-CD46 shed by 
various cancer cells (in response to stress) on microvesicles for example is cleaved by 
metalloproteinases on other tumour cells to create an active CD46, which interacts with the enzyme 
producing tumour cell (Hakulinen et al., 2004). Cell signalling which follows is thought to lead to 
increased tumour resilience to the stress. This can be compared to a similar mechanism surrounding 
the actions of the aerolysin toxin produced by Aeromonas spp. Only when the furin enzyme is 
present on a cell does the inactivated toxin become active following its cleavage leading to its action 
on the target cell, in this case pore formation and apoptosis (Abrami et al., 1998).  
A third potential mechanism of vesicle specificity relies on the pH of the tissue the vesicles enter. 
Tumours have been shown to be an acidic environment, one which is perfect for the fusion of 
exosomes and microvesicles to the plasma membrane of cells within the tumour in particular the 
cancerous cells themselves (Parolini et al., 2009). Although evidence is still required, if necrotic tissue 
is of a lower pH than normal healthy tissue, potentially due to an increase in anaerobic activity and 
consequential lactic acid production, it may provide a mechanism of targeted regenerative action for 
these vesicles. Regarding the use of CM as a therapy it is often an aim of researchers to modify the 
inflammation associated with the necrosis. 
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The role of inflammation in tissue regeneration 
Inflammation has both a role in the aetiology behind pathogenesis but also regeneration of tissue. A 
sustained inflammatory state in tissue often leads to chronic disease of the tissue with pro-
inflammation proving key to a positive feedback loop in which further necrosis of tissue is 
potentiated by pro-inflammatory factors. In a healthy tissue following injury, this pro-inflammatory 
response delivers a chemical flag for inflammatory cells, such as macrophages to enter the tissue and 
remove debris created through tissue destruction. Following debris clearance the pro-inflammatory 
response diminishes and is replaced by an anti-inflammatory response to spark regeneration. If this 
critical pro/anti-inflammatory substitution is in some way interrupted the process of regeneration 
can often be impaired, thus leading to a pathological state. Key to the mediation of an initial 
inflammatory response is the surrounding stromal cells of the damaged tissue.  Following stress of 
necrotic cell death, cells will secrete chemokines and cytokines, which in turn act as a signal to 
activate and attract inflammatory cells.  
Macrophages 
Monocytes, the predecessors of macrophages, circulate in the circulatory systems until activated via 
stromal cell originating inflammatory signals. Upon activation monocytes migrate to enter the 
damaged tissue leading to their differentiation into macrophages. ECM breakdown facilitates 
macrophage infiltration of tissue. Plasminogen, activated by urokinase type plasminogen activator 
(uPA), enzymatically cleaves ECM.  Expression of uPA in macrophages and its secretion promotes 
their migration into damaged tissue. The total expression of uPA in damaged muscle therefore 
increases. uPA is also known initiate regenerative signalling and macrophage uPA adds to the tissue 
regeneration (Novak et al., 2011). Classically, macrophages are known to phagocytose and clear 
tissue debris or foreign particles such as bacteria following infection. Consequentially the phagosome 
merges with the macrophages lysosomes. Enzymes and free radicals located or produced in the 
resulting phagolysosomes aid debris or bacterial breakdown. On the other hand, phagocytic 
macrophages provide no direct induction of regeneration. Their number gradually decline but are 
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replaced by anti-inflammatory macrophages thus outlining two major populations of macrophage, 
M1 macrophages otherwise described as the pro-inflammatory phagocytic type and M2 
macrophages also known to be anti-inflammatory. 
M1 and M2 macrophages 
Exposure of M0 macrophages to IL-10 polarises macrophages towards an M2 phenotype, thought to 
be due to changes in arginine metabolism. These changes reduce pro-inflammatory nitric oxide 
production (Villalta et al., 2009). Furthermore P38/MKP-1 interactions with AKT have been proposed 
to co-ordinate the transition of macrophages from M1 to M2, therefore aiding resolution of 
inflammation and tissue repair (Perdiguero et al., 2011, Perdiguero et al., 2012). MKP-1, a 
phosphatase which reverses MAPK phosphorylation, restricts P38 MAPK activation pushing 
macrophages towards a M2 phenotype. M2 macrophages have been further categorised into M2a, 
M2b and M2c phenotypes, all of which have different but also overlapping roles to play in an anti-
inflammatory response within different situations (Mantovani et al., 2004). Activation of M0 
macrophages with IL-4 and IL-13 leads to macrophages that defend the body against parasites, have 
a role in allergy but also the classic type two inflammatory responses, the M2a macrophages, which 
secrete anti-inflammatory cytokines. M2b macrophages tend to be induced by TLR agonsists and 
immune complexes. They aid in immune-regulation through cytokine production such as Il-6 and IL-1 
but interestingly do not produce high levels of arginine, unlike M2a and M2c macrophages, when 
exposed to specific types of LPS and immune complexes (Mosser, 2003). M2c macrophages, 
polarised with IL-10, are also involved in immune-regulation however are heavily involved in 
promotion of tissue remodelling though matrix deposition. Work by Perdiguero et al. in mice 
suggests that hyperactivation of P38 due to a lack of MKP-1 activity leads to enhanced miR-21 
expression and therefore reduced levels of PTEN mRNA being translated into functional PTEN 
proteins thus preventing AKT inactivation. Prolonged AKT activation is thought to promote an M1 
state and prevent M2 outset (Perdiguero et al., 2011), a potential mechanism to potentiate chronic 
inflammatory diseases. On the other hand, the premature demise of M1 Macrophages, naissance of 
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M2 macrophages and expression of anti-inflammatory cytokines are also contributory to inefficient 
repair. This can lead to early macrophage exhaustion and ‘cytokine silencing’, characterised by 
termination of macrophage cytokine production, and inefficient activation of local stem cells whose 
role is to aid regeneration. Regeneration is also therefore compromised. The fine regulation of a M1 
to M2 switch and finally overall macrophage exhaustion can therefore be seen as key to tissue 
healing and restoration. Altering the endogenous macrophage signalling seen in disease, where the 
switch is compromised, is suggested as being a therapeutic strategy to bring about favourable 
macrophage polarisation. Macrophages have been shown to have a greater propensity to take up 
exosomes compared to non-phagocytic cells therefore providing evidence that exosome uptake by 
macrophages may at least be mediated by phagocytosis (Feng et al., 2010). An increased 
susceptibility to take up exosomes may make macrophages a major target of stem cell exosomes and 
microvesicles, therefore making them potentially responsive to CM. 
Alteration of Inflammatory state with Stem cells and conditioned media 
With an increased interest in stem cell therapeutics a surge of data has suggested that along with 
improving regeneration within tissue a, reduction in inflammation is an important issue. Recently it 
has been proposed that MSCs are, like macrophages, polarisable and can exist as an anti-
inflammatory phenotype, MSC2, or even an inflammatory phenotype, MSC1 (Waterman et al., 2010), 
a process influenced by environmental stimulation. For example if an MSC is injected into a site of 
pro-inflammatory significance it will adopt an inflammatory state, MSC1. If on the other hand the 
stem cell TLR3 is stimulated, as opposed to TLR4 in pro-inflammatory conditions, an anti-
inflammatory status is assumed. The development of MSC1s may sound counterproductive, however 
inducing a pro-inflammatory state via their, or their secretomes, introduction into the site of early 
degeneration may accelerate initial responses to damage and therefore initiate an early regenerative 
response. It is unknown however whether exposure of stem cells to stress such as a hypoxic 
environment with little nutrition will push MSCs towards an MSC1 or MSC2 phenotype. Studies into 
MSC secretomes following this stress will expose any pro or anti-inflammatory mediators being 
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released and a total profile which can be determined and being pro or anti-inflammatory. Further 
investigation has uncovered a range of inflammatory modifying factors being released by stem cells. 
Co-culture of MSCs with macrophages has proven an increased secretion of anti-inflammatory 
cytokines such as IL-10, IL-4 and IL-13 (Adutler-Lieber et al., 2013). Furthermore, co-culture has 
shown a reduction in iNOS:Arg1 ratios of macrophages thus reducing NO production, suggesting a  
polarisation towards an M2 phenotype (Cho et al., 2014). In-vivo experiments also report reduced 
pro-inflammatory cytokines, such as TNF-α and IL-1β, replaced by an increase in anti-inflammatory 
cytokines along with increased regeneration in models of lung, kidney and cardiac injury.  Underlying 
mechanisms behind responses of stem cells to macrophages as described have been studied 
providing a wealth of data into how stem cells regulate regenerative signalling. Interaction of mouse 
derived macrophages with bone marrow derived stem cells shows an increase in IL-10 and Arg1 
levels are due to alteration of the NF-κB (figure 1.5.) and STAT3 pathways (Gao et al., 2014). Evidence 
of macrophage polarisation both in vivo and in vitro suggests that MSCs may have a role to play in 
determining M1:M2 ratios in the body and although an introduction of supplementary MSCs into a 
site of damage does not take place naturally, endogenous MSCs around the body could affect 
macrophage polarisation via paracrine factors. Additionally, monocytes may be attracted to an area 
of infection via a trace of secreted MCP-1 (monocyte chemotactic protein-1) from MSCs, which was 
observed to be exuded from BMDSCs. An increase in MCP-1 secretion follows an increase in TLR-4 
expression allowing higher reception levels of its ligand LPS and downstream signals (Shi et al., 2007). 
As discussed previously paracrine factors, whether protein or RNA based, can be transferred via 
exosomes to circulating monocytes and macrophages. One such example includes Indoleamine 2,3-
dioxygenase 1 (IDO1), an enzyme which catalyses the breakdown of L-tryptophan to N-
formylkynurenine (Yeung et al., 2015). AFSCs have been found to secrete vesicles containing IDO1 
following treatment with IFN-γ, a pro-inflammatory mediator (Romani et al., 2015). Increasing levels 
of N-formylkynurenine due to IDO1 action would suppress pro-inflammatory signalling in not only 
macrophages but also other inflammatory cells such as Th1-cells (Jalili et al., 2007). 
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Figure 1.5: Macrophage inflammatory pathways, alteration of which can cause polarisation. Pro-
inflammatory signalling pathways within M1 macrophages (A) leading to increased NF-kB (P65/P50) 
signalling and subsequent increased NO production via L-arginine conversion catalysed by iNOS. In 
contrast, a generic M2 macrophage (B) has reduced NO production due to the catalysis of L-arginine 
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to polyamines by Arg-1. Increased ARg-1 expression follows STAT6 phosphorylation and its co-
operative DNA binding with KLF4 to the Arg-1 gene. From Tugal et al, 2013 (Tugal et al., 2013). 
Treatment of NEC with AFSC CM 
Research into the use of AFSCs as an NEC therapeutic was conducted in NEC rat models in vivo (Zani 
et al., 2014). IP injection of the GFP labelled AFSCs into 24 hour old NEC rats showed their integration 
into the intestinal wall. Furthermore, AFSC treatment led to increased survival and reduced incidence 
of NEC, which was not seen in BM-MSC treatment (Zani et al., 2014). AFSC treatment also 
corresponded with decreased gut damage and improved function as evaluated with an increase in 
intestinal motility and reduced permeability (Zani et al., 2014). Use of a COX-2 inhibitor, which 
inhibited the effects of AFSCs, showed that the AFSCs increased COX-2 expression helping to explain 
its protective effects (Zani et al., 2014). Often overexpressed in colorectal carcinomas, COX-2 acts as 
a major instigator of prostaglandin synthesis and therefore potentiates cell growth (Kaidi et al., 
2006). In addition to this, the signalling pathways associated with COX-2 are known to cross talk with 
that of NF-κB and is also known to regulate its activity positively and negatively (Poligone and 
Baldwin, 2001). Of particular interest, the beneficial effects seen with AFSC treatment were 
accompanied with a lack of total AFSC integration and was mirrored by the treatment with AFSC 
derived CM collected in α-mem for 30h under normal cell conditions (Zani et al., 2014). As previously 
hypothesised in studies using stem cells, much of the regenerative properties of AFSCs and the AFSC 
CM were therefore believed to derive from the paracrine factors released by the stem cells (Zani et 
al., 2014, Gnecchi et al., 2006, Gnecchi et al., 2005, Gnecchi et al., 2016). 
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Aims, Objectives and Hypotheses 
Background: 
Stem cells have been used in a range of necrotic and disease pathologies to promote regeneration 
(Gnecchi et al., 2006, Gnecchi et al., 2016, Zani et al., 2014). The mechanism of how the stem cells 
bring about the beneficial outcomes remains controversial. It was initially believed that the stem cells 
directly took part in the regeneration process by differentiating to replace dead tissue. However, 
much research has described the beneficial effects of stem cells yet at the same time demonstrating 
that these cells have not integrated into the damaged tissue (Gnecchi et al., 2006, Gnecchi et al., 
2005). This has led to a paradigm shift in thinking and raised the possibility that stem cells bring 
about tissue repair by acting indirectly to promote regeneration. It is postulated that stem cells 
secrete paracrine acting molecules that influence the activity of resident stem cells or somatic cells, 
which facilitate the regeneration process.  Paracrine factors from mesenchymal stem cells have been 
widely collected as part of conditioned media (CM). Data collected by an industrial partner has 
shown that a novel procedure for collecting CM produced under stressful conditions has enhanced 
therapeutic capabilities. However it has also become evident that many of these paracrine factors 
are secreted and packaged within extracellular vesicles (EV), such as exosomes and microvesicles 
(Eirin et al., 2014, Collino et al., 2010, Yu et al., 2014, Lee et al., 2012a). Packaging with the EV not 
only protects molecules from degradation and enables long distance cell-cell signalling but is also 
thought to aid in targeting regenerative factors to the appropriate cell type (Mathivanan et al., 2010).  
Nevertheless, the exact cocktail of paracrine factors within this AF-CM is still to be elucidated. 
Furthermore, the mechanisms by which this set of extracellular factors aid regeneration remains 
unknown. 
Recently, Amniotic Fluid Stem Cells (AFSCs) have been shown through various studies to provide a 
particularly potent regenerative effect. In particular, Zani et al. 2014 showed that AFSCs increased 
survival following their introduction into a Necrotising enterocolitis rat model (Zani et al., 2014). 
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Furthermore this study and much of the literature surrounding how mesenchymal stem cells provide 
a regenerative effect have alluded to an anti-inflammatory mechanism of action therefore 
preventing widespread necrosis but also an ability to upregulate endogenous stem cell population 
regenerative properties (Gnecchi et al., 2016). It was also directly shown that an AFSC CM could 
mimic the whole AFSCs beneficial effects on NEC (Zani et al., 2014). However, this AFSC CM, like 
many other MSC CMs before, was created using non-stressed cells.  It was therefore proposed that 
the use of AFSCs, developmentally naive cells, to create CM in a novel fashion under stressful 
conditions, discussed previously to enhance the quantity and quality of the secretome for 
regenerative purposes, would make a powerful therapeutic for tissue regeneration. Production of 
this AF-CM is such that, unlike many other types of CM detailed in previously published literature, it 
is free from animal derived serum or basal medium that contains uncharacterised constituents and a 
potential for inducing an immunological response following therapy. 
Novelties of Project: 
The industrial partners have extensive clinical evidence showing the efficacy of stem cell CM created 
under stressful conditions hypothesised to increase the regenerative potential of the secretome. 
However the mechanism by which this outcome is achieved remains to be elucidated. This project 
aims to define on the molecular and cellular level how a clinically relevant AF-CM created under 
stressful cellular conditions promotes regeneration. The AF-EV and their cargo will be characterised. 
Causal agents in the AF-CM will be attempted to be identified. The novelty of this project is that it 
will identify the mechanism by which a clinically relevant CM and its EV cargo promote regeneration. 
This will lead to the optimisation of regimes which ultimately could lead to an AF-CM regenerative 
therapeutic and in particular for NEC. 
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Overall Project Hypothesis: 
AFSCs under non-physiological conditions (lacking nutrients and at a sub-optimal culture 
temperature) secrete protein or molecular species that act to support the host’s regenerative 
mechanisms, in particular those controlling stem cell activity and/or the inflammatory process. 
Overall Project aims: 
1. To characterise AFSC CM/EV collected through a novel procedure developed by an 
industrial partner and the AFSCs after CM collection 
• Characterise the multipotency of AFSCs following AFSC CM collection. 
• Study CM fractions such as the extracellular vesicle (EV) fraction using proteomic 
analysis and miRNA arrays to identify potentially regenerative molecules.  
2. Establish the ability of AFSC CM/EV to alter stem cell properties and the state of 
inflammation  
• Test AFSC CM/EV on a proliferation assay, migration assay, senescence assay, NF-kB 
reporter luciferase assay and a THP-1 macrophage polarisation assay. 
3. To determine the influence of AFSC CM/EV on resident stem cells and it’s anti-
inflammatory effects within in vivo or ex vivo models  
• Test AFSC CM/EV on an established cardio-toxin induced acute injury mouse muscle 
model. 
4. To determine the ability of AF-CM to modify altered signalling in LPS or TNF-α stressed 
mouse gut organoids which mimic NEC 
• Create a reproducible model of LPS/ TNF-α stressed organoids 
• Treat LPS/ TNF-α stress induced mouse intestinal organoids with AF-CM 
• Analyses protein and gene expression levels of intestinal markers using western 
blotting and fluorescent staining as well as qPCR respectively. 
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Results Chapter 1: Characterisation of Amniotic Fluid Stem Cell Conditioned Media 
Aims and objectives: 
1. To Characterise AFSC CM/EV and AFSCs used for CM collection 
• Collect CM at 24, 48 and 72 hours to provide three CM fractions.  
• Recover AFSCs after CM collection and differentiate them towards osteogenic, 
adipogenic and chondrogenic lineages. 
• Separate the EV fraction from the soluble CM fraction using step-wise 
ultracentrifugation.  
• Characterise the proteome of AFSC CM fractions using SDS-PAGE and silver staining. 
• Characterise in detail the proteomics of AFSC CM fractions using mass spectrometry.  
•  Bio-analyse samples for RNA using a pico-RNA chip before further Affymetrix array 
analysis of miRNA and or mRNA.  
Outcome: 
AFSCs will be shown to retain their multipotency following CM collection. AFSC CM and EV will 
contain a variety of molecules that are known to have regenerative properties such as being anti-
inflammatory or pro-angiogenic. 
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Results Chapter 2: Investigation into the Regenerative Potential of AFSC CM in Vitro 
Aims and objectives: 
1. Establish the ability of AFSC CM to modify cell behaviour in vitro 
• Test AFSC CM/EV on a stem cell migration assay. 
• Test AFSC CM/EV on a stem cell proliferation assay. 
• Test AFSC CM/EV on a stress induced cellular senescence assay.  
• Inhibit energy production in target cells to identify if EV uptake is inhibited and 
Identify the potential mechanisms of extracellular vesicle uptake in target cells 
 
2. To determine the ability of AFSC CM to alter the inflammatory state of cells in vitro 
• Test AFSC CM/EV on an NF-kB Luciferase reporter assay, which has had exposure to 
Salmonella LPS or human recombinant TNF-α.  
• Compare the complete CM/EV against defined CM molecules NF-kB luciferase 
reporter assay. 
• Test the alteration in inflammatory state of THP-1 macrophages treated with AFSC 
CM/EV. 
Outcome: 
An understanding of how AFSC CM can improve key mechanisms of non-autologous stem cells, 
provide a cyto-protective and an anti-inflammatory effect. 
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Results Chapter 3: Investigation into the Regenerative Potential of AFSC CM in an 
Acute CTX Damage Mouse Muscle Model in Vivo   
Aims and objectives: 
1. To determine if AFSC CM can enhance skeletal muscle regeneration in vivo following an 
acute injury 
• Treat a Cardio-toxin induced acute TA damage mouse model with AFSC CM/EV or a 
Vehicle control.  
• Dissect TA muscles 5 days after damage before cryo-embedding and sectioning.  
• Stain muscle sections for H&E, Acid phosphatase, CD-68/F4-80 and embryonic 
Myosin Heavy Chain (eMHC) to analyse the level of damage and rate of regeneration. 
Outcome: 
Learn whether AFSC CM/EV provides a regenerative effect in vivo and accelerates the regeneration 
of muscle fibres following injury. Understand whether the AFSC EV has the same regenerative 
capabilities as whole AFSC CM. 
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Results Chapter 4: Establishment of an NEC Intestinal Organoid Model to Test the 
Regenerative Capability of AFSC CM 
Aims and objectives: 
1. To ascertain if AFSC CM/EV can enhance regeneration in acutely stressed  mouse intestinal 
organoids specifically due to the protection of endogenous stem cells 
• Mouse organoids will be stressed with E.coli LPS/ TNF-α stress and organoids will be 
treated with AFSC CM/EV.  
• Paraffin embed organoids and section for immunofluorescent staining and analysis 
of Indication of Ki-67, CC3 and Lysozyme markers of proliferation, apoptosis and 
Paneth cells respectively. 
2. To establish if AFSC CM/EV can modify the inflammatory response seen in acutely stressed  
mouse intestinal organoids 
• Measure the levels of NF-kB-p65 nuclear translocation within stressed organoids 
following AFSC treatment using immunofluorescent techniques. 
• Use qPCR to establish relative levels of pro-inflammatory and intestinal markers 
within the stressed organoids following AFSC CM treatment. 
Outcome: 
Understand whether AFSC CM/EV can also protect the endogenous stem cell population and reduce 
a pro-inflammatory state within an NEC organoid model.  Results will suggest if this novel AFSC CM 
can assist in the regeneration of gut associated pathology as an anti-inflammatory and/or 
endogenous stem cell activity controlling therapy. 
 Aims, Objectives and Hypotheses 
Page | 55  
 
 
Figure 1.6: Overview of project plan and key steps undertaken. 
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2. Methods 
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Ethical Approval  
Human amniotic fluid samples were collected from women having amniocentesis for prenatal 
diagnosis for therapeutic purposes in Foetal Medicine Unit of University College London Hospital 
(UCLH). All patients gave informed written consent to an approved researcher under ethical approval 
(UCL/UCLH Joint Committee for the Ethics of Human Research, REC Reference: 08/0304).  Invasive 
procedures were performed under ultrasound guidance using sterile equipment.  In vivo animal 
experiments were performed under a project license from the United Kingdom (UK) Home Office, in 
agreement with the Animals (Scientific Procedures) Act 1986. 
Animal maintenance 
Male wild-type C57BL/6 mice were obtained from Harlan Laboratories, UK and were maintained in 
accordance with the Animals (Scientific Procedures) Act 1986 (UK). Mice were housed under 
standard environmental conditions (20-22ᵒC, 12h-light-12h-dark cycle) and were provided with food 
and water as libitum. Mice used for cardiotoxin injection experiments were aged 2-3 months (project 
licence - PA6190E59). Mice used for intestinal organoid isolation were aged 6 weeks. 
Euthanasia procedure 
All animals were culled via carbon dioxide asphyxiation with secondary cervical dislocation as per 
schedule 1 euthanasia protocol. 
Cell culture and In-vitro experimentation 
Cell culture conditions 
All cells were cultured at 37°C with 5% CO2 and passaged on reaching 70% confluency unless 
otherwise stated. 
AFSCs 
Human amniotic fluid stem cells were harvested from a single volume of second trimester amniotic 
fluid collected at 18 weeks pregnancy from a mother aged 38 via amnioscentesis due to suspected 
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Down syndrome. Cells were of a normal karyotype. Amniotic fluid was centrifuged at 300g for 5 
minutes and supernatant aspirated and discarded. Cells were re-suspended in 3ml AFSC media and 
seeded over a glass coverslip covering the inside of a 35mm × 10mm petri dish. Cells were incubated 
at 37ᵒC, 5% CO2 for 5-7 days until cells of a mesenchymal morphology could be identified. Media was 
then changed thus discarding any cells that had not adhered to the glass. Cells were passaged for 
immune-selection. Cells were purified according to positive selection of C-kit expression using MACS 
(Miltenyi Biotec) following 1 passage. MACS selection was carried out by washing cells in pre-cooled 
MACS buffer (1X PBS, pH 7.2, 0.5% bovine serum albumin (BSA), and 2mM EDTA).  Cells were 
pelleted at 300g for 10 minutes, supernatant was aspirated and then cells were diluted in 300μL for 
every 1x106 cells. 100μL of MACS FcR reagent was added for every 300μL buffer used. C-Kit 
microbeads were added using 100μL/1x108 cells. Cells and solutions were mixed well before 
incubating for 15 minutes at 4ᵒC. 2ml of buffer was then added to every 1x108 cells and cells were 
centrifuged at 300g for 10 minutes. Supernatant was aspirated and cells were re-suspended in buffer 
at 1x108/500μL. An MS MACS column was placed into a MiniMACS separator. The column was rinsed 
with 500μL of buffer before applying cells to the column. Cells that passed through the column were 
discarded. The column was removed was the separator and cells eluted from the column using 1ml 
buffer and the syringe/ plunger provided in the kit. C-kit+ AFSCs were cultured on non-tissue culture 
treated plastic in α-MEM medium containing 15% FBS, 1% glutamine and 1% pen/strep, 
supplemented with 18% Chang-B and 2% Chang –C (Pozzobon et al., 2013).  
U251 NF-κB reporter cells 
U251 NF-κB reporter cells were a gift of by D Widera (University of Reading). U251-NF-kappaB-Puro 
cells had been stably transduced using a lentivirus collected following the transfection of HEK293-FT 
cells with lentiviral package plasmids containing the pGreenFire-NF-κB-Puro vectors (Zeuner et al., 
2017). They were selected for with puromycin for 2 weeks and clonally selected via serial dilution 
(Zeuner et al., 2017). Cells were cultured in antibiotics- free high glucose (4.5g/l) DMEM, FBS (10%) 
and L-glutamine (1%).  
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IMR-90 Lung Fibroblast cells 
Human foetal IMR-90 Lung Fibroblast cells (IMR-90) were a gift of Dr. Debacq-Chainiaux (University 
of Namur, Belgium). Cells were used at 27-30 population doublings. IMR-90 cells were cultured in α- 
MEM medium containing FBS (10%), L-glutamine (1%) and pen/strep (1%). 
Adipose Derived Stem Cells 
StemPro® Human Adipose Derived Stem Cells, derived from a 49 year old female donor were from 
Stem Pro (Life technologies/ lot no. 2117- 510070). hADMSCs were cultured in MesenPro RSTM, L-
glutamine (1%) and pen/strep (1%). 
THP-1 Monocytes and Macrophages 
THP-1 monocytes (ATCC) were cultured as a suspension in ATCC-formulated RPMI-1640 Medium, FBS 
(10%), L-glutamine (1-%), pen/strep (1%) in non-tissue culture treated flasks. 
Differentiation to M0 THP-1 macrophages:  
THP-1 monocytes were stimulated with 25nM Phorbol 12-myristate 13-acetate (PMA) for 72 hours 
within a suitable tissue culture treated plate (40,000 cells/cm2). M0 macrophages were rested for at 
least 72h. Adherent cells were removed with a cell scraper. 
Differentiation of M0 to M1 THP-1 macrophages:  
M0 macrophages were treated with E.coli LPS (25ng/ml) and IFNγ (20ng/ml) in culture medium for 
72h before flow cytometry analysis.  
Differentiation of M0 to M2 THP-1 macrophages:  
M0 macrophages were treated with IL-4 (20ng/ml) and IL-13 (20ng/ml) in culture medium for 72h 
before flow cytometry analysis.  
Thawing of cells for culture 
Cells were removed from liquid nitrogen and thawed in a 37ᵒC water bath within 1 minute. Warm 
culture media (37ᵒC, 1ml) was pipetted into the vial of thawed cells. Cells were transferred to warm 
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culture media (10ml) in a 15ml Falcon tube. Cells were centrifuged at 300g for 5 minutes and the 
resultant supernatant discarded.  The cell pellet was re-suspended in 10ml culture media and 
transferred to a T75 culture flask. Cells were incubated under normal culture conditions for 24h, thus 
allowing cells to adhere, before changing media and removing non-viable cells.  
Passaging cells 
Media was removed on cells reaching 70% confluence (unless otherwise stated), media was 
removed. Cells were washed once with sterile 1X PBS. Cells were detached from the surface of the 
flask using TrypLE™ Select enzyme. Culture media was added to the cells in a 1:1 dilution and then 
transferred to a 15ml Falcon tube. A sample of cells was taken and Trypan blue along with a 
hemocytometer was used to determine a cell viability count. Stock cells were centrifuged at 300g for 
5 minutes and supernatant discarded. Cells were re-suspended in a volume of media calculated so 
that a known number of cells could be transferred to new culture flasks. 
Freezing of cells for storage 
Cells were trypsinised, counted and pelleted as previously described. Passaged cells were re-
suspended in freezing media (1ml/5x103 cells) and transferred to cryogenic vials as 1ml aliquots. 
Aliquots were frozen at -80°C overnight within a Mr. Frosty™ freezing container before being stored 
long term in liquid nitrogen. 
Conditioned media (CM) generation  
Following a maximum of 10 passages, AFSCs were trypsinised and collected into 50ml Falcon tubes 
and centrifuged at 300g. Supernatant was discarded and the cell pellet re-suspended in 1-2ml sterile 
PBS. Centrifuging at 300g was repeated and supernatant discarded again. Wash in PBS was repeated. 
Cells were counted using a haemocytometer. Following centrifugation at 300g for 5 minutes, the PBS 
was discarded and cells re-suspended at 1x106/ml cells of sterile ultra-centrifuged PBS (centrifuged at 
100,000g). 1ml of cell suspension was pipetted into 1.5mL microfuge tubes at a density of 
1x106cells/tube. Microfuge tubes were centrifuged at 300g for 5 minutes, supernatant aspirated and 
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replaced with 400μl ultra-centrifuged sterile PBS. Cells were incubated 24 hours at room 
temperature.  Following incubation the cells were centrifuged at 300g for 5 minutes, the supernatant 
was aspirated, pooled and centrifuged at 2,000 g for 20 minutes.  The supernatant (AF-CM) was 
collected and stored at -20°C. Aspirated supernatant was replaced in equal amounts and incubation 
repeated for a 48h and 72h collection.  
Extracellular vesicle (EV) isolation 
AF-CM was made up to 8.9ml with ultra-centrifuged sterile PBS and transferred to a polyallomer 
centrifuge tube (Optiseal). AF-CM was centrifuged at 100,000g using a 70.1Ti fixed-angle rotor 
(Beckman Coulter) for 18h. Supernatant was carefully removed and discarded. EVs were re-
suspended in ultra-centrifuged PBS at an equal volume to that of the AF-CM used to isolate them. 
Fixation of cells  
After the removal of culture medium, cells were fixed in 4% PFA/PBS for 15 minutes at RT. Fixative 
was aspirated and cells washed 3 times for 5 minutes in 1X PBS. 
Flow Cytometry  
AFSCs were trypsinised and collected in a 15ml Falcon tube. Cells were centrifuged at 300g, 5 
minutes. Supernatant was removed and cells re-suspended in sterile PBS (1ml). 4% PFA (1ml) was 
added to cells for 15 minutes. Cells were centrifuged at 300g for 5 minutes and the supernatant 
discarded. Non-specific binding was blocked with 10% FBS/PBS at room temperature for 1h.  Cells 
were centrifuged as before, supernatant discarded and cells washed once with PBS. Cells were 
transferred to a round bottom suspension cell plate (200μl/well, 2x105cells/well).  Cells were 
centrifuged at 500g for 5 minutes in a Heraeus Multifuge X3R using the plate attachment. 
Supernatant was removed, cells re-suspended in PBS. Antibodies were diluted in PBS (1:200) and 
incubated with the AFSCs for 1 hour at 4°C.  Supernatant was removed; cells were re-suspended and 
washes were repeated 3 times. The 96 well plate containing re-suspended cells was placed in a BD 
Accuri C6 flow cytometer C-sampler and 10,000 events were captured and recorded. Unstained cells 
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were gated to remove debris using a side scatter area (SSC-A) vs forward scatter area (FSC-A) density 
plot. Subsequently a forward scatter height (FSC-H) vs. forward scatter area (FSC-A) density plot was 
used to gate and remove doublets from recordings. A single parameter histogram was then used to 
gate and remove effects of auto-fluorescence. Data was analysed using the FlowJo v10 analysis 
software (FlowJo LLC). 
Adipogenic Differentiation  
AFSCs cultured following CM collection were allowed to reach 70% confluency and then passaged 
into 24 well plates at 20000cells/well in Chang-C media and allowed to reach 95% confluency. 
Growth media was then removed, cells were washed once with PBS and cultured for 21 days with 
Stem XVivo Adipogenic Base Media (R&D Systems) supplemented with Stem XVivo Adipogenic 
Supplement (100X) made according to the suppliers instructions. Media was changed every 3 days 
without passaging. Differentiation medium was removed; cells washed once with PBS and fixed in 4% 
PFA/PBS and washed as previously described. PBS was removed and cells were washed with 70% 
isopropanol for 10 seconds. Isopropanol was removed and replaced with Oil Red O working solution 
for 30 minutes under gentle agitation. Stain was removed, replaced with 70% isopropanol for 10 
seconds to remove excess stain and replaced with PBS. PBS was removed and cells allowed to air dry. 
Images were taken using a Zeiss A1 Inverted Epifluorescent Microscope and Zeiss Axiovision 4.8 
software. 
Osteogenic Differentiation  
AFSCs cultured following CM collection were allowed to reach 70% confluency and then passaged 
into 24 well plates at 20000 cells/well using Chang C media and allowed to reach 95% confluency. 
Growth media was then removed, cells were washed once with PBS and cultured for 21 days with 
Stem XVivo Osteogenic Base Media supplemented with Stem Pro Osteocyte/Chondrocyte basal 
medium (Life Technologies) according to the supplier’s instructions. Media was changed every 3 days 
without passaging. Differentiation medium was removed; cells washed once with PBS and fixed in 4% 
PFA/PBS and washed as previously described. PBS was removed and replaced with Alizarin Red S 
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working solution for 30 minutes under gentle agitation.  Stain was removed and cells washed once 
with PBS and allowed to air dry. Images were captured using a Zeiss A1 Inverted Epifluorescent 
Microscope and Zeiss Axiovision 4.8 software. 
Chondrogenic Differentiation  
AFSCs cultured following CM collection were allowed to reach 70% confluency before trypsinising 
and collected in a 15 ml falcon tube.  Cells were centrifuged at 300g, supernatant was removed and 
cells were re-suspended in 10 ml growth medium. 1x106 AFSCs were taken and pelleted at 300g for 5 
minutes in a 15ml Falcon tube. Growth medium was removed and replaced with 1ml Stem Pro 
Osteocyte/Chondrocyte basal medium supplemented with StemPro Chondrogenesis supplement 
according to the supplier’s instructions. Cells were centrifuged at 300g for 1 minute and then allowed 
to fall and sediment naturally to the bottom of the tube. Cells were incubated for 37ᵒC, 5% CO2 for 21 
days, changing media every 3 days. Medium was removed, spheroids carefully washed once in PBS 
and fixed in 4% PFA/PBS and washed as previously described.  Chondrogenic cultures were stained 
overnight with Alcian blue working solution at RT in the dark. Spheroids were washed 3 times for 2 
hours in 6:4 ethanol/acetic acid de-stain solution. Pellets were washed once in ddH2O before 
freezing and blocking in OCT. 10µm cryo-sections were taken using a Bright OT5000 cryostat and 
mounted on glass slides with Hydromount. Sections were imaged using a Zeiss Axioskope 
microscope. 
Cellular Proliferation Assay  
hADMSCs were seeded into 96-well culture plates at a density of 400 cells/well and allowed to 
adhere for 24 hours in growth media at 37ᵒC, 5% CO2. Subsequently, media was removed before 
replacing with corresponding treatments. Cells were treated for 48 hours, washed with PBS and fixed 
with 4% PFA/PBS for 15 minutes at RT. Fixative was removed and cells washed three times in PBS. 
Nuclei were stained with DAPI mounting medium and nuclei counted using a Zeiss Axioimager A1 
microscope with an Axiocam digital camera and Zeiss Axiovision 4.8 software. 
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Migration Assay  
ADMSCs were seeded and cultured in a 24 well plate at 40000 cells/well until 100% confluent. Then a 
200ul pipette tip was used to scratch a single uniform line down each well to create an artificial 
wound. Media was removed and cells washed once with PBS to remove cell debris created through 
wound production. PBS was removed and corresponding treatments added. A hole was created in 
the side of the plate using a hot needle enabling the introduction of a 5% CO2 line. Immediately 
after, 3 uniformly spaced and separate image co-ordinates were taken for each well along the scratch 
at a 10X magnification for T=0h. At T=9h images were retaken at exactly the same points as 
characterised previously. Using Fuji Image J software the area of the wound was analysed for T=0 and 
T=9 for each co-ordinate and the difference in wound area determined for wound closure. 
Cellular Senescence Assay  
IMR-90 cells used were between 27-32 population doublings, 50% of the Hayflick limit, and were 
seeded into 12 well plates at 30000cells/well and cultured until 70% confluency at 37°C, 5% CO2. 
Media was removed and replaced with media containing AF-CM and left for 24 hours. Media was 
then removed and cells were washed once with PBS. PBS was removed and cells stressed for 2 hours 
with 100μM H2O2 in serum free media at 37°C, 5% CO2. Media was removed and cells washed twice 
with PBS and replaced with growth media for 48 hours in normal culture conditions.  Cells were 
passaged into 3 wells of a 24-well plate at 800cells/well. After 24 hours, media was removed and 
cells were fixed with 0.2% glutaraldehyde/ 2% PFA for 5 minutes at RT. Fixative was removed and 
cells washed twice in PBS. Cells were incubated with 2.5mg/ml X-Gal solution for 18 hours at 37ᵒC in 
the dark with no additional CO2. Wells were rinsed twice with PBS and then twice with methanol 
before air drying. Cells stained blue were considered senescent and counted to establish the 
percentage of senescent cells using a Zeiss A1 inverted Epi-fluorescent Microscope. 
NF-κB p65 Nuclear Translocation Assay  
U251 cells were cultivated on cell-culture treated cover slips at 4000cells/cm2 for 24h. Media was 
removed and replaced with AF-CM containing media for 24h under normal culture conditions. 
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Treatment was removed and replaced with serum free media for 2 hours. Media was removed and 
cells were exposed to 10 ng/ml of TNF-α containing serum free media with AF-CM for 30 minutes. 
Treatment was removed and cells washed twice with PBS before being fixed in 4% PFA, 15 min, RT. 
Permeabilisation and blocking was carried out as described [24]. NF-κB-p65 was detected by 
immunostaining overnight 4ᵒC with p65 antibody (1:100, sc-8008, Santa Cruz Biotechnology). Primary 
antibody was removed and cells washed 3 times for 5 mins with wash buffer. Wash buffer was 
removed and cells incubated with Alexa fluor 488 goat anti-mouse IgG secondary antibody 
(Molecular probes 1:200) in wash buffer for 1h at RT. Secondary Ab was removed, cells washed 3 
times for 5 minutes and mounted in DAPI mounting medium. Imaging was carried out using Zeiss 
Axioimager Epifluorescence microscope at the same exposure and p65 nuclear pixel intensity was 
measured using ImageJ software. 
NF-κB luciferase gene reporter assays  
U251 NF-κB reporter cells were seeded into 24 well plates at 4000cells/cm2. After 24h cells media 
was removed and replaced with AF-CM containing culture medium for 24h. Pre-treatment was 
removed and cells were treated with 10ng/ml TNF-α or 1μg/ml of ultrapure E.coli LPS containing 
serum free media with AF-CM for 24h.  GFP expression of cells of positive control assays were 
checked to ensure suitable expression. Cells were rinsed with PBS and 100ul of 1X passive lysis buffer 
was then added to each well. Plates were gently shaken for 15 minutes at room temperature before 
lysates were collected into separate tubes. 10μl of each lysate was pipetted into a separate well of a 
white, clear bottom, non-treated 96-well BRAND plate. 40ul of LAR II was quickly added to each well 
before measuring firefly luciferase activity in a Lucy 1 luminometric plate reader (Anthos). 
Uptake of PKH26-stained EVs by IMR-90 cells  
AF-EV (1ml) was diluted in Diluent (1ml - PKH26 Red Fluorescent Cell Linker Kit). PKH26 stain (2μL) 
was diluted in diluent (1ml) as described in the PKH26 Red Fluorescent Cell Linker Kit (Sigma) and 
added to dilute AF-EV for 3 minutes.   BSA/PBS (0.1%, 1ml) was added to the stained AF-EV for 5 
minutes. Stained AF-EV were made up to 8.9ml with sterile ultra-centrifuged PBS and pipetted into a 
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polyallomer centrifuge tube. AF-EV was centrifuged at 100,000g using a 70.1Ti fixed-angle rotor 
(Beckman Coulter) for 18h. Supernatant was carefully removed and discarded. EVs were re-
suspended in ultra-centrifuged PBS (1ml). U251 cells were cultured in a 12 well cell culture plate until 
70% confluency was reached. Media was removed and cells were washed twice with PBS. Cells were 
treated for 3 hours with stained AF-EVs (10%) in serum free media for 3 hours. Cells were washed 
twice with PBS and EV uptake visualised using a Zeiss Axioimager Epifluorescence microscope. 
Intestinal organoid Culture and Isolation 
Complete Medium without growth factors (AdDMEM) containing advanced DMEM/F12, GlutaMax 
(1:100), HEPES (10mM) and pen/strep (1%) was made up in advance. C57BL/6 mice were culled by 
schedule 1 killing as described. A 10cm stretch of small intestine was dissected 1cm below the 
stomach, halved into two 5cm lengths transferred to ice cold PBS in a 10cm dish. Fat was removed 
from the outside of the two portions of small intestine with small scissors. Using a syringe the 
intestines were flushed with cold PBS. A cut was made longitudinally down one side. Villi were gently 
scraped off from the inside of the intestines with a glass microscope slide. Intestines were 
transferred to a 50ml Falcon tube containing 20ml ice cold PBS and briefly vortexed. Intestines were 
transferred to a new 50ml tube and washed repeated 10X, each with fresh PBS. The intestines were 
transferred to fresh 50ml falcon tubes containing 30ml EDTA (2mM) in cold PBS and put on a rotating 
mixer for 30 minutes at 4ᵒC. Intestines were placed into a new 50ml tube containing 30ml cold PBS 
and inverted 5X. Intestines were transferred to a new 50ml tube with 10ml cold PBS and shaken 5X 
to create supernatant 1. Intestines were transferred to a new tube containing 10ml cold PBS and 
shaking repeated as before to create supernatant 2. This process was repeated to create 12X 
separate supernatants for each 5cm length of intestine. A 50ml sample from each supernatant was 
placed on a 10cm petri dish and each checked for crypts. Crypt containing supernatants were pooled 
in 50ml Falcon tubes and filled with cold AdDMEM. Crypts were spun at 200g for 10 min. 
Supernatant was removed carefully and pellet  re-suspended in 5ml cold AdDMEM.  Crypts were 
pipetted onto a 70μm cell strainer over a 50ml tube. Suspension was transferred to a 15ml falcon 
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tube and spun at 300g for 5 min. Supernatant was discarded pellet put on ice. Pellet was re-
suspended in growth factor reduced phenol red free Matrigel (50ul for each intended well). Matrigel-
crypt suspensions were pipetted into a pre-warmed 24-well plate (50μl/well) and incubated for 8-10 
minutes at 37ᵒC 5% CO2 until matrix solidified. To each well 500μl of adDMEM containing freshly 
added N2 Supplement (1:100), B27 Supplement (1:50), N-Acetylcysteine (1μM), Mouse-rEGF 
(50ng/ml), Mouse rNoggin (100ng/ml), human rR-spondin1 (500ng/ml), Valproic acid (1mM) and 
CT99021 (3µM) and incubated at at 37ᵒC 5% CO2 . After 3 days medium was refreshed without the 
addition of Valproic acid and CT99021. 
Passage of Matrigel containing Crypts 
Before starting the tips of glass pipettes were stretched over a naked flame, broken to form a fine 
end and edges smoothed over fire. Waste media was removed from around Matrigel. Cold Cell 
recovery solution (500μl) was pipetted in wells and over Matrigel to break it up. Cell recovery 
solution/Matrigel/Crypt mix from each well was pooled into a 15ml Falcon tube and left for 30 
minutes on ice, occasionally inverting the tube. Crypts were centrifuged at 300g for 3 min.  Waste 
was removed. Crypts were re-suspended in 1ml PBS and with a pre-wetted glass tip pipette the 
crypts pipetted up and down 5-6X to mechanically break them up.  Crypts were centrifuged for 3 
minutes at 300g. Waste supernatant was removed and crypts re-suspended in Matrigel. Crypt 
containing Matrigel was pipetted and media added as previously described into pre-warmed 24-well 
plates. 
Fixing of organoids  
Media was removed from around Matrigel. Organoids and Matrigel were fixed with 500ul of 4% 
PFA/PBS overnight at RT. Fixative was removed and organoids washed three times with PBS as to not 
disturb Matrigel. Agarose gel (2%) made up in PBS was pipetted over Matrigel in each well and 
allowed to set. Agarose was removed with forceps, thus also removing embedded 
Matrigel/organoids, and stored in 70% ethanol until paraffin embedding. 
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Molecular analysis: 
SDS-PAGE: 
Sample protein concentration was established using the BioRad DC protein assay as instructed. The 
volume required for loading a specific number of µg of protein was calculated. Knowing the protein 
concentration of each sample, loading samples were prepared ensuring each contained equal totals 
of protein. 3.4ul of 6X RSTB reducing buffer was added to each sample and then made up to 20ul 
total volume per sample using ultrapure dH2O. Samples were heated to 100ᵒC for 15 minutes using a 
heat block, briefly vortexed and centrifuged for 1 minute at 300g before immediately placing on ice. 
Stamps were taken out of pre-cast 1.0mm NuPAGE 4-12% Bis-Tris gels (Novex by Life Technologies) 
and wells washed with running buffer to remove bubbles. Tape from the base of the gel was 
removed and XCEll SureLock (Novex by Life Technologies) electrophoreses apparatus set up with the 
prepared gel as instructed by the manufacturer. The central chamber was filled with 200ml of 
antioxidant 1X running buffer (check for leaks) and outer chamber with 800ml 1X running buffer. A 
volume, corresponding to the future requirements of the gel as instructed by the manufacturer, of 
protein ladder was loaded into the desired wells. All 20µL of each loading sample was then loaded 
into a well. The apparatus lid and circuit connections were fitted and the electric field applied to 80V 
for the first 15 minutes until samples until dye had passed the stacking gel. The voltage was then 
increased to 120-150V for at least 1h until sample dyes reach the very edge of the gel before the 
electrophoresis was switched off and gel retrieved ( CM samples should be run at 100V due to the 
high salt content). 
Silver staining 
Silver Staining was carried out using the SilverXpress® silver staining kit. Protein bands were imaged 
using a Syngene G:Box and GeneSys software. 
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Western Blotting 
Wet 5 sponges (XCell II Blot module kit – Novex), blot and 4 filter papers (cut equal to size of blot 
equipment) in transfer buffer and methanol (only for the blot paper). Materials were placed in the 
XCell II Blot module in the order from the anode (negative charge): 2 sponges, (complex of 2 filter 
papers), gel, blot, (complex of 2 filter papers), rest of sponges. Bubbles were rolled out carefully and 
the cathode portion of the blot module assembled thus sandwiching materials and it was assembled 
again in the XCELL SureLock tank as instructed by the manufacturer. Blots were run at 30V for 3 
hours. 
Western Blot Staining and visualisation 
Blot was removed and placed in blocking buffer for 40 minutes. Primary Antibody was prepared by 
diluting as required in blocking buffer. The blot was cut as desired and placed into 50ml falcon with 
3ml primary antibody containing blocking buffer to be left overnight on a rotator at 4ᵒC. Blots were 
washed three times with PBS-T (5 minute/wash). The 2nd Antibody was diluted in blocking buffer 
and 3ml pipetted into the blot containing 50ml falcon for 40 minutes on a rotator at room 
temperature. Washes in PBS-T were repeated 3 times. The blot was placed on a black imaging tray 
and 500µl of a 1:1 solution Amersham ECL prime western blotting detection reagent kit was pipetted 
on and a clear plastic film was placed over the top to ensure a uniform spread before imaging in an 
ImageQuant LAS 4000 mini and corresponding software. 
Real Time- Quantitative Polymerase Chain Reaction 
Organoid RNA was collected using buffer RLT lysis buffer (Qiagen, RNeasy mini kit) and transferred to 
1.5 mL microfuge tubes. Total RNA was isolated and purified following the protocol included in the 
RNeasy Mini Kit (Qiagen-74104) and RNase-Free DNase set (Qiagen-79254).  The Nanodrop 2000 
(Thermo Scientific) was used to quantify RNA concentrations. 
Sample RNA concentrations were normalised to the sample with the lowest total RNA content using 
nuclease free water up to a total volume of 11μl. Oligo(dT)18 primers (1μl) were added to each 
sample totalling 12μl. 5x reaction buffer (4μl), RiboLock RNase inhibitor (1μl), 10mM dNTP mix (2μl) 
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and RevertAid H minus MULV Reverse Transcriptase (1μl) were added to each sample respectively. 
Samples were gently mixed and briefly centrifuged. Samples were incubated at 42ᵒC for 60 minutes. 
The reaction was terminated by heating samples at 70ᵒC for 5 Minutes. Samples were incubated at 
65ᵒC for 5 mins, chilled on ice and briefly centrifuged. cDNA samples were analysed for quantitative 
real-time RT-PCR on a StepOnePlus™ Real-Time PCR system using the Applied Biosystems SYBR Green 
PCR Master Mix (Applied Biosystems 4309155) and StepOne software v.2.1.  Primers were designed 
using the primer designing tool on the NCBI website. Primer efficiencies were quantified from serial 
dilutions made with nuclease free water and mixture of all sample. A standard curve was created to 
identify an R value and equation for the line of best fit. Individual sample quantification was carried 
out using a 1:20 sample dilution. Reactions were carried out using SYBR® Green PCR master mix.  All 
data were normalised to Hypoxanthine Phosphoribosyltransferase 1 (HPRT) and Cyclo expression. 
Sample preparation for Mass Spectrometry (MS) 
AF-EV and non-EV fraction isolated from AFSCs secretome were obtained as described above. 
Proteins were suspended in SDS-PAGE loading buffer 1x (NuPAGE, Invitrogen, Darmstadt, Germany), 
denaturated and reduced with 1 mM DTT for 10 minutes at 95°C then, alkylated using 5.5 mM 
iodoacetamide for 30 minutes at 25°C in the dark. Proteins were resolved by SDS-PAGE using 4-12% 
Bis-Tris mini gradient gels (NuPAGE, Life Technologies). Each lane was cut into 10 equal slices, 
proteins therein were in-gel digested with trypsin (Promega). Peptides were extracted, purified by 
STAGE tips, dried to less than 5µl and re-suspended in 15 µl of 0.5% acetic acid for the MS analysis.  
Mass Spectrometry Analysis  
LTQ Orbitrap XL mass spectrometers (Thermo Fisher Scientific) coupled to an Agilent 1200 nanoflow-
HPLC (Agilent Technologies GmbH) were used to measure peptides derived from trypsin digestion. 
Samples, applied directly onto self-packed HPLC-column tips of around 20 cm, were subjected to a 
gradient formed by solution A (0.5% acetic acid in LC-MS  grade water) and by increasing organic 
proportion of solution B (0.5% acetic acid in 80% LC–MS grade ACN in water) within 120 minutes 
[25]. MaxQuant software version 1.4.1.2 was used to identify proteins based on peptides and to 
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perform label-free quantification [26]. Both mass spectrometry and MaxQuant parameters were set 
as previously described [27]. The analysis of Molecular Function GO terms was performed trough 
Perseus software version 1.5.8.5 using Fisher’s exact test with a p-value threshold of 0.02 [28]. 
miRNA Array and analysis  
GeneChip® miRNA 4.0 Arrays were used to analyze the miRNA content of AF-EVs using FlashTag™ 
Biotin HSR RNA Labeling Kits according to the manufacturer´s instructions. 
Probe cell intensity data (CEL) from Affymetrix GeneChip miRNA 4.0 Arrays were analyzed in the 
Affymetrix Expression Console™ software. Normalization was performed using the Robust Multichip 
Analysis (RMA) + DABG algorithm [29]. Only miRNAs calculated as present in all 3 samples were 
declared as generally expressed after 24 hours. Focus was given to the miRNAs present with the 
highest signal intensities (top 50). For these top 50 miRNAs validated target mRNAs were 
amalgamated using miRWalk2.0 software [30]. In the next step, GO Slim classification for biological 
process was performed using WebGestalt software to provide a high-level functional classification for 
validated target mRNAs [31]. Morpheus software was used to design the Heat-map showing intensity 
variability between biological replica (n=3) for the top 50. 
Transmission Electron Microscopy  
For TEM extracellular vesicle pellets were re-suspended in 40 µl of 0.1M PBS. Drops of the 
suspensions were placed on parafilm. Carbon-coated copper meshed grids (Plano, Germany) were 
placed on the drops for 5 minutes for probe adsorption. After five minutes of fixation on drops of 1% 
glutaraldehyde (Roth, Germany) grids were washed 4 times for 30 seconds and negative contrasted 
using 1% uranyl acetate. Grids were air dried and analysed using a Zeiss 906 transmission microscope 
(Zeiss, Germany). 
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In-Vivo experimentation: 
In Vivo Cardiotoxin induced Mouse TA Injury and AFSC CM/EV Treatment  
C57BL/6 mice (12 week old) were placed under general anaesthetic using isoflurane. Mice were tail 
vein injected with 100μL either hAFSC CM, hAFSC EV or ultra-centrifuged PBS. After 30 minutes, hind 
limb fur was shaved and then the exposed skin sprayed with 70% ethanol. TA muscles located on the 
anterior-medial surface were chosen for their anatomical location allowing ease of injection. Three 
separate IM injections of 10µl 50mg/ml Naja pallida cardiotoxin (CTX) were carried out in the right 
TA muscle of the mice, one injection in the distal portion and one either side of the muscle situated 
proximally. This same procedure was repeated with a vehicle (PBS) in the left hind limb. Mice were 
left 5 days to recover before culling. Muscle was collected and frozen on frozen isopentane.  
Dissection of Tibialis anterior (TA): 
Mice were culled by schedule 1 killing as described. Once death was confirmed animals were 
weighed. Hind limbs were shaved fully and cleaned with 70% ethanol. TA muscles were taken from 
the hind limb following a circular incision around the proximal end of the thigh through the skin using 
a sterile scalpel blade. The TA was then exposed by pulling isolated skin distally towards and over the 
ankle joint. Slicing down the foot plate allowed skin to be fully removed exposing further the foot 
and tendons. Insertion of forceps between the EDL and TA distal tendons allowed the removal of the 
fascia covering the TA by drawing it up towards the knee. The distal tendon, situated above the tarsal 
and metatarsal bone, was cut. Holding the cut distal tendon, the TA was pulled proximally to the 
tibial tuberosity. Cutting the muscle at the proximal end allowed the muscle to be freely transferred 
immediately into PBS. 
Preparation of Muscles for Cryo-sectioning: 
TA muscles were transferred from PBS onto aluminium foil anterior side down, which was then 
placed on frozen isopentane allowing them to snap-freeze. Muscles were then transferred to pre-
cooled Eppendorfs for storage at -80ᵒC using dry ice pre-cooled forceps.  Tissue-TEK® Optimal Cutting 
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temperature compound (OCT) (PST) was used to fill aluminium foil wells. OCT containing wells were 
then placed into dry ice super cooled in 100% ethanol allowing OCT to freeze. As quick as possible 
frozen muscles were placed into the OCT as it began to freeze. OCT was then used to cover the 
muscle and allowed to freeze as one continual process. OCT-muscle blocks were stored at -80ᵒC 
ready for cryo-sectioning. Blocks were mounted on pre-cooled chucks in a cryo-sectioning chamber (-
20ᵒC) (Bright 5040 Cryostat) using OCT. Sections of 12µm were cut from the mid-region of the muscle 
and transferred to poly-L-lysine coated slides. After 1 hour at room temperature sections on slides 
were stored at -80ᵒC or directly used for analytical staining.  
 
Histology: 
Paraffin embedding and processing: 
Agarose/Matrigel/organoid complex was placed into an embedding/processing cassette and 
transferred to the following solutions in the designated order: 
•         70% Ethanol – 1h 
•         70% Ethanol – 1h 
•         80% Ethanol – 1h 
•         95% Ethanol – 1h 
•         95% Ethanol – 1h 
•         100% Ethanol – 1h 
•         100% Ethanol – 1h 
•         100% Ethanol – 1h 
•         Xylene – 2h 
•         Xylene – 2h 
•         Paraffin – 2h 
•         Paraffin – 2h 
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 Paraffin permeated agarose/organoids were placed in plastic moulds and embedded in paraffin 
before allowing to cool on ice until solid. Sections were cut (5μm thick) using a Leica RN 2155 
microtome and floated in a water bath at 37ᵒC so that they could be floated onto a positively 
charged glass slide. Sections were allowed to dry at 45ᵒC overnight. 
De-paraffinisation and rehydration: 
Section perimeters were marked with a diamond tip pen showing organoids location before de-
paraffinization. Sections were placed in the following solutions in the designated order: 
• Xyline – 5mins 
• Xyline – 5mins 
• Xyline – 5mins 
• Xyline – 5mins 
• 99% EtOH – 5 min 
• 99% EtOH – 5 min 
• Ethanol series (few seconds each) 99%, 96%, 70%, 50%  
• ddH2O (2X 5 min) 
Antigen retrieval 
Slides were placed in a plastic box and covered with citrate buffer (10mM pH6). Slides were boiled 
for 4-5 minutes (maximum wattage) in a microwave. Slides were boiled at 600 Watt for 8 minutes 
before adding the remaining buffer and repeating for another 8 minutes. Slides were allowed to cool 
for 25 minutes before continuing with immuno-histology protocol. 
Haematoxylin and Eosin staining 
Following 10 minutes of drying sectioned slides were washed for 2 minutes in PBS then placed in 
Mayers Haematoxylin for 18 minutes. Slides were then washed with distilled water for 2 minutes 
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before immersing slides in acidic alcohol (0.1% HCL) and then rinsing with running tap water for 5 
minutes. For 2 minutes slides were submerged in Eosin stain and then washed in 70% ethanol for 1 
minute, 90% ethanol for 2 minutes and 100% ethanol three times for 2 minutes. Sections were then 
washed twice in xylene for 3 minutes and then immediately mounted and cover-slipped using DPX 
medium. 
Acid phosphatase staining 
Frozen sections were washed three times with PBS (5 minutes/wash) to remove OCT. 150ul-200ul of 
acid phosphatase staining solution was pipetted/slide onto sections. Sections were incubated at 37ᵒC 
(no additional CO2) for 90 minutes or until desired staining was reached. Sections were washed three 
times with dH2O. Sections were then incubated with Mayers haematoxylin solution (1:30 dilution in 
dH2O) for 1 minute. Sections were then rinsed with dH2O and then placed in a slide bath in order to 
run tap water over them for 3-5 minutes. Sections were then rinsed with dH2O before mounting with 
hydro-mount and covering with a glass cover-slip. 
Immuno-histochemical staining 
Sectioned slides were allowed to dry for 10 minutes before an ImmEdge Hydrophobic barrier pen 
(Vector) was used to draw around sections to reduce the amount of antibodies and solutions used.  
Sections were washed twice for 5 minutes with PBS to remove surrounding OCT, which was then 
poured off and replaced with permeabilisation buffer for 15 minutes. Permeabilisation buffer was 
washed off with three 5 minute PBS washes. Incubation of sections for 30 minute in wash buffer was 
then used to block non-specific antibody binding. Whilst incubating in wash buffer, primary 
antibodies were diluted in wash buffer and then used to incubate sections overnight at 4ᵒC or 1 hour 
at room temperature. Primary antibody was then removed with 5 washes of wash buffer. 
Corresponding Alexa Fluor 488 or 594 secondary antibodies were diluted and then sections 
incubated in them for 45 minutes in the dark. Another 3 washes in wash buffer was repeated and the 
sections mounted with 2.5µg/ml DAPI and then cover slipped for visualisation. 
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Pearson’s co-localisation statistical test 
Images were opened in Image J Fiji and colour channels split. The Analyse tab was selected, followed 
by the subsequent co-localisation option and then Coloc 2. Channel colours of interest were slected 
in the drop down selection menu before running the test. The Pearsons R value was taken as a 
measure of co-localisation between the two channels.  
Statistics  
Experiments were repeated in triplicate unless otherwise stated. Statistical analysis was performed 
using GraphPad Prism software. Data analysed between multiple groups was tested using one-way 
ANOVA followed by Tukey’s post-hoc testing. For comparison between two groups, independent 
sample t-tests were completed. Significance values were always set at the 95% confidence interval. 
All p values were indicated as p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). All data are displayed as 
mean ± SEM. 
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3. Chapter 3  
Characterisation of Amniotic Fluid Stem Cell 
Conditioned Media 
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Introduction 
The enthusiasm surrounding the use of stem cells for regenerative therapy, especially MSCs has 
stemmed from an ability to differentiate into a number of different cell types. Originally found to 
differentiate down osteogenic and chondrogenic lineages, these cells were proposed to be able to 
replace lost or damaged tissues following their differentiation into a desired cell type (Caplan, 1991). 
Following these discoveries and others, which exhibited the differentiation potential and potency of 
other MSCs such as umbilical cord MSCs, BM-MSCs and AFSCs, research into their use for 
regenerative therapy increased (Honmou et al., 2011, Rodrigues et al., 2017, Piccoli et al., 2012, Zani 
et al., 2014). The characteristics which are used to define and select for MSCs prior to use have been 
outlined in ‘The International Society for Cellular Therapy’ position statement. Minimal criteria for 
classification of a MSC include being plastic-adherent when sustained in standard culture conditions 
(Lv et al., 2014, Dominici et al., 2006). Secondly, relating to surface markers, MSCs must express 
markers such as CD73, CD105, CD-44 and CD90, but lack expression of CD45, CD34, CD14, CD11b, 
CD79alpha, CD19 and/or HLA-DR (Lv et al., 2014, Dominici et al., 2006). Furthermore, an MSC must 
be proven in vitro to differentiate into osteogenic, adipogenic and chondrogenic cells (Dominici et al., 
2006, Lv et al., 2014). CD73, an ecto-5’-nucleotidase and CD90, also known as Thy1, are known to 
mediate the transduction of signals within immune cells but also provide cell-cell and cell-
extracellular matrix interactions (Barker and Hagood, 2009, Hunsucker et al., 2005). CD105, also 
known as Endoglin, binds to the TGF-β family of receptors and is also known to interact with Activin 
and therefore has an important role in regulating differentiation and growth of cells (Barbara et al., 
1999). CD105 has been classically used as a marker of MSCs, however it has recently been shown to 
vary in expression between MSCs of which some do not express this marker at all (Mark et al., 2013, 
Barbara et al., 1999, Anderson et al., 2013). CD 44, a cell-cell interacting glycoprotein has also been 
identified as a marker of stem cells, it’s function is believed to provide many known stem cell 
properties including resistance to stress, such as hypoxia (Zöller, 2015).  However, it is understood 
that phenotypic profiles of MSCs, as with most cells, vary depending on the environment in which 
they exist (Pozzobon et al., 2014, Bussolati et al., 2012, Lv et al., 2014). 
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The application of AFSCs for regenerative therapy has become a focus for a number of researchers 
(Prusa and Hengstschlager, 2002, Moorefield et al., 2011a, Piccoli et al., 2012, Ramachandra et al., 
2014, Zani et al., 2014, Mellows et al., 2017). AFSCs are isolated from AF and therefore inherently 
originate from an early developmental time-frame compared to their adult MSC counterparts (De 
Coppi et al., 2007). CD117 is used to select for the AFSCs following isolation from AF (Di Trapani et al., 
2015, Pozzobon et al., 2014, Zani et al., 2014). CD117, otherwise known as C-kit, is a surface tyrosine 
kinase receptor which binds to ‘stem cell factor’. Due to their foetal origins, AFSCs are hypothesised 
to be more comparable to embryonic stem cells, which are believed to be the gold standard in stem 
cell research (De Coppi et al., 2007). Furthermore, the ability to isolate the AFSCs with little ethical 
constraint from second trimester AF makes them a strong candidate for therapeutic purposes. 
However, the use of whole AFSC and other MSCs for therapeutic research has led to the conclusion 
that the regenerative capabilities of the MSCs mainly reside in the paracrine factors that they secrete 
into the environment (Shabbir et al., 2010, Zani et al., 2014, Mellows et al., 2017). 
Paracrine factors secreted by stem cells have been reported to consist of a variety of cellular 
products ranging from growth factors to RNA based transcripts (Waszak et al., 2012, Robinson et al., 
2014, Balbi et al., Gnecchi et al., 2005, Gnecchi et al., 2016, Mellows et al., 2017). Furthermore, 
collection of the MSC paracrine factors and then introducing them to an area of significant pathology 
may provide a more efficient form of therapy compared to the whole stem cell alone. Introduction of 
whole stem cells has shown that few survive to graft and differentiate to replace lost tissue due to 
host rejection (Ikegame et al., 2014). Rejection not only reduces the efficacy of the population of 
MSCs but may also cause an unwanted and damaging cytokine response. Injected MSCs, such as 
AFSCs, find themselves in other organs like the lungs and spleen as opposed to the tissue of interest 
(Zani et al., 2014, Ikegame et al., 2014). Therefore injection of the paracrine factors collected in CM 
to the site of interest would deliver a more targeted and efficient approach without the risk of 
immune rejection.  
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Protocols developed by our industrial collaborators led to the development of a method consisting of 
pelleting cells, here in particular AFSCs, in PBS with the aim of collecting an AF-CM free of serum and 
therefore making them clinically compliant. Pelleting of the cells is hypothesised to create a hypoxic 
environment in which cell-cell contact is also amplified due to the increased cell density (Balbi et al., 
Roemeling-van Rhijn et al., 2013). Along with the lack of nutrients, brought about by the use of PBS 
and lack of normal culture medium, it is believed that the AFSCs experience a high level of cellular 
stress. Heightened levels of stress are also known to increase the exosome release from cells. 
Therefore, the collection of CM from AFSCs under these conditions is proposed to contain higher 
levels of exosomes and other EVs, which are imbued with cyto-protective properties (Lee et al., 
2012a, Balbi et al., Yu et al., 2006).  Additionally, the literature surrounding the stress responses of 
cells and their resultant exosome release would also suggest that the method of CM collection used 
for this study may increase protein concentrations which could further change with increased stress 
exposure (Waszak et al., 2012, Yu et al., 2006). 
Furthermore, the exact nature of the paracrine factors released from each type of MSC will most 
likely vary. An extensive characterisation of AFSCs and more specifically under the stated CM 
collection protocol has not been previously carried out. Techniques such as silver staining of SDS-
PAGE gels run with samples of AFSC CM provide a sensitive means of detecting protein in the CM at 
ng concentrations, unlike staining techniques such as Coomassie, but also enable further processing 
of proteins within the gel such as mass spectrometry. However, pooling conclusions from the 
literature surrounding AFSC paracrine factors would suggest that it is likely that CM produced from 
AFSC will have a multitude of proteins and RNA species likely to have advantageous properties 
(Savickiene et al., 2015, Liang et al., 2014, Zani et al., 2014, Lo Sicco et al., 2017, Ti et al., 2015, 
Collino et al., 2010). Work here aims to establish whether the AFSCs used to create AF-CM are indeed 
MSCs and therefore differentiate down the described lineages as well as expressing correct levels of 
MSC markers. Additionally, the nature of any EVs are hoped to be elucidated along with their protein 
and RNA based cargo. Any proteins and RNA identified will aid the clarification of any signalling 
processes that the AF-CM may modify or effect in target cells. 
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Results 
Flow Cytometric Analysis of AFSCs Before and After AF-CM Collection 
To ensure the AFSCs used to collect AF-CM are MSCs, the expression of surface markers identifiable 
as MSC markers must be confirmed. Further to this, a lack of surface markers not attributable to 
mesenchymal stem cells must be proven. Flow cytometry analysis of AFSCs was therefore carried out 
for positive (CD-44, CD-73, CD-90) and negative (CD-45 and CD34) mesenchymal stem cell markers 
(Figure 3.1. A-E). All AFSCs expressed the cell surface glycoprotein CD-44, whilst most (98.2%) 
expressed CD-73. The majority of cells were positive (64.6%) for CD-90.  Fewer than 10% expressed 
CD-34 and fewer than 5% expressed CD-45. 
Collection of CM is designed to induce stress in the pelleted AFSCs. We established the CD profile of 
cells after the period of induced stress. Expression of CD-44 and CD-73 on AFSCs after CM collection 
dropped very marginally to 97.5% and 92.7% respectively. CD-90 expression of AFSCs post-CM 
generation was found in 42.7% of cells. Furthermore a reduction of over 99.9% and 94% of AFSCs 
were shown to be negative for CD-45 and CD-34 respectively. 
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Figure 3.1 
 Chapter 3 
Page | 83  
 
Figure 3.1: Surface marker expression analysis of AFSCs before and after CM collection. Flow 
cytometry analysis of AFSCs before CM collection for (A) CD44, (B) CD-73, (C) CD-90, (D) CD-45) and 
(E) CD-34. Flow cytometry analysis of AFSCs after CM collection for (A) CD44, (B) CD-73, (C) CD-90, 
(D) CD-45) and (E) CD-34.  
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Differentiation of AFSCs Post AF-CM Collection 
A key characteristic of mesenchymal stem cells is that they can differentiate into a variety of cell 
types. AFSCs not only successfully survived the CM collection protocol but were able to proliferate 
once returned to normal culture conditions. AFSCs in differentiating conditions after CM collection 
underwent adipogenesis, osteogenesis and Chondrogenesis (Figure 3.2.A-C’). 
 
AF-EV Size Distribution 
It is well known that the environment in which the cell exists influences the type of EV secreted. TEM 
images of the AF-CM were taken in order to identify the type of EV being secreted into the AF-CM 
(Figure 3.3.A).  The average AF-EV diameter was 97.8±4.9 and therefore lay within the known 
boundaries of exosome size. Size distribution of AF-EVs also suggested that the majority consisted of 
exosomes, with over 92% being under 150nm in diameter. Although low, the presence of larger EVs 
suggested that other EV species were present within the AF-CM. 
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Figure 3.2: Multipotency of post-CM generated AFSCs. AFSCs cultured in (A’) adipogenic, (B’) 
osteogenic and (C’) chondrogenic media. (A, B) scale bar equal to 50µm,  (C) equal to 100μm. 
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Figure 3.3: Characterisation of AF-EV type and size (N=3). (A) TEM images of AF-EVs. (B) AF-EV size 
distribution from TEM images. 
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Basic Protein and Nucleic Acid Analysis of AF-CM 
Collection of AF-CM was carried out every 24 hours over a 72 hour period thus providing three 
fractions, T24, T48 and T72. Basic analysis of secretome composition was carried out to determine 
the protein and nucleic acid concentrations within each fraction.  Nucleic acid concentrations 
between T24, T48 and T72 AF-CM samples did not differ significantly (Figure 3.4.A) with an average 
of 21.93ng/μl ± 2.23 (n=4), 14.88ng/μl ± 1.23 (n=4) and 19.93ng/μl ± 3.88 (n=4) at 24, 48 and 72 
hours respectively. Average protein concentration of AF-CM (Figure 3.4.B) were 834.25μg/ml ± 72.73 
(n=3) and 889.25μg/ml ± 162.62 (n=3) at T24 and T48 respectively. However, both had significantly 
higher protein concentrations compared to that of AF-CM collected at T72 (241.75μg/ml ± 5.20 (n=3, 
P<0.05)). Silver staining of proteins within AF-CM fractions was carried out to compare their size 
profiles. Comparison of T24, T48 and T72 silver staining profiles suggested that fractions did not 
differ in protein composition (Figure 3.4.C). However, differences in protein band intensities between 
each fraction were discernible. T24 AF-CM containing bands with higher intensities compared to T48 
and T72.  Differences in silver staining profiles were also compared between T24 AF-CM and its 
constitutive AF-EV fraction (Figure 3.4.D). Silver stain comparisons between whole AF-CM and AF-EV 
suggested that a lot of the protein in the AF-CM was to be located in the subsequent soluble 
fractions as opposed to the AF-EV. The AF-EV silver stain profile also showed that the majority of the 
proteins in the 40-50KDa range.  
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Figure 3.4: Basic protein and nucleic acid content characterisation of AF-CM fractions. (n=3) (A) 
Nucleic acid concentrations of AF-CM taken at 24 hours (T24), 48 hours (T48) and 72 hours (T72). (B) 
Protein concentrations of AF-CM taken at T24, T48 and T72.  (C) Silver staining of AF-CM taken at 
T24, T48 and T72. (D) Silver staining of T24 AF-CM vs T24 AF-EV. L, Ladder.  
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Mass Spectrometry Analysis of AF-CM Protein Content 
Mass spectrometry was performed in order to identify protein species and compare any differences 
in the species of protein contained within the AF-EV and the soluble fraction. A total of 856 proteins 
were identified between the AF-EV and soluble fraction (Figure 3.5.A). In addition to this, 416 of 
these protein species were found in both fractions. However, many of the proteins (190) were found 
to be specific to the AF-EV fraction and even more (250) specific to the soluble fraction. This stark 
contrast in protein distribution is illustrated in the heat map (Figure 3.5.B) which shows that some 
proteins found in the AF-EV are of a high concentration whilst they are low in the soluble fraction 
and vice versa. Gene ontology molecular function terms (GOMF) describe the ability of the proteins 
found and therefore reveals how the proteins could interact with target cells following a treatment 
with AF-CM. Although proteins were found to be enriched in the different AF-CM fractions, many 
potentiated the functioning of shared cellular processes (Table 3.1.) and therefore were identified 
under GOMFs including many global RNA metabolic processes such as the metabolic processing of 
tRNA and ncRNA.  In contrast, many of the proteins found solely in the soluble or AF-EV fraction were 
shown to be involved in distinctly different cellular processes. Proteins highly enriched within the 
soluble fraction (Table 3.2.) were involved in processes such as translational initiation and its 
regulation. Proteins enriched within the AF-EV fraction only were shown to be implicated in 
pathways constructive of viral transcription and membrane targeting. A large number of heat-shock 
protein (HSP) species were found within the AF-CM. Similarly to other proteins found, some of the 
HSPs were found only within the AF-EV and not the soluble fraction, specifically HSPA (70KDa)-4L. 
Other HSPs were found specifically within the AF-CM soluble fraction such as the mitochondrial 
60KDa heat shock protein (HSPD-1).  HSP species were also found to be conserved across both 
fractions and included HSPA-6 protein. In addition, other proteins of interest present within the AF-
CM include CD63, HSP70, HSP90, ACTB, GAPDH, 14-3-3 protein zeta/delta (YWHAZ) and the ‘Alarmin’ 
protein HMGB1. Further to this, the AF-EV fraction was found to contain the A2B1 ribonucleoprotein 
although no member of the RNA-induced silencing complex (RISC) associated proteins were found 
either the AF-EV or soluble fraction. 
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Much of the literature surrounding EVs has suggested that they may retain receptors on their 
membrane that enable specific targeting to cellular membranes (Montecalvo et al., 2012, 
Mathivanan et al., 2010, Wiklander et al., 2015, Mulcahy et al., 2014). Many proteins within the AF-
EV fraction were found to be enriched towards processes commonly known to aid viral infectious 
cycles. At the individual protein level it was found that transmembrane transporters and receptors 
were enriched within the AF-EV (Figure 3C), including ABCE1, ABCF1, ABR, AP2A1, CYFIP1, CYFIP2, 
DNM1, DNM2, DNM3, HDAC2, HDAC1, HK1, MAPK1, NCKAP1, PPP1CB, ROCK2, RTN4, STRAP, USP9X, 
USP9Y and XPO1. 
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Figure 3.5 
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Figure 3.5: Mass spectrometry analysis of AF-CMs soluble and EV fraction. (A) Comparison of the 
number of unique and shared proteins between the AF-soluble and AF-EV fractions. (B) Heat map of 
the GO terms found within the AF-EV and AF-soluble fraction. (C) GO terms of transmembrane 
transporters and receptors enriched within the AF-EV. GO, gene ontology. 
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Category value Selection size Category size 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
nucleic acid metabolic process 112 126 2,5057 2,66E-33 8,10E-27 
RNA metabolic process 112 105 2,6531 2,88E-30 4,38E-24 
metabolic process 192 297 1,3423 9,33E-28 9,46E-22 
proteolysis 32 42 8,3571 8,10E-27 4,92E-21 
Aminoacyl-tRNA biosynthesis 13 13 32 6,73E-25 8,87E-20 
proteolysis 21 42 9,9048 4,58E-24 9,29E-19 
small molecule metabolic process 192 112 1,8571 5,27E-24 1,00E-18 
tRNA metabolic process 13 14 29,714 9,43E-24 1,51E-18 
nucleobase-containing compound 
metabolic process 112 159 2,0323 1,03E-23 1,56E-18 
ribonucleoprotein complex 78 58 3,8621 3,95E-23 1,74E-17 
regulation of gene expression 112 107 2,3605 1,74E-21 2,52E-16 
cytoskeleton 49 81 3,9829 1,24E-21 2,73E-16 
nucleic acid metabolic process 48 126 3,0265 2,17E-21 3,00E-16 
ncRNA metabolic process 13 18 23,111 5,77E-21 7,02E-16 
primary metabolic process 192 279 1,3357 6,13E-21 7,17E-16 
regulation of RNA metabolic 
process 112 78 2,619 1,05E-19 1,18E-14 
RNA processing 78 42 4,1905 1,85E-19 2,01E-14 
regulation of catalytic activity 29 62 5,7842 2,53E-19 2,66E-14 
nitrogen compound metabolic 
process 112 183 1,8064 3,14E-19 3,19E-14 
cellular nitrogen compound 
metabolic process 112 180 1,8159 4,90E-19 4,81E-14 
regulation of RNA metabolic 
process 48 78 3,8889 6,94E-19 6,59E-14 
mRNA metabolic process 78 46 3,942 1,33E-18 1,23E-13 
RNA processing 112 42 3,2721 1,44E-18 1,29E-13 
mRNA metabolic process 112 46 3,1491 2,33E-18 2,02E-13 
 
Table 3.1: Soluble and Extracellular Vesicles GOMF terms enrichment. 
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Category value Selection  Category 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
translational initiation 13 12 17,628 1,94E-16 3,05E-10 
regulation of translational initiation 13 10 19,231 1,31E-15 1,02E-09 
translational initiation 15 12 15,278 3,37E-15 1,76E-09 
regulation of gene expression 46 63 2,9331 4,56E-15 1,79E-09 
regulation of translational initiation 15 10 16,667 1,37E-14 3,07E-09 
regulation of macromolecule biosynthetic 
process 46 53 3,1788 1,21E-14 3,16E-09 
regulation of cellular macromolecule 
biosynthetic process 46 53 3,1788 1,21E-14 3,79E-09 
regulation of cellular biosynthetic process 46 55 3,0632 5,54E-14 9,66E-09 
regulation of biosynthetic process 46 55 3,0632 5,54E-14 1,09E-08 
nucleic acid metabolic process 23 47 4,6253 6,93E-14 1,09E-08 
translational initiation 26 12 9,6154 1,01E-13 1,33E-08 
regulation of translation 15 14 13,095 9,88E-14 1,41E-08 
regulation of transcription, DNA-dependent 23 38 5,1487 5,90E-13 7,12E-08 
translation 13 10 17,308 7,74E-13 8,67E-08 
regulation of translation 13 14 13,736 1,24E-12 1,30E-07 
 
Table 3.2: Soluble only GOMF terms enrichment. 
Category value Selection Category 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
Ribosome 28 28 6,7857 3,87E-34 2,17E-29 
viral transcription 28 28 6,7857 3,87E-34 8,96E-29 
translational termination 28 28 6,7857 3,87E-34 1,20E-28 
protein complex disassembly 28 28 6,7857 3,87E-34 1,79E-28 
cellular protein complex disassembly 28 28 6,7857 3,87E-34 3,58E-28 
viral reproductive process 28 29 6,5517 1,12E-32 1,16E-27 
viral infectious cycle 28 29 6,5517 1,12E-32 1,30E-27 
translational elongation 28 29 6,5517 1,12E-32 1,49E-27 
macromolecular complex disassembly 28 29 6,5517 1,12E-32 1,73E-27 
cellular macromolecular complex disassembly 28 29 6,5517 1,12E-32 2,08E-27 
SRP-dependent cotranslational protein 
targeting to membrane 28 30 6,3333 1,68E-31 1,04E-26 
protein targeting to membrane 28 30 6,3333 1,68E-31 1,11E-26 
protein targeting to ER 28 30 6,3333 1,68E-31 1,20E-26 
nuclear-transcribed mRNA catabolic process 28 30 6,3333 1,68E-31 1,30E-26 
establishment of protein localization in 
endoplasmic reticulum 28 30 6,3333 1,68E-31 1,42E-26 
 
Table 3.3: Extracellular Vesicles only GOMF terms enrichment 
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AF-CM RNA Content 
EVs are able to alter target cell signalling through the activity of RNA molecules (Lotvall and Valadi, 
2007, Ratajczak et al., 2006, Valadi et al., 2007, Villarroya-Beltri et al., 2013). Bioanalyser RNA 
profiling of the AF-EV collected at T24 was therefore carried out (Figure 3.6.A). Evidently the RNA 
species found within the AF-EV consisted almost entirely of small species about 21-25 nucleotides in 
length. Due to the size of the RNA species found within the AF-EV further analysis was carried out 
into to specific miRNA species present. Through detailed analysis of the miRNA species, 586 species 
of miRNA were identified. 21399 pathway targets were found from the miRNA species identified 
(Figure 3.6.C). Metabolic processing was found to be how most of the miRNAs were known to 
influence signalling pathways. More precisely, 21.87% of miRNAs found were known to be involved 
in responding to stress and 10.2% in immune system processes. A list of top 50 miRNAs present 
within all 3 batches of AF-EV used was compiled (Figure 3.6.B). Many of the miRNAs within the top 50 
identified are believed to support proliferation, migration, differentiation, angiogenesis and 
autophagy for example miR3960, miR24-3p and miR382 (Seok et al., 2014, Yu et al., 2017, Xia et al., 
2015). Inhibition of apoptosis is known to be achieved with miR3196, miR125b-5p, miR1273-3p and 
miR762 also found to be present within AF-EV (Xu et al., 2016, Ma et al., 2016, Yang et al., 2016, Niu 
et al., 2016). Similarly present was miRNA Let-7b-5p recognised as retaining anti-inflammatory 
properties (Ti et al., 2015, Landskroner-Eiger et al., 2013). On the other hand, other miRNAs present 
such as miR-1273g-3p have been known to induce injury via inhibited proliferation facilitated by 
acute glucose fluctuation (Guo et al., 2016). 
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Figure 3.6: RNA profiling of T24 AF-EV. (A) Bioanalyzer profile of AF-EV RNA size (s) and frequency 
(FU). (B) Top 50 expressed miRNAs in AF-EV (n=3). (C) General cell process targets of miRNA found 
within AF-EV. (D) Specific cellular processes targeted by miRNA present within AF-EV. 
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Discussion 
Ensuring MSC Characteristics of AFSCs 
Much controversy surrounds the use of stem cells for therapy. One aspect of this debate is the 
validation of the stem cell nature of the cell in question. It is now recognised that a number of 
cellular membrane expressed markers can be used to identify a mesenchymal stem cell. It was 
therefore important that the AFSCs used to generate CM were characterised according to guidelines 
published (Lv et al., 2014, Dominici et al., 2006). The initial isolation of AFSCs involved culturing them 
on non-tissue culture treated plastic is a characteristic attributable to stem cells. Furthermore, the 
collection of CD-117+ (C-Kit) cells via MACS sorting isolated a population of cells previously 
characterised as AFSCs (De Coppi et al., 2007). Finally, flow cytometric characterisation of the cell 
membrane markers clearly showed that most cells expressed the positive MSC markers; CD-44, CD-
73 and CD-90 (Figure 3.1.A-C). AFSCs also expressed low levels of CD-45 and CD-34 (Figure 3.1.D-E).  
In summary of these expression profiles, the AFSCs expressed markers of MSCs and very low levels of 
markers believed to be negatively expressed in MSCs. However, the levels of CD-45 and especially 
CD-34 were not completely absent and the level of CD-90 was not expressed in 100% of the 
population. This exemplifies the heterogeneity of the population of cells as is found with most cell 
populations, even that of a clonal population where micro-environments around individual cells will 
affect phenotypic profiles (Singh et al., 2014). Furthermore, the frequently changing stance towards 
expression of specific markers for MSCs is reflected by the growing evidence that there are 
exceptions when it comes to the expression of, or lack of expression of specific membrane markers. 
There are inconsistencies in the acceptance of CD34 as a positive or negative marker for MSCs (P et 
al., 2011). Furthermore, the accepted positive MSC marker, CD-105 expression is suggested to 
diminish over time in serum free culture, something that should be considered as the need to reduce 
cell contact with animal derived serum increases in order to become therapeutically compliant (Mark 
et al., 2013). The growing evidence for marker expression variability between different MSCs may 
simply suggest that the current rules for defining a mesenchymal stem cell must be altered.  
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AFSCs Retain Stem Cell Characteristics Following CM Collection 
Ensuring the absence of animal derived products such as serum, is one of the first steps in creating a 
clinically compliant cell derived therapeutic. The collection of the AFSC secretome was therefore 
collected within PBS to negate the use of basal or growth medium as others have previously done. 
Use of animal derived serum and products, without steps to remove their traces later on in the 
production line will lead to levels higher than that of the FDAs code of regulations acceptable level of 
1ppm (Carmen et al., 2012). Due to the removal of the AFSCs from their normal culture conditions 
throughout the CM collection for 24-72 hours, it was imperative to ensure that the AFSCs had not 
become less stem cell like or worse had differentiated and were therefore no longer stem cells.  
Following CM collection, AFSCs were once again characterised for the phenotypic expression of CD-
44, CD-73, CD-90, CD-45 and CD-34. The maintenance of high levels of CD-44 and CD-73 positivity 
went some way to show that the AFSCs retained their stem cellness. This was further illustrated by 
the fact that the populations expression of CD-45 and CD-34 reduced further. This further reduction 
in the negative MSC markers suggests that the CM collection protocol may have led to a slight 
selection in the cells that survived and therefore led to a purer stem cell population. On the other 
hand, levels of CD-90 had also diminished and may reflect the increased mechanical stimulation on 
the cells during the pellet phase of CM collection (Wiesmann et al., 2006). This increased mechanical 
stimulation and therefore reduced CD-90 expression may have also started to drive the AFSCs 
towards an osteogenic pathway (Moraes et al., 2016). The reduction in CD-90 expression can almost 
certainly be hypothesised as accumulating over the 72h period and therefore would be important to 
recognise when looking at the most suitable time fraction of AF-CM in order to consider which is 
more potent and stem cell derived.  
However, consistent with current guidelines, AFSCs following CM collection were also shown to 
differentiate and undergo adipogenesis, osteogenesis and chondrogenesis when placed in the 
correct environments to promote differentiation (Figure 3.2.). Although a reduced CD-90 expression 
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was seen, the AFSCs must still retain the stem cell potency to differentiate down all of the three 
lineages tested.  
Extracellular Vesicles within the AFSC CM 
An increasing number of EVs are being characterised, of which have been grouped into certain size 
ranges (Willms et al., 2016, Zhang et al., 2018).  Many of these different types of EVs are known to 
have different origins within the cell and can be generated in response to certain changes in 
environmental cues or secreted constitutively. TEM imaging of the AF-CM clearly showed that most 
of the EVs collected within the AF-CM were relatively small and under 150nm in diameter, with an 
average diameter of 97.8nm (Figure 3.3.A-B). Exosomes are known to be the main extracellular 
vesicle of this size. As discussed previously, exosomes are known to be secreted constitutively but 
also at an increased rate following periods of stress. The ratio of these small EVs, hypothesised to be 
exosomes, corresponds with the prediction that the CM collection process would induce stress upon 
the AFSCs leading to an AF-CM with increased exosome concentrations (Yu et al., 2006).  
Basic Nucleic acid and Protein Content of AF-CM Fractions 
AF-CM collected at different time-points was assayed for nucleic acid and protein. Interestingly, 
nucleic acid content did not significantly differ between fractions (Figure 3.4.A). This suggests that 
the signalling pathways involved in the alteration of nucleic acid secretions is not visibly affected over 
the time course selected. However, it cannot be ruled out that some nucleic acids are being 
produced at higher levels, whilst the production of other species is reduced. This would lead to no 
overall net change in nucleic acid concentration.  
On the other hand, protein concentrations dropped off dramatically after 48 hours of the cells being 
pelleted (Figure 3.4.B). Due to the reduction in cell viability at T72 following CM it is suggested that 
an increase in cell death has a negative effect on AF-CM protein concentration. Although the levels of 
Protein differ between T24 and T72 or T48 and T72, the profile created following silver staining of the 
AF-CM taken at the differing time-points did not. It was therefore evident that the two fractions to 
concentrate experimentation on were at the two extreme time-points, T24 and T72. T24 did not 
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seem to differ significantly in both nucleic acid and protein content to T48 but the T72 fraction was 
believed to have more extreme differences to the T24 fraction due to significant levels of apoptosis. 
AF-EV isolation and subsequent profiling of its proteins via silver stain implied that the majority of 
proteins were retained within the soluble fraction of AF-CM as opposed to the AF-EV. Secretion of 
these freely secreted proteins can be anticipated as having a shorter half-life when alone compared 
to those protected within an EV and therefore more likely to have an effect on the local milieu of 
cells as opposed to the distant tissues within the body if introduced as a therapy. However, free 
proteins could be bound to albumin, one of the main binding proteins within the circulation, thus 
protecting soluble factors from being degraded rapidly. It would therefore be suggested that protein 
based soluble paracrine factors could act over larger distances if bound to albumin. On the other 
hand, diseases leading to damaged kidneys and liver reduce the level of freely available albumin 
(Klammt et al., 2012). This therefore shows the importance of the EVs within the AF-CM as a 
protector of cargo if injected into a patient presenting with a multitude of dysfunctions and 
potentially reduced albumin levels as a consequence. 
Extensive Characterisation of AF-CM Protein Content 
Identifying the specific protein in the AF-CM was carried out using mass spectrometry. The mass 
spectrometry analysis revealed that both AF-EV and soluble fraction shared 416 protein species and 
the AF-EV contained 190 species specific to this fraction (Figure 3.5.A). The soluble fraction of AF-CM 
contained only 60 more species of protein specific to that fraction. Furthermore, the relative levels of 
proteins found within the AF-EV were comparatively high when looking at the heat map of the two 
fractions (Figure 3.5.B). However, the potential therapeutic value of both the AF-EV and soluble 
fraction is exemplified in the fact that both contain proteins specific to that fraction and therefore 
both could provide differing advantages for use. This is in contrast to many other studies which 
suggest that an EV fraction is superior for therapy and retains all that is needed to promote 
regeneration (Balbi et al.).  
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Further evidence of exosomes within the AF-EV fraction was shown with the existence of exosome 
specific markers such as CD-63, HSP70, HSP90, GAPDH, ACTB and 14-3-3 protein zeta/delta (YWHAZ) 
(Mathivanan and Simpson, 2009, Lötvall et al., 2014). The presence of HSPs is of particular interest 
because they are believed to have dramatic effects on cellular signalling processes involved in the 
stress response.  Although many studies show an increase in HSPs during pathogenesis, which would 
suggest that they potentially play a factor in creating or amplifying the pathology, much of our 
understanding now revolves around them preparing the unaffected tissues for incoming stress 
(Bangen et al., 2007, Danzer et al., 2011, Bianchi, 2007). A cycle of damage, necrosis and 
inflammation could hypothetically be curbed. Preparatory responses to stress through the inhibition 
of cell death and reduced inflammatory responses would therefore halt or slow the spread of 
damage making it easier to regenerate or resect the affected area.  
A number of ABC binding cassette transporters were found including ABCE1. ABCE1 protein is also 
known as an RNase L inhibitor and is therefore capable of inhibiting the catalysis of ribonuclease-L 
and thus in turn promotes the upregulation of protein synthesis (Bisbal et al., 1995).  The promotion 
of protein synthesis is mirrored by the fact that many proteins within the AF-EV fraction were 
enriched within cellular processes that are shared in viral reproduction and the viral infectious cycle. 
Viral replication associated proteins are hypothesised to be present due to the EV manufacturing and 
shedding processes but may also endorse EV uptake as would be required for viral dissemination. 
Additionally many proteins within the soluble fraction of AF-CM were enriched in processes such as 
translational initiation and regulation of translation. On the other hand, proteins enriched in 
processes shared by the soluble and AF-EV such as proteolysis may reflect the cell death seen during 
the CM collection process. However, this cell death was seen to be minimal at T24 and the majority 
of apoptotic bodies were removed. In contrast, if AF-CM contains factors that also direct autophagy 
signalling, which controls proteolysis, it can be hypothesised that it could help to remove diseased 
organelles and dysfunctional cell machinery thus being beneficial for maintaining functional 
regeneration (Nichenko et al., 2016, Garcia-Prat et al., 2016). 
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Identification of a number of receptor proteins in the AF-CM and more specifically the AF-EV is 
important in identifying how AF-EVs are targeted to the membranes of cells thus potentiating some 
or all of its contents paracrine activity. However, no proteins were found to specifically target the EVs 
to a particular cell type. This is in contrast to the literature which suggests that EVs target specific cell 
types or tissues (Camussi et al., 2010). However, a number of integrins such as integrin-β-1 and 
integrins-α-1/2/3/5 were found to be present in the AF-CM and highly present within the AF-EV 
suggesting that mechanisms are in place to initiate EV-cell membrane contact and binding. This EV 
membrane to cell membrane binding could facilitate the uptake of AF-EVs and their contents into the 
cell. Many receptors or membrane bound proteins on the surface of the EVs reflect what is found 
within or on the membrane of the cell they originate from (Deregibus et al., 2007).  
Interestingly, A2B1 ribonucleoprotein was found in the AF-EV. A2B1 ribonucleoprotein has been 
described as being important for the transport of miRNA into EVs during the production and 
packaging process (Villarroya-Beltri et al., 2013). The presence of A2B1 therefore indicated that there 
may be miRNA within the AF-CM and that it has been loaded into EVs. To further this evidence, RISC 
complex proteins were not detected within the expanse of proteins identified. RISC complex proteins 
both aid as a transport protein and serve as protection for the miRNA from enzymatic degradation. 
The lack of RISC proteins therefore provided supplementary proof that any miRNA present would be 
packaged within the AF-EV fraction. The controlling of mRNA levels is further exaggerated with the 
enrichment of proteins known to be important for nuclear-transcribed mRNA catabolic processes 
(Table 3). 
Extensive Characterisation of AF-CM RNA Content 
The identification of RNA species within MSC EVs has been noted on many occasions (Eirin et al., 
2014, Collino et al., 2010). A bioanalyzer profile of RNA content revealed that RNA was present but 
remarkably was almost entirely made up of RNA of around 20-25 nucleotides (Figure 3.6.A).  RNA of 
21-25 nucleotides corresponds to the size of miRNA and not the larger mRNA. This finding is 
especially important because the majority of research has detailed the presence of high quantities of 
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mRNA within MSC EV fractions (Eirin et al., 2014, Deregibus et al., 2007, Alvarez et al., 2012, Valadi et 
al., 2007). The presence of miRNA and not mRNA would also suggest that the AF-EVs are more likely 
to regulate already existing endogenous mRNA within the target cell and not impress new mRNA and 
its subsequent protein production upon the cell. Following the confirmation that miRNA were the 
predominant species present within the AF-EV, 586 species of miRNA were identified using the 
miRNA arrays. Subsequent to this, 21399 pathway targets of the miRNA were revealed and exhibited 
the potential of a single miRNA species being complimentary to a number of mRNAs as opposed to a 
single mRNA species within the target cell.  
Many of the identified targets of the miRNAs found (Figure 3.6.D) were attributed to stress 
responses. It can therefore be speculated that the pelleting of AFSCs and removal of them from their 
normal culture environment with sufficient nutrients had induced the production or secretion of 
these miRNAs. Furthermore once in the target cell they may enhance the protective mechanisms to 
incoming stress and increase the chance of cell survival thus reducing widespread cell death. Such 
miRNAs identified capable of pro-survival included miR3196, miR125b-5p, miR1273-3p and miR762 
found within the AF-EV (Xu et al., 2016, Yang et al., 2016, Ma et al., 2016, Niu et al., 2016, Mendell 
and Olson, 2012). This can be achieved in a number of ways. The miRNA may lead to the direct 
translational downregulation of proteins involved in promoting stress response pathways such as p53 
and PTEN, which could have otherwise induced apoptosis (Niu et al., 2016, Xu et al., 2016). 
Alternatively the miRNA may downregulate the synthesis of proteins which buffer pro-survival 
signalling processes thus allowing hyper-activation of pro-survival proteins (Mendell and Olson, 2012, 
Xu et al., 2016, Ma et al., 2016, Yang et al., 2016, Niu et al., 2016).  
As well as preventing apoptosis miRNAs identified were found to be important in promoting 
proliferation, migration, differentiation, angiogenesis and autophagy such as miR3960, miR24-3p and 
miR382 (Villarroya-Beltri et al., 2013, Xia et al., 2015, Valadi et al., 2007).  Regulated by hypoxia and 
HIF1α, miR382 is hypothesised to be upregulated within the ASFSC due to the pelleting process 
which induces reduced oxygen levels, especially in those cells at the centre of the pellet. Through the 
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direct targeting of the tumour suppressor PTEN translation, miR-382 is believed to promote AKT and 
mTOR signalling and subsequent VEGF production leading to endorsement of angiogenesis (Seok et 
al., 2014). Increased angiogenesis and therefore increased blood flow to the site of injury would 
provide a significant boost to the regenerative process. Translational suppression of the death 
effector domain-containing protein DEDD by miR24-3p has been shown to increase autophagy, 
proliferation, migration and inhibit apoptosis within bladder cancer cells (Yu et al., 2017). Reduced 
DEDD inhibition of the LC3/ p62 autophagy signalling pathway would lead to increased autophagy 
and potentially remove damaged and pathological organelles promoting regeneration (Nichenko et 
al., 2016, Yu et al., 2017). Due to the resultant increase in p62 activity, an increase in cellular 
migration and proliferation is implicated. This alteration in cell activity may be potentiated through 
the binding and subsequent stabilisation of Twist1 (Qiang et al., 2014). An increase in cellular 
migration and proliferation of cells in the milieu local to damage or from distant sites may be 
sufficient to replace tissue lost to disease. However, the introduction of cells outside the locally 
affected area is not always beneficial in the case of an exaggerated immune response. Immune 
system processes made-up 10.2% of the targets for the identified miRNAs. One of the most 
researched of these miRNAs includes Let-7b-5p. Let-7b-5p, as previously stated is recognised as 
primarily an anti-inflammatory miRNA as are many of the Let-7 miRNA species (Ti et al., 2015). Let-7b 
in LPS pre-conditioned human umbilical cord MSC derived exosomes has been shown to inhibit 
TLR4/NF-κB-p65 signalling whilst supporting the phosphorylation of Akt and STAT3. As previously 
identified, Let-7b was discovered to target the mRNA of TLR4 (Bao et al., 2013). Reduced TLR4 
signalling would mean that less NF-κB-p65 is phosphorylated and therefore unable to translocate 
into the nucleus to up-regulate pro-inflammatory gene transcription (Ghosh and Dass, 2016). On the 
other hand, disruption of p65 signalling can increase STAT3/ Akt phosphorylation further 
potentiating the negative feedback loop which controls and hinders NF-κB signalling (Ti et al., 2015). 
Reduced pro-inflammatory signalling in the face of massive infiltration of M1 macrophages within a 
diseased tissue may attenuate the destructive power of these cell types.  
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4. Chapter 4 
Investigation into the Regenerative Potential of AFSC 
CM in Vitro 
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Introduction 
It was found that AF-CM contained a wide variety of constituents from proteins to miRNA, some of 
which were contained within EVs. However it was important to establish how the mixture of these 
soluble components along with the EVs and their cargo interacted with a variety of cells types and if 
they altered their properties. Changes to the cell properties following AF-CM treatment would help 
us understand if AF-CM has regenerative capabilities. Regeneration of tissue can be influenced by a 
number of factors; namely proliferation, migration, senescence and inflammatory status. However, it 
is the role of a multitude of cell types ranging from those found within the milieu, such as the local 
stem cells and other stromal cells, to those that are foreign to the damaged tissue to aid the 
facilitation of this regeneration. Furthermore, the inflammatory status of the damaged tissue and 
how it transitions towards that found in regenerating tissue is of the upmost importance. 
Overzealous inflammatory signalling as well as too little signalling will often cause further damage 
and hinder regeneration. As discussed local paracrine and autocrine signalling within the damaged 
region and from distant sites in the body have a significant influence on how these cellular processes 
and signalling events prevail.  
Proliferation of resident stem cells provides a source of cells for tissue repair. Stem and progenitor 
cells are capable of differentiating into specific cell types to replace lost or damaged mature cell 
types (Lee et al., 2009). For example, skeletal muscle satellite stem cells must proliferate upon 
activation to replace those lost from the stem cell pool after they begin to differentiate and fuse with 
others to form muscle fibres. Similarly, proliferation of Lgr5+ stem cells within the crypts of the 
intestine serve to replace lost cells within the villi as well as due to normal homeostatic sloughing or 
damage (Yan et al., 2012, Sato et al., 2011, Zani et al., 2014). Increasing the proliferation of intestinal 
stem cells during a pathogenic state when more tissue is being lost than replaced is believed 
ameliorate the disease (Zani et al., 2014). Additionally, the ability to proliferate is especially 
important for terminally differentiated cell types, such as endothelial cells, which must divide to 
extend the vasculature within a tissue thus providing blood supply (Rahbarghazi et al., 2013). Often 
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stimulation of cells to proliferation comes from molecules such as cytokines released by the locally 
damaged stromal cells. Following stimulation, a variety of signalling pathways can be activated such 
as those involving the upregulation of PI3Kinase, Akt, NF-κB, Wnt, notch, Oct4, C-Myc (Zani et al., 
2014, Neal et al., 2012, Zhao et al., 2014, Widera et al., 2006, Lee et al., 2009). It is recognised that 
proteins, heavily recognised as being regulators of inflammation such as the Myd88 and NF-κB 
pathways and their regulators, also assist in modulating proliferation levels (Brown et al., 2007, 
Kaltschmidt et al., 1999, Widera et al., 2006). The dual role and function of these pathways stresses 
the importance of their tight homeostatic control and regulation as to not induce exaggerated pro-
inflammation or too little proliferation. 
The capacity to migrate is important for stem cells to locate themselves to an area of damage from 
where they reside. Migrating to an area of damage both provides more efficient localising of 
paracrine factors but also positions the stem cell to replace the damaged cells upon its 
differentiation. Resident stem cells such as the satellite cells within muscle not only migrate from 
under the basal lamina of muscle fibres but also travel along the fibre to an area of damage utilising 
an amoeboid type migration (Otto et al., 2011). Once the target location is reached the satellite cell 
can begin to differentiate, fuse with others to form myotubes and mature to eventually new muscle 
fibres (Otto et al., 2011). Although, classically thought of as scar forming cells, fibroblasts provide a 
trophic environment for the stromal cells within a tissue (Jung et al., 2007). Migration of fibroblasts 
to an area of damage is therefore vital for the regeneration of that tissue following damage. 
Cytoskeletal rearrangements permit migration and this is often triggered through chemokine and 
cytokine induced signalling. Chemokines exist as soluble molecules or transmembrane proteins 
(Hattermann et al., 2016, Ludwig et al., 2005). Binding of the chemokines such as CXCL16 or 
cytokines such as TNF-α to their appropriate receptor often leads to an increase in NF-κB signalling. 
Ultimately NF-κB will either translocate to the nucleus where it can alter gene expression important 
for migration, or potentiate post-translational modifications important for actin mobilisation (Prisco 
et al., 2016). 
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However, following an initial acute injury or during a chronic pathological state, inflammatory factors 
along with other stressors are continually released by the local milieu. One such response to these 
factors, other than cell death, is for the cell to become senescent. Levels of senescent cells increase 
with aging [10].Sometimes the senescent state is triggered by an increase in the production of 
reactive oxygen species (ROS). ROS are damaging to DNA and can therefore cause mutagenesis. A 
senescent like state is an attempt by the cell to prevent cell division and therefore the proliferation 
of a cell with mutated DNA (Campisi and d'Adda di Fagagna, 2007). Although not clearly understood, 
a marker found to increase within senescent cells is β-galactosidase. This enzyme is found in the 
lysosomes of senescent cells and it is important in energy production. β-galactosidase catalyses the 
breakdown of lactose into glucose and galactose. This breakdown is potentially important to the 
alteration of metabolism and creating a state of senescence (Campisi and d'Adda di Fagagna, 2007, 
Gary and Kindell, 2005). However, senescent cells are also known to produce above basal levels of 
pro-inflammatory factors thus slowly causing damage to other surrounding cells (Salminen et al., 
2008). Furthermore, the ability of a tissue to regenerate following damage is diminished if a large 
proportion of the cell population is senescent and therefore unable to proliferate or hindered in their 
ability to migrate.   
Inflammation and the signalling pathways that facilitate it are important for the initiation of the 
regenerative response. However an overpowering pro-inflammatory response following at acute 
injury or persistence of chronic inflammation can cause further damage. A bacterial infection or 
imbalance in the body’s microflora in favour of more pathogenic bacteria can often lead to the 
introduction of higher toxin concentrations, such as gram-negative bacterially derived 
lipopolysaccharide (LPS).  LPS is known to bind to a number of receptors, including toll like receptors 
(TLR) such as TLR2 and TLR4 (Andreakos et al., 2004). Use of ultrapure LPS from bacterial species 
such as E.coli or S. minnesota ensures the specific activation of downstream responses from TLR4 
activation alone. The main and most widely described signalling pathways associated with TLR4 
signalling is that involving NF-κB (Kawai and Akira, 2007). In addition TNF-α, a pro-inflammatory 
cytokine often released by cells as a consequence to damage or LPS/ TLR4 signalling, also has a 
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strong influence on NF-κB signalling following its binding to the TNF receptor (TNFR). Alternatively, 
heightened NF-κB activity can lead to increased TNF-α gene transcription. Heightened signalling via 
these toxins, cytokines and pathways can lead to both regulated cell death like apoptosis and or cell 
death classically defined as being unregulated, such as necrosis.   
LPS stimulation of TLR4 is capable of activating both myeloid differentiation primary response gene 
88 (MyD88) dependent and independent pathways. The MyD88 dependent pathway triggers NF-κB 
activation and therefore pro-inflammatory gene expression (Kawai and Akira, 2007, Kawai et al., 
1999). On the other hand signalling via the MyD88 independent pathway, via Toll-interleukin 
receptor-domain-containing adapter-inducing interferon-β (TRIF), results in the anti-viral and anti-
inflammatory associated IRF3 activation (Tarassishin et al., 2013, Zeuner et al., 2016, Fitzgerald et al., 
2003). Use of S. minessota LPS to stimulate TLR4 signalling has been shown to initially induce higher 
levels of IRF3 activation but is then replaced by MyD88 dependent NF-κB-p65 nuclear translocation 
after a longer period of stimulation (Zeuner et al., 2016). However, E.coli LPS has been shown to 
elevate NF-κB-p65 nuclear translocation from the start of TLR4 stimulation (Zeuner et al., 2016). The 
differences in LPS mediated signalling have been hypothesised to be attributed to the type of 
membrane micro-domain binding within the same TLR-4 (Zeuner et al., 2016). 
Activation of inflammatory signalling pathways including NF-κB by stimulants such as LPS or acute 
stressors often potentiates the transcription and translation of cytokines such as TNF-α. TNF-α can 
also further enhance pro-inflammatory signalling, for example via NF-κB in an autocrine and 
paracrine manner. For TNF-α to facilitate downstream signalling it must bind to either TNFR-1 or 
TNFR-2 (Chen and Goeddel, 2002). Binding to TNFR-1 leads to the assembly and recruitment of a 
protein complex containing TNF-R1-associated death domain (TRADD) protein, FAS-associated death 
domain (FADD) protein, the TNF receptor-associated factor 2 (TRAF2), and then finally  the receptor-
interacting protein kinase RIP1 (Hsu et al., 1996b, Hsu et al., 1996a). As with most signalling, a range 
of signalling pathways and effects can follow from this phenomenon. An apoptotic programme is 
initiated with the association of FADD with TRADD (Hsu et al., 1996b). On the other hand, binding of 
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TRAF2 and RIP to TRADD triggers the association of the IκB kinase (IKK) complex and Jun N-terminal 
kinase (JNK), ultimately leading to NF-κB-p65 translocation to the nucleus as described. The 
activation of NEMO, the major subunit of IKK also known as IKKγ, is suggested to be aided via the 
poly-ubiquitination of RIP-1 at Lys-377 and subsequent binding of the ubiquitin binding domain of 
NEMO (Ea et al., 2006). 
An increase in proliferation and migration capacity of cells is believed to improve the efficiency of 
regeneration. Protection from senescence is thought to aid tissue regeneration by maintaining the 
number of cells, in particular stem cells, able to facilitate regeneration. If these factors can be 
regulated by paracrine activity, potentially capable of AFSC CM, then overall regenerative capabilities 
should also increase. 
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Results 
Proliferation Assays 
After identifying specific protein and miRNA components within the AF-CM it was important to show 
that AF-CM could also modify cell function. T24 and T72 AF-CM fractions were collected and they 
could therefore have very different effects on how cells operate because of the varying time-points 
at which they were collected.  The effect of AF-CM was first tested on cellular proliferation. Cellular 
proliferation is known to be an important component within the regenerative process. Proliferation 
levels of the local stem cell population within or near to an area of damage can prove critical to the 
replacement of dead or damaged tissue (Brown et al., 2007, Collins et al., 2005, Zani et al., 2014).  
Increasing concentrations of AF-CM fractions, T24 and T72, were tested to see if they could increase 
the proliferation of an allogeneic MSC, in this case adipose derived MSCs (ADMSCs).  
Varying concentrations of T24 AF-CM were first tested (Figure 4.1.A). The supplementing of ADMSC 
culture media with 2.5% T24 AF-CM significantly increased the relative cell number by 23.1% (from 
1.10±0.04 to 1.43±0.04 (n=6, p<0.001)). Increasing the concentration of T24 AF-CM also led to a 
significant increase in relative cell number to 1.43±0.03 (n=6, p<0.001) compared to the control. 
Finally, a concentration of 10% T24 AF-CM significantly increased relative cell numbers by 24% from 
the control to 1.44±0.08 (n=6, p<0.001). However, no significant differences in relative cell number 
were found between the varying concentrations of T24 AF-CM treatment.  
As T24 AF-CM was found to increase relative numbers of ADMSCs, the same concentrations of T72 
AF-CM were tested to find out whether ADMSC proliferation was increased with treatment.  A 
significant increase from the control, 1.51±0.14, to 2.13±0.06 with 2.5% T72 AF-CM was found (n=6, 
p<0.001). 5% treatment of T72 AF-CM also led to a significant increase in relative cell number, by 
26% to 2.04±0.07 (n=6, p<0.01). Likewise, a treatment of 10% T72 AF-CM was seen to increase 
relative cell numbers by 26% to 2.03±0.05 (n=6, p<0.01). A comparison of the T72 AF-CM 
concentrations showed no significant difference in relative ADMSC number.  
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Figure 4.1: ADMSC proliferation over 72 hours following AF-CM treatment. (A)  Relative number of 
ADMSCs with increasing concentrations of T24 AF-CM. (B) Relative number of ADMSCs with 
increasing concentrations of T72 AF-CM. Values are expressed as means ± SEM (n=6). p < 0.05 (*), p < 
0.01 (**) or p < 0.001 (***). 
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Migration Assays 
The ability of cells to migrate is an important feature of the regeneration. AF-CM fractions were 
tested to determine whether they facilitated a change in artificial wound closure and therefore a 
change in migration behaviour of ADMSCs (Figure 4.2.A-B). Firstly increasing concentrations of T24 
AF-CM were used to treat the ADMSCs following the creation of a wound (Figure 2C). Only the 2.5% 
concentration of T24 AF-CM increased the extent of wound closure. T24 AF-CM at 2.5% 
concentration increased relative wound closure by 25% from 2.68±0.33 to 3.57±0.14 (n=6, p<0.05). 
On the other hand, concentrations of 1, 5 and 10% did not increase relative levels of wound closure 
significantly. ADMSCs were then treated with increasing concentrations of T72 AF-CM (Figure 4.2.D).  
After 9 hours of wound closure none of the tested concentrations of T72 AF-CM increased the level 
of relative wound closure from the control treated with 0% AF-CM. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4 
Page | 114  
 
 
Figure 4.2: Closure of an artificial wound over 9 hours created within a confluent population of 
ADMSCs with AF-CM treatment. (A) Artificial wound at T=0 hours. (B) Artificial wound at T=9 hours. 
(C) Relative wound closure with increasing concentrations of T24 AF-CM. (D) Relative wound closure 
with increasing concentrations of T72 AF-CM. Scale bar representative of 100µm. Values are 
expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Senescence Assays 
Acute and high levels of stress such a physical trauma can lead to necrosis. Chronic but high exposure 
to a stressor such as a chemical damage may lead to a more regulated type of cell death such as 
apoptosis. On the other hand, lower exposures to stress can cause cells to become senescent. 
Senescence, a form of permanent growth arrest, whereby cells will no longer divide will occur with 
age induced telomere shortening or is forced through stress exposure (Campisi and d'Adda di 
Fagagna, 2007). Treatment of cells with low but damaging levels of H2O2 can also induce senescence. 
IMR90 lung fibroblast cells are a cell line especially susceptible to damage and can be driven into 
senescence with 100µM H2O2 (Debacq-Chainiaux et al., 2009). Furthermore, staining cells blue with 
X-gal (5-Bromo-4-Chloro-3-Indolyl β-D-Galactopyranoside) for the substrate β-galactosidase, found in 
lysosomes, permits the identification of senescent cells (Figure 3A)(Debacq-Chainiaux et al., 2009). 
IMR90 cells were treated with varying concentrations of AF-CM before and after being stressed with 
100μM H2O2 in a bid to determine whether AF-CM protected the cells from senescence. Firstly, 
increasing concentrations of T24 AF-CM was tested to identify if it reduced the percentage of 
senescence within the IMR-90 population (Figure 4.3.B). The positive control group, treated only with 
PBS, showed a significant increase in the percentage of senescent cells by 24.6% following exposure 
to H2O2 from 67±6.48% to 88.75±4.36% (n=4, P<0.01). Although a stepwise decrease in the levels of 
senescence can be seen with increasing concentrations of T24 AF-CM, no significant decrease was 
seen with 2.5% and 5% concentrations of AF-CM treatment, 80.5±3.80% and 76.75±1.11% 
respectively. However, treatment of IMR-90 cells with 10% T24 AF-CM led to a significant decrease in 
the percentage of senescent cells compared to the stressed untreated cells by 17.5% to 73.25±1.89% 
(n=4, p<0.05). Furthermore, all concentrations of T24 AF-CM led to levels of senescence non-
significantly different to that of the non-stressed control. 
The protection from senescence afforded by T24 AF-CM was compared to that of the T72 fraction 
and (Figure 4.3.C). The positive stress control also increased the level of senescence as seen 
previously from 21.08±1.75% to 85.58±0.61% (n=4, P<0.001). The senescent levels of T24 and T72 
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fraction treated cells were also significantly increased from the non-stress control to 50.75±0.79% 
(n=4, p<0.001) and 42.92±1.64% (n=4, p<0.001), respectively. However, both the T24 and T72 AF-CM 
fraction treatments led to a reduction in the number of senescent cells, although this time 
insignificant. In addition, the T72 fraction led to a significantly reduced level of senescence compared 
to the T24 fraction (n=4, p<0.01). Further to this result, a mix of T24 and T72 (T24/T72) was 
compared to the individual fractions (Figure 4.3.D). T24/T72 treatment further significantly reduced 
the level of senescence from T24 AF-CM by 52.12% compared to the T72 fraction which showed on 
average 33.6% less senescence; 19.83±4.09%, 41.42±4.32% and 27.5±2.79% respectively (n=4, 
p<0.01). 
Following the isolation of AF-EVs from the T24 AF-CM, AF-EV was also tested and compared to the 
AF-CM in its ability to alter the levels of senescence (Figure 4.3.E). All stressed groups of cells such as 
the positive control, AF-CM and AF-EV treated cells showed significantly higher levels of senescence 
to the non-stressed control which had basal levels of 0.83±0.27% senescence, at 35.50±1.99%, 
6.17±1.06% and 7.58±6.94% respectively (n=4, p<0.001; p<0.05; p<0.01). As shown previously the 
whole AF-CM significantly reduced the level of senescent cells from the positive control, by 82.6% 
(n=4, p<0.001). Additionally, the AF-EV fraction also significantly reduced the percentage of 
senescent cells, by 78.6% (n=4, p<0.001). On the other hand, comparison between the AF-CM and 
AF-EV treatments showed no significant difference in senescence levels.  
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Figure 4.3: H2O2 induced senescence within a population of IMR-90 lung fibroblasts. (A) A non- 
senescent and senescent (blue) IMR-90 cell stained for β-galactosidase. (B) Percentage of senescent 
cells following treatment with increasing concentrations of T24 AF-CM.  (C) Comparison in protection 
against senescence between 10% T24 and T72 AF-CM compared to a non-stressed vehicle (PBS) 
treated control without AF-CM or 100µM H2O2 (NS-CNT) and a vehicle treated (PBS) H2O2 stressed 
control without AF-CM (S-CNT). (D) Comparison in protection against senescence between 10% T24, 
T72 AF-CM and a 1:1 T24/T72 AF-CM mix (T24/T72) compared to a non-stressed control (NS-CNT) 
 Chapter 4 
Page | 118  
 
and a stressed control (S-CNT). (E) Comparison in protection against senescence between AF-CM and 
its AF-EV fraction compared to a non-stressed control (NS-CNT) and a stressed control (S-CNT). Scale 
bar representative of 20µm. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or 
p < 0.001 (***). 
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NF-κB Nuclear Translocation and Transcription 
As previously discussed, the level and type of inflammatory response is important not only in 
promoting and aiding regeneration but can also cause further damage if uncontrolled. Uncontrolled 
pro-inflammation usually occurs due to widespread necrosis and cytokine release both from the 
damaged or dead cells but also from infiltrating macrophages. Such cytokines include TNF-α, a strong 
stimulus of the NF-κB pathway subsequent to it binding to the TNF-α receptor (Ea et al., 2006). NF-κB 
is a key regulator of inflammatory signalling along with its major sub-unit p65. Phosphorylation of IκB 
and the revealing of the nuclear translocation site on NF-κB leading to the subsequent nuclear 
translocation are known to facilitate the up-regulation of pro-inflammatory genes and therefore a 
downstream pro-inflammatory cell response (Ghosh and Dass, 2016). A reduction in NF-κB-p65 
nuclear translocation or a reduction in NF-κB protein is known to reduce the level of this pro-
inflammatory response.  
MSCs and their paracrine factors have been shown to have anti-inflammatory properties. Therefore 
we determined whether the AF-CM had anti-inflammatory properties (Zhang et al., 2013, Liu et al., 
2014, Cho et al., 2014, Lo Sicco et al., 2017). Treatment of U251 cells with 10ng/ml TNF-α was used 
to induce p65 nuclear translocation (Figure 4.4.A-D). As seen in the immunofluorescent images 
(Figure 4.4.A), control cells without inflammatory stimulation had only cytoplasmic p65. Upon the 
addition of the strong pro-inflammatory stimulus, cells had a high level of nuclear p65 (Figure 4.4.B). 
The nuclear p65 stain intensity was shown to be 76.7% higher in the positive control compared to the 
unstimulated control, 2.28±0.02 and 1.29±0.11 respectively (n=5, p<0.001). Treatment of cells with 
1% AF-CM before and during inflammatory stimulation led to a significant decrease in nuclear p65 
intensity from the positive control to 1.31±0.11 (figure 4C-D; n=5, p<0.001). The level of nuclear p65 
intensity between the non-stimulated control and that of the AF-CM treated (TNF-α stimulated) cells 
were not significantly different. 
U251 NF-κB reporter cells which had been previously transfected produce cumulative levels of 
luciferase and short lasting levels of GFP following NF-κB gene expression. Lysates of treated cells 
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were used to quantitatively determine luciferase levels within the population which is therefore 
indicative of the NF-κB activity. U251 reporter cells were utilised to show a significant increase in NF-
κB dependent luciferase activity following TNF-α stimulation to 47.26±2.02 times that of the 
unstimulated control, 1±0.67 (Figure 4E; n=3, p<0.001). The level of luciferase activity was also 
measured for AF-CM treatment alone and showed no significant difference between that and the 
non-stimulated control. Treatment with T24 AF-CM before and during TNF-α stimulation led to a 
significant decrease in NF-κB dependent luciferase activity to 40.00±1.63, a decrease of 15.4% from 
the positive control (n=4, p<0.05). This was also decreased with T72 and T24/T72 mix treatment, 
38.25±2.21 and 36.22±1.84 (n=4, p<0.01). However, luciferase activity of AF-CM fraction treated cells 
following TNF-α stimulation remained significantly higher than that of the non-stimulated control 
(n=4, p<0.001). Finally, we found that without any TNF-α stimulation that T72 AF-CM treatment 
alone, unlike the T24 or T24/T72 mix, led to a small but significant increase in luciferase expression 
4.72±0.86 (n=4, p<0.05). 
In addition, U251 reporter cells were stimulated with S. minnesota LPS for 24 hours (Figure 4.4.F). 
Ultrapure LPS is known to stimulate only TLR-4, unlike TNF-α (Zeuner et al., 2016). S. minnesota LPS 
stimulation also leads to an increase in NF-κB activity as seen with the positive control versus the 
non-stimulated control, 6.84±0.49 and 1±0.36 respectively (n=4, p<0.001). A step-wise decrease in 
NF-κB dependent luciferase  was seen with T24, T72 and T24/T72 treatment although no significant 
reduction was seen with the T24 treatment; 6.45±0.27, 5.18±0.26 and 3.87±0.20. Furthermore, 
T24/T72 treatment led to a significantly lower level of luciferase compared to that of U251 cells 
treated with T24 AF-CM (n=4, p<0.001).  
The AF-EV fraction was compared to whole AF-CM (Figure 4.5.). AF-EV was shown to be significantly 
more potent at reducing the level of p65 nuclear translocation compared to the whole AF-CM (n=5, 
P<0.001). AF-EV showed 38.5% less p65 nuclear translocation compared to AF-CM, 1.46±0.16 and 
2.39±0.12 respectively. However, comparison between the whole and AF-EV fraction looking at NF-
κB dependent luciferase activity showed no significant difference between the two treatments. 
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Figure 4.4 
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Figure 4.4: Modulation of NF-κB activity by AF-CM. (A-C) Malignant U251 Glioblastoma cells 
stimulated with 10ng/ml TNF-α and treated with 1% AF-CM, stained for NF-κB-p65 (green) and DAPI 
(blue) immunofluorescence (n=4). (D) Nuclear translocation of p65 analysed by mean nuclear p65 
staining intensity. (E) Lentiviral transfected U251-NF-kB- GFP-Luciferase cells were used to 
quantitatively assess the ability of AF-CM collected at T24 and T72 to modulate NF-κB signalling 
following 10ng/ml TNF-α stimulation over 24 hours. (F) Ability of AF-CM collected at T24 and T72 to 
alter NF-κB dependent luciferase activity was further assessed following S. Minnasota LPS stimulation 
of U251 cells. Images were taken at a 20x Magnification. Green and white arrows representative of 
weak and strong nuclear localisation respectively. Scale bar representative of 50µm. Values are 
expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Figure 4.5 
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Figure 4.5: Comparison of AF-CM and AF-EV effects of NF-κB activity. (A-D) Malignant U251 
Glioblastoma cells stimulated with 10ng/ml TNF-α  and treated with AF-CM or AF-EV, stained for NF-
κB-p65 (green) and DAPI (blue) immunofluorescence (n=4). (E) Comparison between AF-CM and AF-
EV treated U251 cell nuclear translocation of p65 analysed by mean nuclear p65 staining intensity. (F) 
Lentiviral transfected U251-NF-kB- GFP-Luciferase cells were used to quantitatively assess the ability 
of AF-CM and AF-EV to modulate NF-κB signalling following 10ng/ml TNF-α stimulation over 24 
hours. Images were taken at a 20x Magnification. Green and white arrows representative of weak 
and strong nuclear localisation respectively. Scale bar representative of 50µm. Values are expressed 
as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Figure 4.6: Potential sites of action within the NF-κB pathway that AF-CM may be acting. AF-CM 
may prevent the phosphorylation and therefore activation of IκB Kinase by effecting any one or a 
multitude of IκB kinases subunits; IκKα, IκKβ and IκKγ (commonly known as NEMO). Active IκB kinase 
phosphorylates IκB at amino acid residues Serine 32 and 36 thereby inhibiting its binding to NF-κB. 
Subsequently, IκB is poly-ubiquitinated and therefore destined for proteasomal degradation. The 
nuclear localisation site (NLS) of NF-κB is uncovered following its split from IκB and NF-κB is therefore 
transported into the nucleus to act as a transcription factor. The ability of AF-CM to inhibit the 
phosphorylation of IκB directly or indirectly would facilitate the binding of NF-κB to IκB and thus 
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prevent NF-κB nuclear translocation.  AF-CM could also inhibit NF-κB activity by directly or indirectly 
preventing NF-κB gene transcription, translation and/or post-translational modification. 
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AF-CM Treatment of Polarised THP-1 Macrophages 
To identify whether AF-CM had the ability to alter the inflammatory state of inflammatory cells, THP-
1 monocytes were differentiated into macrophages and polarised towards a pro-inflammatory M1 
status and treated with AF-CM (Figure 4.7.). CD80, a molecule found on the surface of macrophages 
and known to aid the facilitation of T cell activation, is increased in macrophages driven towards and 
M1 pro-inflammatory state (Peach et al., 1995, Genin et al., 2015). The level of THP-1 cells was 
therefore examined. Levels of CD80+ cells did not increase upon CM treatment of M0 cells or upon 
M2 polarisation compared to an M0 control. On the other hand, polarisation towards an M1 like 
state led to a significant increase in CD80+with or without AF-CM by at least 78.0% (n=3, p<0.001). 
However, although AF-CM treatment of M0 cells before and during polarisation had not led to a 
change in CD80+ cells, AF-CM treatment only during polarisation significantly reduced CD80+ cell 
levels by 11.1% (n=3, p<0.05).  
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Figure 4.7: AF-CM treatment of pro-inflammatory polarised THP-1 macrophages. THP-1 count vs 
CD80 intensity for (A) M0 THP-1 cells (red) vs M1 THP-1 cells (blue), (B) M1 THP-1 cells (red) vs M1 
THP-1 cells treated with AF-CM (CM) only during (D) polarisation. (C) % of CD80 expressing THP-1 
cells after differentiation to M0 and subsequent polarisation towards M2 and M1 states with or 
without AF-CM treatment either 24 hours before and during polarisation (B+D) or just during (D). 
Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Cellular Uptake of AF-EVs  
Many potential mechanisms have been identified for the interaction of EVs with their target cells 
(Mathivanan et al., 2010, Urbanelli et al., 2013). Firstly EV membrane bound receptors may simply 
bind to ligands on the surface of the target cell leading to the activation of downstream signalling 
pathways and vice versa without any EV uptake. On the other hand, cell membranes could fuse with 
that of the EV allowing EV cargo to be released into the cells cytoplasm. Additionally an endocytic 
process where the EV is enveloped by the target cell membrane and internalised could be facilitated 
through mechanisms such as phagocytosis, pinocytosis and receptor-mediated endocytosis. 
Fluorescent dyes such as PKH that bind to the lipid membrane can be used to stain EVs (Balbi et al.). 
Once stained, EVs up taken by a cell and their location once target cell interaction can be 
determined. 
AF-EVs were therefore stained with PKH26, a long lasting red fluorescent dye suitable for EV tracking. 
U251 cells were treated with PKH26 stained EVs (Figure 4.8.). Images of U251 cells after treatment 
showed that AF-EVs had been taken up into the cell cytoplasm (Figure 4.8.B-C).  The uptake of 
stained AF-EVs was then analysed in single cells by examining PKH26 intensity throughout the cell 
(Figure 4.8.D). Control cell membranes were stained with PKH26 without AF-EV treatment and 
showed that the cells had an average relative PKH26 fluorescent intensity of 74.90±8.35. Staining the 
target cell membrane directly as a positive control led to a significantly higher fluorescent intensity to 
that of cells treated with PKH26 stained AF-EVs or NaAzide and PKH26 AF-EVs, 11.68±1.04 and 
5.56±0.95 respectively (n=4, p<0.001). Cells were treated with NaAzide, a mitochondrial ATP 
production inhibitor, to reduce the level of any actively regulated endocytic like pathways (Harvey et 
al., 1999, Schwoebel et al., 2002). Comparison of the PKH26 relative intensity within the cells using 
ANOVA statistical analysis with the control cells did not show any significant reduction compared to 
AF-EV treated cells without NaAzide. On the other hand, a statistical T-test comparing just the PKH26 
AF-EV treated cells and cells treated with NaAzide and the PKH26 stained AF-EV did show a 
significant reduction in relative fluorescent intensity (n=4, P<0.01).  
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Flow cytometric analysis was carried out to identify the percentage of cells taking up the PKH26 
stained AF-EVs in the population of U251 cells. Cells were treated with PBS that had been introduced 
to PKH26 stain and ultra-centrifuged as carried out with the AF-EVs, thus acting as a negative control. 
After treatment with the negative control 1.68±0.95% of U251 cells proved positive for PKH26 
staining. The percentage of cells proving positive for PKH26 were significantly higher in the positive 
control where cells were stained directly beforehand with PKH26, 99.6±0.15% (n=3, p<0.001). Both 
treatments with PKH26 stained AF-EVs with and without NaAzide showed a significant increase in the 
percentage of cells positive for PKH26 compared to the negative control, 79.93±0.15% without 
NaAzide and 77.6±1.92% with NaAzide (n=4, p<0.001).  On the other hand, both AF-EV treatment 
groups showed a significant reduction in PKH26 stained cells compared to the positive control (n=4, 
<0.001). However, there was no significant difference in the level of stained cells between that of the 
AF-EV treated cells and those treated with both NaAzide and the AF-EVs. 
Overall results showed that AF-CM and its resulting AF-EV modulated a number of cellular properties 
both in stem cells and non-stem cells. Ability of ADMSCs to proliferate was increased by all 
concentrations of AF-CM tested. Migration capacity of ADMSCs was increased by the T24 AF-CM, 
although only at the lower 2.5% concentration. Although the T72 AF-CM fraction proved more 
potent, both T24 and T72 AF-CM fractions protected IMR-90 cells from H2O2 induced senescence. 
Additionally, the AF-EV fraction similarly showed protective properties against senescence. Fractions 
of AF-CM were also shown to reduce NF-κB activity in U251 cells. Finally the uptake of AF-EVs in 
U251 cells was proven and shown to reduce following treatment of cells with a known mitochondrial 
toxin, NaAzide. 
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Figure 4.8: Uptake of PKH26 stained AF-EVs by U251 cells. (A-C) Uptake of PKH26+AF-EVs (red) by 
U251 cells (outlined in yellow) as indicated with red arrows. (D) The relative uptake of PKH26 stained 
AF-EVs per cell compared to cells treated with sodium azide (NaAz) to inhibit ATP production. (E) The 
percentage of U251 cells within a population to take up PKH26 stained AF-EVs compared to cells 
treated with NaAz. Scale bar is representative of 20μm. Values are expressed as means ± SEM (n=4). 
p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Discussion 
Numerous cellular properties contribute to the outcome of a diseased and damaged tissue and 
whether it regenerates. Often upon damage a wave of pro-inflammatory cytokines and molecules 
are released from the damaged area (Karalaki et al., 2009). The pro-inflammatory response triggers 
the initiation of a regenerative programme. Proliferation, migration, senescence and inflammatory 
status play a large role in the regeneration process. 
AF-CM Increases Allogeneic Stem Cell Proliferation Capacity 
The first phase of regeneration usually consists of the proliferation of the local stem cell pool. In 
order to maintain the native stem cell population of the tissue, they must undergo asymmetric 
division, thus producing daughter cells for stem cell pool replenishment but also another for lost/ 
damaged cell replacement. Treatment of ADMSCs with AF-CM showed a marked increase in MSC 
proliferation (Figure 4.1.A-B).   Both the T24 and T72 fraction of AF-CM proved to be effective at 
increasing the proliferation of the ADMSCs by more than 20%. Interestingly, all of the tested 
concentrations of AF-CM led to a significant increase in cell number and the lowest concentration 
tested, 2.5%, did not significantly differ in its effect on cell number to the highest concentration, 
10%. This suggests that the AF-CM is potent enough at low concentrations to induce an increase in 
MSC numbers and that this effect seems to plateau at this low concentration. This may be explained 
by a complete saturation of the signalling molecules required for proliferation. The results also 
suggest that no negative feedback mechanisms have been initiated by the higher concentrations of 
AF-CM therefore preventing a decrease in proliferation. Furthermore, because AF-CM had led to an 
increase in cell number within the ADMSC population, an allogenic MSC population, it would be 
expected to also improve the proliferation of other allogeneic stem cells found within the location of 
damaged tissue. Increasing the proliferation of the local stem cell population would create a higher 
capacity for cell replacement improving regenerative efficiency. 
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AF-CM Improves the Ability of ADMSCs to Close an Artificial Wound 
Following or prior to the proliferation of the local stem cell population, the ability of an MSC to reach 
its target destination so that it may aid regeneration is dependent on its ability to migrate. 
Application of an artificial wound closure assay enabled the ability of ADMSCs to migrate into an 
unoccupied and damaged area within the cell population to be measured (Figure 4.2.A-D). Results 
showed that the 2.5% concentration of T24 AF-CM was optimum for increasing wound closure. None 
of the other concentrations of AF-CM led to a significant increase in wound closure. The difference in 
effects between the different concentrations may arise due to homeostatic control mechanisms in 
place within the cell. Too much AF-CM may initiate negative feedback loops in signalling required for 
migration therefore reducing migration.  Too little AF-CM is simply hypothesised to be not enough to 
provide a significant effect. On the other hand, treatment of ADMSCs with T72 AF-CM did not lead to 
any significant increases in relative wound closure. This suggests that the T72 fraction contains lower 
concentrations of migration capacity enhancing cargo to the T24 fraction of AF-CM.  However, 
looking at the pattern of results produced by the T72 treatment, the 2.5% promoted the largest 
mean wound closure. All other concentrations of T72 AF-CM showed noticeably comparable levels of 
wound closure to that of the control. Higher levels may have initiated negative feedback signalling 
pathways thus leading to lower levels of migration in comparison to the 2.5% treatment. Differences 
in potency towards enhancing migration between the two fractions may stem from stress levels 
within the AFSCs during the CM collection process. Upon culturing cells to a higher confluency it can 
be noted that cells become more static. The longer exposure of the AFSCs to being at a high density 
during CM collection may therefore have initiated a response within the cell to inhibit migration. The 
secretome of the AFSCs at this stage is therefore expected to mirror that of the mother cells state 
and thus does not promote migration. In conclusion, the T24 AF-CM provided an increase in cellular 
migration unlike the T72 fraction. Many pathways can affect the outcome of migration such as the 
type of migration and/ or speed of migration. Actin remodelling is arguable the most important of 
these mechanisms potentiating migration. The extent of actin filament extension, recycling and 
branching promotes the polarisation of the cells lamellipodia or bleb formation thus directing the cell 
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(Otto et al., 2011). The degree of actin re-organisation can be partly attributed to the type and level 
of chemokine reception. Activation of Src kinase via growth factor binding to its receptor such as that 
of epidermal growth factor or integrin – integrin receptor binding would activate Src kinase thus 
phosphorylating FAK. Consequentially, Calpain mediated disassembly of the focal adhesion complex 
is activated therefore enabling migration (Westhoff et al., 2004).  The activation of Src/ FAK signalling 
is also known, although not well understood, to promote cell survival (Westhoff et al., 2004, Park et 
al., 2004). If the AF-CM AF-EVs contain growth factors and or integrins, it may be stimulating Src 
kinase and FAK dependent signalling therefore promoting migration but also acting to protecting 
cells from apoptosis. 
Protection from Senescence Following AF-CM or AF-EV Treatment 
The ability of a cell to both proliferate and migrate can be severely compromised or completely 
inhibited if a cell becomes senescent. As discussed, in the event of ageing or cellular stress a cell may 
be driven into a senescent state. Therefore protection from senescence would be hypothesised to 
both maintain proliferation and migration of the local stem cell population or stromal cells. Unlike, 
the previous proliferation and migration assays, T24 AF-CM was shown to be more effective at 
reducing senescence at the higher concentration tested, 10% (Figure 4.3.B). It was also noted that in 
comparison to the T24 fraction the T72 fraction protected IMR-90 cells more so from senescence 
(Figure 3C). This may be because AFSCs used to collect the AF-CM at T72 had simply been exposed to 
stress for longer than that collected at T24. The AFSCs at T72 may therefore be producing more 
paracrine factors aimed at protecting from the imminent stress as opposed to that collected at T24 
warning of a stress to potentially come. However, it was also found that the AF-CM was able to 
modulate NF-κB activity and therefore has the potential to reduce inflammation. Cells in a senescent 
state are known to produce above basal levels of pro-inflammatory factors (Rodrigues et al., 2017). It 
is therefore suggested that the AF-CM is reducing inflammation via the dampening of NF-κB 
signalling in the IMR-90 cells following their stress exposure. When the T24 and T72 were mixed they 
provided even more protection from senescence (Figure 4.3.D). Although not significantly different 
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to the T72 fraction protection, the result reflects the differences in T24 and T72 constituent make-up. 
In unison the T24 and T72 fractions seem to work synergistically. In addition, the AF-EV fraction also 
provided a protective effect and did not significantly differ from the whole AF-CM (Figure 4.3.E). This 
suggests that the AF-EV contains most if not all of the capacity to protect IMR-90 cells from 
senescence. 
The combined results from the proliferation, migration and senescence assays suggest that a 
multitude of paracrine effectors may provide a role in controlling these processes. Much of the 
signalling which leads to increased migration and proliferation is also involved in driving the cell 
towards a senescent state when  signalling activity is increased. Therefore, it could be hypothesised 
that to drive both an increase in proliferation and migration whilst protecting from senescence, the 
signalling in differing pathways to those common to all three features may also be modified by the 
AF-CM. 
AF-CM and AF-EV Treatment Reduces NF-κB Activity  
One of the main signalling molecules important in regulating the three previously described cell 
characteristics is NF-κB. Furthermore, NF-κB serves as an important hub protein controlling the 
inflammatory status of a cell and therefore subsequent to this, that of others (Figure 4.6.). The tightly 
controlled homeostatic regulation of NF-κB is very important in keeping not only inflammation in 
check but also the level of cellular proliferation, migration and senescence.  
Significantly the AF-CM was shown to reduce the level of NF-κB-p65 nuclear translocation when cells 
were stimulated with TNF-α (Figure 4.4.A-D). Signalling involving the p65 subunit of NF-κB, also 
known as RelA, is controlled through the NF- κB canonical pathway as described previously 
(Siebenlist et al., 1994). Reduced p65 nuclear translocation would correspond to an increased level of 
IκBα binding.  The increase in binding and therefore p65 inhibition may be induced at several 
different levels within the canonical pathway (Figure 4.6.). The first would be that the AF-CM 
decreased the level of IκB phosphorylation by the inhibitor of IκB, IκB kinase (IKK) and its main 
subdomain NEMO at serine 32 and 36 thus leading to more p65 nuclear translocation domain 
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coverage by IκBα. Secondly, AF-CM may cause a decrease in p65 transcription and/or translation.  
However, many more regulatory processes such as ubiquitination and acetylation of NF-κB and its 
subunits which control and modify its signalling function may be affected.  
Further to the reduced p65 nuclear translocation, NF-κB dependent luciferase expression subsequent 
to TNF-α stimulation, was also reduced with AF-CM treatment (Figure 4.4.E). This suggests that AF-
CM has a direct effect on NF-κB gene expression. As explained, a reduced level of NF-κB subunit gene 
expression could lead to reduced levels of p65 and therefore explain at least in part why reduced p65 
nuclear translocation was seen with AF-CM treatment. Less p65 would enable easier sequestration 
by IκB. Comparison between the two fractions, T24 and T72, as well as treatment with a T24/T72 mix 
showed no significant differences in luciferase expression. However, a step-wise decrease in 
luciferase expression can be seen with the T24, T72 and T24/T72 mix respectively. Additionally, the 
effect of stimulation of U251 cells with S. minnesota LPS to increase NF-κB dependent luciferase 
expression levels was seen to decrease in the same manner with the various fractions (Figure 4.4.F). 
Conversely, T24 AF-CM did not significantly reduce luciferase levels unlike the T72 fraction and 
T24/T72 mix. Although not significant in this case, the mix of the two fractions is seen to be more 
potent at reducing NF-κB activity. This suggests that the T24 and T72 fraction have differing 
components and when mixed are able to act on independent pathways or levels within the same 
pathway to bring about a more desirable effect. For example it has been shown that hypoxia induced 
release of factors such as HIF have an anti-senescent effect through mechanisms such as TWIST 
activated E2A-p21 signalling downregulation (Tsai et al., 2011). Downregulation of p21 is known to 
reduce senescence and therefore it’s associated inflammation via NF-κB (Tsai et al., 2011, Yao et al., 
2008). Increased exposure to hypoxia as would be expected from the cells used to collect T72 AF-CM 
would therefore be expected to contain more hypoxia related factors such as HIF compared to the 
T24 fraction. On the other hand, the T24 fraction may contain factors that reduce NF-κB signalling 
that are not strictly associated with hypoxia. Therefore a mix of the two fractions would provide a 
number of different mechanisms of action to reduce inflammation, more so than that of any single 
fraction alone. The ability to reduce the LPS and TNF-α stimulated NF-κB escalation suggests that the 
 Chapter 4 
Page | 137  
 
AF-CM is acting further down from the receptor level in the signalling pathway where both TLR-4 and 
TNFR share signalling proteins. Overlap between the two pathways is most evident from IKK 
activation and therefore a change in NF-κB signalling is suggested to be altered from here to the 
genetic level of NF-κB. Furthermore, AF-CM may have the potential to reduce NF-κB signalling 
through a reduction in CD80 expression. Reduced CD80 expression in M1 pro-inflammatory 
macrophages would reduce their ability to bind to CD28 thus activating downstream NF-κB signalling 
in other inflammatory cells which would otherwise potentiate the inflammatory response (Schulze-
Luehrmann and Ghosh, 2006, Peach et al., 1995). 
Additionally, when the AF-CM was compared to its AF-EV fraction in their ability to reduce p65 
nuclear translocation, AF-EV was shown to be more potent (Figure 4.5.A-E). On the other hand, the 
AF-EV was shown to be comparable to the whole AF-CM when looking at NF-κB dependent luciferase 
levels. These results suggest that the AF-EV cargo may provide the majority of the NF-κB activity 
modulation.  
Further analysis of the NF-κB dependent luciferase expression shows that the inhibition of NF-κB 
gene expression by AF-CM is not sufficient to reduce it to levels comparable to that of non-
stimulated cells. This may explain why the AF-CM is also able to increase the level of proliferation 
and migration whilst protecting from senescence and reducing NF-κB signalling in a simulated stress 
condition. It can be hypothesised that AF-CM is able to reduce levels of NF-κB activity, decreasing 
potentially damaging pro-inflammatory signalling and subsequent senescence, but also not too low 
which could have an inhibitory effect on proliferation and migration levels (Kaltschmidt et al., 1999). 
It could therefore be concluded that AF-CM and the AF-EV fraction help to bring the homeostatic 
regulation of NF-κB back under control but also to a level optimum for regenerative purposes. 
AF-EV Uptake by Target Cells is at Least Partly Dependent on Active Processes 
Facilitation of the signalling modifications discussed by the AF-CM and AF-EVs is dependent on how 
the AF-EV interacts with the target cells. PKH26 stained AF-EVs were found within the cytoplasm of 
U251 cells (Figure 4.8.A). This suggests that the AF-EV has been taken up by the target cell. However, 
 Chapter 4 
Page | 138  
 
ANOVA statistical analysis showed that treatment of cells with NaAzide prior to exposure to the AF-
EVs did not lead to a significant decrease in AF-EV uptake per cell or the percentage of cells overall 
taking up the AF-EVs (Figure 4.8.D). This would suggest that this uptake is not entirely an active 
process as previously suggested by others (Ronquist et al., 2016, Mulcahy et al., 2014, Camussi et al., 
2010, Urbanelli et al., 2013). However statistical testing between the AF-EV treated and NaAzide 
affected AF-EV treated cells only did show a significant decrease in AF-EV uptake due to the NaAzide 
treatment. Some of the pathways expected to decrease following NaAzide induced ATP depletion 
include pinocytosis but also phagocytosis. Pinocytosis has been shown to be the major mechanism in 
the uptake of small complex particles below 250nm as opposed to phagocytosis which is employed 
with those over this size (Panariti et al., 2012). The NaAzide may not have blocked all active transport 
into the target cell thus leading to a lack of a complete block of AF-EV uptake. Furthermore, any 
uptake at all within a cell would lead to a cell being counted as positive within the flow cytometric 
readout (Figure 4.8.E). Due to a significant drop in AF-EV uptake per cell within the NaAz treated 
U251 cells it can be concluded that AF-EV uptake is at least partly dependent on active processes. On 
the other hand the occurrence of some PKH26 uptake in NaAz treated cells may also illustrate the 
variety of AF-EV types or subtypes present within the AF-EV. Some AF-EVs may therefore be taken up 
into the cell via integration of their phospholipid membrane with the cell plasma membrane in a non-
energy dependent manner. A difference in AF-EV structure and membrane make-up could influence 
the mechanisms of uptake. 
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5. Chapter 5 
Investigation into the Regenerative Potential of AFSC 
CM in an Acute CTX Damage Mouse Muscle Model in 
Vivo   
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Introduction: 
In-vitro results had shown that the AF-CM contained a diverse range of molecular protein species but 
also miRNA. Some of these molecules were not only found to be in a soluble fraction of AF-CM but 
were also contained as cargo within or on small EVs. Furthermore, treatment of a number of 
different cell types in-vitro with AF-CM, suggested that the AF-CM potentiated some key cellular 
properties. Cell migration, proliferation and enhanced protection from stress induced senescence 
were increased by the AF-CM and or its resulting fractions.  Additionally, some of the AF-CMs effects 
were suggested to derive from its ability to reduce NF-κB signalling and therefore inflammation. 
Because AF-CM and its fractions could enhance cellular properties known to be important in 
regeneration, it was therefore proposed that AF-CM could accelerate regeneration in-vivo.  Testing 
the effectiveness of AF-CM regenerative capabilities in-vivo would potentially aid the identification of 
any single or multi mechanistic mode of action using histological techniques.  Furthermore, an acute 
injury to regeneration model would allow the gathering of information about whether the AF-CM 
could accelerate regeneration in-vivo over a short period of time and clues as to how. The major 
stages that can be described to take place within such an in-vivo scenario are well documented and 
include the initial trauma to the tissue, inflammation and regeneration of tissue through remodelling 
and maturation. In this particular case, the use of a myotoxic phospholipase A2 cardiotoxin (CTX) 
from a species of Cobra, Naja Pallida, can be utilised to create an acute injury within the skeletal 
muscle of a mouse. This initial damage is followed up, as described, with various phases of 
inflammation and then regeneration. 
Regeneration in Muscle 
Muscle is a large and important organ of the body derived from the mesoderm, which not only 
allows movement, but is also essential for the body’s glucose regulation, respiratory functions such 
as diaphragm mobility and metabolism. Degeneration of this organ can take place due to genetic 
defects including muscular dystrophies, neurodegenerative diseases leading to lack of motor end 
plate activity or acute trauma, which can occur physically for example due to a sporting injury or 
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blunt trauma. Skeletal muscle consists of a number of major cell types, forming both the fibres 
themselves (derived from the mesoderm) and the stromal tissue, all of which interact to provide 
healthy function (Murphy et al., 2011). Upon the muscle fibres exists a small population of stem cells, 
known as satellite cells, important for regeneration of muscle fibres following necrosis. Within the 
milieu of cells are resident fibroblasts whose main role is to provide an environment perfect for the 
existence of cells within the tissue by producing ECM, such as collagen and growth factors. However, 
fibroblasts also play a major role in scar formation following damage and induce pathological fibrosis 
(Li et al., 2008). Blood vessels penetrate the tissue thus providing the surrounding cells with oxygen 
and nutrients from around the body and are made up mainly of endothelial cells, which line the 
vessels. Endothelial cell health is also maintained by pericytes which lie upon the capillaries to ensure 
vessels maintain adequate blood to tissue junctions (Bergers and Song, 2005). Angiogenesis, the 
process of blood vessel growth and development is vital for revitalisation of not only skeletal muscle 
but all tissues, and hindrance due to necrosis or inflammation can have major consequences for 
regeneration. Following injury otherwise non-resident cells such as inflammatory cells (mainly 
macrophages) infiltrate muscle adding to the interplay of cell to cell signalling. 
Following damage and initiation of a pro-inflammatory response, satellite cells awaken from a 
quiescent state and commence a proliferative stage in muscle regeneration. In a quiescent state, 
satellite cells reside under the basal laminae of the myofibre. This quiescent state is believed to be 
maintained through environmental niche derived Notch ligand binding with Notch receptors on the 
satellite cells, and in particular downstream RBP-J (Bjornson et al., 2012, Mourikis et al., 2012). Upon 
damage to the tissue and the initiation of a pro-inflammatory phase, cytokines such as INF-γ lead to 
the activation of the satellite cells (Qin and Zhang, 2017, Collins et al., 2005). Activation of satellite 
cells usually occurs between 6-12 hours after damage (Vater et al., 1994).The stem cells will then 
proliferate in an asymmetric manner producing two daughter cells, one to replace the mother stem 
cell and replenish the stem cell pool whilst the other can be used for tissue replacement and repair 
(Zammit et al., 2004, Ono et al., 2011, Collins et al., 2005).  Activation is switched on through p38-
 Chapter 5 
Page | 142  
 
MAPK signalling, known to be associated with stress and growth factors binding to their receptor 
such as HGF, leading to increased expression of genes including MyoD (Tatsumi et al., 2002, Jones et 
al., 2005). Satellite cell proliferation coincides with expression of MyoD and Myf5 (figure 5.1.), a basic 
helix-loop-helix family (bHLH) of protein which bind muscle specific genes (Cornelison et al., 2000, 
Cornelison and Wold, 1997).  
 
Figure 5.1: Expression markers of satellite cells from the point of quiescence to activation and then 
differentiation into myocytes prior to myotube formation. Modified from Motohashi and Asakura,  
2014 (Motohashi and Asakura, 2014). 
 
Acute or chronic damage can however lead to the exhaustion of a stem cell population because of 
over activation and the overwhelming need of stem cells for replacement of damaged cells (Yue et 
al., 2016). However, exhaustion of this critical cell population stifles the regeneration of the tissue in 
chronic disease (Heslop et al., 2000). Active stem cells that have migrated to or localise in the area of 
damage undergo differentiation. Initially residing under the myofibre basal lamina, the satellite cells 
migrate via lamellipodia towards the fibre surface. Upon reaching the surface, lamellipodia based 
migration is replaced by amoeboid migration mediated through blebbing (Otto et al., 2011). Satellite 
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cells will then progress towards the area of damage before differentiating, which does not take place 
until pro-inflammatory M1 macrophage levels have dropped and are at least partly replaced with M2 
macrophages classically defined as anti-inflammatory (Perdiguero et al., 2011, Perdiguero et al., 
2012).  
At the stage of differentiation MyoD and Myf 5 become activated and lead to the expression of 
myogenin and Myf4 (Molkentin et al., 1995, Cornelison et al., 2000, Cornelison and Wold, 1997). This 
differentiation of satellite cells is however tightly regulated by the inflammatory status of the 
environment which in turn is highly dependent of the infiltration and type of macrophages. The 
infiltration of macrophages depends on the influx and differentiation of monocytes in the local 
vasculature. The initial pro-inflammatory response created by the necrosing cells and, in the case of 
muscle, the myofibre acts as the driving force behind this macrophage assault. In an attempt to clear 
the scene of cellular debris as a result of damage, M1 macrophages classically known to be pro-
inflammatory remove fragments via phagocytosis. Markers highly attributed to the M1 macrophage 
state and function includes Ly6, iNOS and CD80 (Arnold et al., 2007, Daigneault et al., 2010). M1 
macrophages also secrete large quantities of pro-inflammatory cytokines both recruiting further 
waves of macrophages and increasing the activity of other cells types within the vicinity.  
On the other hand differentiation of the activated satellite cells is triggered by a reduction in pro-
inflammatory cytokines, M1 macrophages that are associated with them but also clearance of debris. 
Following the clearance of debris a timely transition takes place whereby M1 macrophages are slowly 
replaced by M2 macrophages, generally thought of as being anti-inflammatory (Perdiguero et al., 
2011, Perdiguero et al., 2012, Arnold et al., 2007). This transition from M1 to M2 is believed to be 
under the control of the p38 MAPK and the MAPK phosphatase, MKP-1 (Perdiguero et al., 2011, 
Perdiguero et al., 2012). Reduction in MKP-1 activity and therefore increased p38-MAPK 
phosphorylation leading to its increased signalling is suggested to facilitate the anti-inflammatory 
state of the macrophage population. The development of the M2 response brings about tissue 
remodelling and differentiation of cells because of the secretion of cytokines including TGF-β (Arnold 
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et al., 2007, Lefaucheur and Sebille, 1995). In particular the M2 response promotes satellite cell 
differentiation and fusion with other satellite cells into a myotube structure. The myotube will 
eventually mature and materialise into a functional myofibre. 
Classically, satellite cells will differentiate into myoblasts, which fuse to form multi-nucleated 
myotubes and finally differentiate into myofibres, thus replacing those previously lost (Motohashi 
and Asakura, 2014). Nevertheless, satellite cells appear to possess multipotent properties and can 
also differentiate into other cell types including adipocytes and osteocytes, although for this to take 
place they must not have been pushed towards a myogenic lineage (Asakura et al., 2001). Expression 
of the transcription factor Pax-7 is indicative of satellite cells and can be seen to be expressed in cells 
of regenerated muscle fibres following injury (Lepper et al., 2009, Lepper and Fan, 2010, Seale et al., 
2000).  In mice at least the ability to express Pax-7 has been shown to maintain the satellite cell 
population prior to an age of P21 (Oustanina et al., 2004). Moreover as with most stem cells, satellite 
cells will produce paracrine acting factors to stimulate and direct other cell types within the 
environment and presumably throughout the body if secreted factors enter and circulate the blood 
stream (Rahbarghazi et al., 2013, Rhoads et al., 2009, Fry et al., 2014).   
Cardiotoxin Induced Muscle Damage 
CTX can be used to create an acute muscle injury model. CTX is an amphiphilic polypeptide, defined 
as having a polar water-soluble terminal group attached to a water insoluble hydrocarbon chain, it is 
able to penetrate cellular membranes leading to osmotic shock, lysis and widespread necrosis within 
the tissue (Wang et al., 1997). Furthermore, cells that survive lysis can be additionally affected by 
mitochondria membrane disruption, which similarly to whole cell osmotic shock can cause cell 
fragmentation (Wang and Wu, 2005, Ramadasan-Nair et al., 2014). The spike in intracellular calcium 
following sarcolemma disruption leads to sustained high levels of Ca2+, prompting muscle fibres to 
change morphologically from a rod shape to becoming round due to hypercontraction (Wang et al., 
1997). Ca2+-dependent proteases are activated and wreak havoc within the cell leading to mass 
protein breakdown. Mitochondria can also take up  Ca2+, which is exaggerated by the increased 
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intracellular levels created by CTX leading to dysregulation of mitochondrial homeostasis 
(Ramadasan-Nair et al., 2014). As a consequence of abnormal Ca2+ levels in mitochondria, an increase 
in the production of damaging ROS follows and the ability of mitochondria to effectively undertake 
respiration fails. However, not only does CTX IM injection provide a model of acute degeneration 
within muscle it also presents with many pathological features observed in chronic disease, including 
that of many muscular dystrophies, which can be experimentally evaluated. Characteristics include 
sustained pro-inflammation, apoptosis and loss of sarcoplasm and structure. Importantly, the 
satellite cells are not killed by CTX and drive regeneration in the following days after CTX muscle 
exposure (Harris, 2003). 
The Satellite cells of skeletal muscle are highly resilient, this along with the position they reside 
between the plasma membrane and basal lamina of the muscle fibre whilst quiescent means that 
they are protected and not killed by CTX (Harris, 2003). Due to the sparing of satellite cells from CTX 
induced damage, the stem cell pool stays intact. Furthermore the CTX, which is comprised mainly of 
phospholipases as opposed to enzymes such as collagenases that catalyse the breakdown of the 
ECM, is therefore sparing of the subsequent basal laminae tubes after fibre death. Activated satellite 
cells can therefore use the leftover fibre ‘skeleton’ not only as highway for travelling along but also 
as a scaffold developing fibres following satellite cell differentiation (Harris, 2003). Depending on the 
turnover of cells within the tissue the local stem cells can stay in a quiescent state until damage 
occurs and they are activated (Fu et al., 2015, Villalta et al., 2009, Karalaki et al., 2009).  
As discussed, CTX has been found not to affect the ECM of the muscle fibres. The ECM and its 
elasticity is an important regulator of stem cell differentiation and its lineage specification (Engler et 
al., 2006, Kundu and Putnam, 2006, Kuang et al., 2008). Therefore preservation of the ECM following 
CTX damage plays an important role in directing the satellite cell down a myogenic lineage and 
ultimately its ability to facilitate regeneration. In addition to this preservation, the innervation of 
fibres has been found not to be affected by CTX. It has been suggested as being at least in part the 
reason why the transition of regenerating fibres (following CTX) to express adult myosins from 
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embryonic forms is that much quicker than the transition in normally developing fibres (d'Albis et al., 
1988).  Finally, during the stages of differentiation a state of macrophage exhaustion and dispersal 
from the tissue follows, as correlated by the complete loss of MKP-1 activity in the macrophages 
(Perdiguero et al., 2011, Perdiguero et al., 2012). 
As discussed, the delivery of macrophages to the damaged area relies heavily on the vasculature. The 
capillary network in the given area also provides a source of oxygen and nutrients for both the 
healthy and regenerating tissue. Inflammation and hypoxia due to damage in the existing vasculature 
initiates an angiogenic programme (Szade et al., 2015). A necrotic and therefore often hypoxic 
environment leads to the stabilisation and dimerization of hypoxic inducible factor (HIF) family 
members HIFα and HIFβ (Schofield and Ratcliffe, 2004, Szade et al., 2015). Acting as a transcription 
factor the dimerised forms of HIF induce gene transcription of genes such as NF-κB, VEGF and COX2 
(Kaidi et al., 2006, Ceradini et al., 2004, Cummins et al., 2006, Oliver et al., 2009).  Like-wise, 
inflammatory signalling such as that via NF-κB leads to the upregulation of HIF genes (Oliver et al., 
2009, Cummins et al., 2006). VEGF or more specifically VEGF-A, in the case of angiogenesis, binds to 
VEGF receptors (VEGFR-1/2) (Shibuya, 2011). Under the VEGFR-2 receptor signalling pathway the 
PLCγ-PKC-MAPK signalling pathway is highly active (Takahashi et al., 1999, Takahashi et al., 2001). 
Activation of this signalling pathway is known to induce mitogenesis and differentiation of vascular 
endothelial cells. 
 
 
 
 
 
 
 Chapter 5 
Page | 147  
 
Results 
AF-CM Treatment in an Acute Damage Model 
To determine if AF-CM can promote regeneration in vivo in an acute damage model, treatment with 
AF-CM was carried out on mice with cardiotoxin (CTX) induced muscle injury.  Damage to the mouse 
Tibialis Anterior muscle with 100μM Naja Pallida CTX is known to generate localised necrosis within 
the muscle followed by regeneration. The extent to which AF-CM could accelerate regeneration was 
therefore analysed. Mice TA muscles were either damaged with CTX and treated with a vehicle (PBS) 
or damaged with CTX and treated with AF-CM and collected 5 days after damage.  
Haematoxylin/ Eosin and Acid Phosphatase Staining of Damaged Muscle 
First, the extent and location of damage was assessed using haematoxylin and eosin staining (H&E) 
(Figure 5.2.A-C). The set of negative control muscles showed no damage and normal muscle fibre 
morphology as seen by the coverage of tissue pink in colour. On the other hand, CTX damaged 
muscles presented with regions depleted of the pinkish haematoxylin staining and appeared more 
purplish thus indicating the regions of interest. At a higher magnification, the damaged regions 
contained many small fibres with centrally located nuclei (Figure 1C high magnification). In addition, 
a clear increase in the concentration of nuclei within the area surrounding the myofibres could be 
seen compared to undamaged regions and that of the undamaged control sections of muscle.  
The extent of necrosis and inflammation was determined using acid phosphatase staining (Figure 
5.2.D-F). Present within the lysosomes, acid phosphatase can be found in a number of tissues, in 
particular tartrate-resistant acid phosphatase (TRAP5a) is found in cells such as macrophages. 
Naphthol acid phosphate within the staining solution is hydrolysed by acid phosphatases within the 
tissue producing napthol derivatives. The unstable diazonium salt, hexazonium pararosanilin, within 
the stain couples with the naphol derivatives thus creating a red azo dye. A deep red stain correlated 
to the regions described in the H&E stained sections with fibres consisting of centrally located nuclei. 
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Images of acid phosphatase stained sections were blindly assessed for intensity and coverage (Figure 
5.2.G). No significant differences between other parameters were found. 
 
Figure 5.2: Cardiotoxin induced muscle damage histology after 5 days. Haematoxylin and Eosin 
staining of (A) non-damaged control TA muscle sections, (B) CTX damaged vehicle treated control TA 
muscle sections and (C) CTX damaged AF-CM treated TA muscle section. Acid phosphatase staining of 
(D) non-damaged control TA muscle sections, (E) CTX damaged vehicle treated control TA muscle 
sections and (F) CTX damaged AF-CM treated TA muscle sections. (G)Acid phosphatase stain scores 
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carried out blindly for stain intensity and coverage with 0 = no stain/coverage and 5 = highly stained/ 
complete coverage. Scale bar represents 500μm. Values are expressed as means ± SEM (n=5). p < 
0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
Cross-Sectional Area of Newly Regenerated Fibres 
Embryonic Myosin heavy chain (eMHC), also known as MHC3, is expressed in developing muscle 
fibres before being replaced by the mature forms of myosin heavy chain (Schiaffino et al., 2015). 
However, following damage eMHC gene expression is switched back on within newly forming muscle 
fibres and can therefore be used to identify newly regenerating myofibres. Once identified, the sizes 
of these newly regenerating fibres were compared to understand whether AF-CM treatment had 
accelerated the regeneration process (figure 5.3.A-B).  
Comparison between the two CTX damaged groups of muscles showed that treatment with AF-CM 
(CTX-CM) led to a significant increase in newly regenerating fibre size compared to the vehicle 
treated (CTX).  Fibres in the deep region (Figure 5.3.C) were 74.84% larger in the AF-CM treated 
muscle compared to the vehicle treated, (630.79±10.36μm2 and 360.79±6.10μm2 (n=5, p<0.001)). 
Within the superficial region of the TA, AF-CM treatment also led to a significant increase in newly 
regenerating fibre size (Figure 5.3.D). (67.29% from 405.07±7.49μm2 in the vehicle treated to 
677.63±12.59μm2 (n=5, p<0.001)). Collating data from the deep and superficial regions of muscle 
(Figure 2E), newly regenerating fibres from AF-CM treated mice were 73.59% larger than in the 
vehicle treated muscles, 661.66±11.93μm2 and 381.16±6.66μm2 respectively (n=5, p<0.001). 
Frequency-distribution profiles of fibres from the AF-CM treated and vehicle treated muscles 
damaged due to CTX were also developed. The majority of fibres within the vehicle treated group 
200-400μm2. On the other hand, the majority of fibres within the AF-CM treated group were 400-
600μm2. The majority of AF-CM treated fibres had a larger cross-sectional area than muscles 
damaged with CTX but not treated with AF-CM. This was further corroborated by a statistical Chi test 
of variance which showed a significant difference in variance between the AF-CM treated and vehicle 
treated. 
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Figure 5.3: Newly regenerated TA muscle fibres following CTX damage. (A-B) embryonic Myosin 
heavy chain expression in damaged muscle (green) with DAPI (blue staining comparing CTX damaged 
vehicle treated muscles (CTX Control) and CTX damaged AF-CM treated muscles (CTX CM). (C) 
Quantification of cross-sectional area of newly regenerated fibres in the deep region of the TA 
muscle sections. (D) Quantification of cross-sectional area of newly regenerated fibres in the 
superficial region of the TA muscle sections. (E) Quantification of cross-sectional-area of newly 
regenerated fibres across the total TA muscle sections. (F) Frequency distribution graph of 
regenerated muscle fibres. Scale bar represents 50μm. Values are expressed as means ± SEM (n=5). p 
< 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Satellite Cell Activity within the Regenerating Tissue 
In muscle, the number of quiescent and active satellite cells along with their transition down the 
myogenic lineage is a key factor in muscle fibre replacement. The expression of Pax7, a transcription 
factor, in the absence of MyoD expression represents these quiescent satellite cells as they reside 
under the basal laminae of the muscle fibre. Upon satellite cell activation, MyoD gene expression is 
switched on and begins to repress the expression of Pax7 as the satellite cell begins to differentiate 
towards the mature muscle cell. Upon differentiation, Pax7 expression becomes absent and the cell 
fuses with other myoblasts forming a syncytium of cells and providing the classic morphology of a 
muscle fibre. Following CTX damage no significant differences were found between the AF-CM 
treated and vehicle treated groups in terms of the number of quiescent (Pax7+/MyoD-) cells or the 
number of activated (Pax7+/MyoD+) cells (Figure 5.4.B). However, a significant increase in the 
number of committed progenitor cells (Pax7/MyoD+) from the AF-CM treated group of muscles was 
found compared to that of the vehicle treated, 50.20±5.62 cells/mm2 and 28.45±4.65 cells/mm2 
respectively (n=5, P<0.05).  
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Figure 5.4: Assessment of regeneration with CTX damaged muscle treated with vehicle or AF-CM. 
(A) Immunofluorescent staining for Pax7 (green), MyoD (Cyan) and DAPI (Magenta) in TA muscle 
damaged with CTX. (B) Quantification of quiescent satellite Pax-7+/MyoD-, activated satellite cells 
Pax-7
+
/MyoD
+
 and muscle lineage committed progenitor cells Pax-7
-
/MyoD
+ 
within vehicle and AF-
CM treated muscles damaged with CTX. (A) Scale bars are equal to 100µm. Values are expressed as 
means ± SEM (n=5). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Blood Supply to the Regenerating Tissue 
In addition to satellite cell activities, the ability to provide a source of blood, oxygen and the nutrient 
content that comes with it is critical for regeneration of tissue. The smallest of the blood vessels that 
provide this source of blood, capillaries, and the endothelial cells that make them up undergo 
angiogenesis following the initial cytokine response along with VEGF and HIF signalling pathway 
stimulation due to stressors such as hypoxia. CD31, also known as platelet endothelial cell adhesion 
molecule (PECAM-1), is highly expressed at endothelial cell junctions. CD31 is widely used as a 
marker for capillaries and the endothelial cells that comprise them (Figure 5.5.A). The number of 
CD31+ vessels were analysed within a given area of the treatment groups to understand the extent of 
vascularisation within the regenerating muscle (Figure 5.5.B). Although not significant between both 
CTX damaged muscle groups, the number of CD31+ vessels had increased following CTX damage 
compared to the non-damaged control muscles. There was however a significant increase in the 
number of CD31+ vessels/mm2 in the AF-CM treated (1008.86±116.33 cells/mm2) CTX damaged 
muscles compared to the non-damaged muscles (494.68±17.90 cells/mm2). On the other hand, a 
decrease in the number of CD-31+ cells/fibre was found upon CTX damage with treatment with the 
vehicle, although not significant (Figure 5.5.C). However, treatment with AF-CM increased the 
number of CD31+ vessels from the damaged control by 71.43% from 0.98±0.10 CD31+ vessels/ fibre 
to 1.68±0.25 CD31+ vessels/ fibre (n=5, p<0.05). The increase in vessels from the damaged control 
with AF-CM treatment brought levels of CD31+ vessels to a level that was not significantly different to 
that of the undamaged control. 
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Macrophage Infiltration 
Many of the processes involved in regeneration as well as degeneration are profoundly affected by 
the inflammatory status of the tissue affected.  In the case of the skeletal muscle as with many 
tissues following damage, inflammation is further increased by the infiltration of macrophages 
following their differentiation from monocytes in the circulating blood. Although not believed to be 
necessary for development of macrophages, F4-80 an extensively characterised marker commonly 
used for mouse macrophages is thought to play a key role in their function, such as adhesion and 
activation of other cell types including natural killer cells and those of the immune system (Lin et al., 
2005). The number of F4-80+ cells/mm2 in the CTX damaged AF-CM treated muscles were 
significantly higher than that of the vehicle treated CTX damaged muscles by 19.3% ((n=5, 
p<0.05)(Figure 5.5.D-E)). 
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Figure 5.5: Assessment of regeneration with CTX damaged muscle treated with vehicle or AF-CM. 
(A) CD31 staining for capillaries in healthy (PBS) and regenerating muscle treated with vehicle (CTX) 
or AF-CM (CTX CM). (B) Quantification of capillary density (no. per mm2) and (C) quantification per 
fibre.  (D) F4-80 staining for macrophages in healthy (PBS) and regenerating muscle treated with 
vehicle (CTX) or AF-CM (CTX CM). (E) Damaged areas assessed for the number of F4-80+ cells. Black 
arrows indicate F4-80
+
 cells. (A, D) Scale bar represents 50μm. Values are expressed as means ± SEM 
(n=5). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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AF-EV Treatment in an Acute Damage Model 
Next, we examined the ability of the AF-EV to accelerate regeneration in the damage model in vivo 
(Figure 5.6.). Firstly, staining of eMHC was carried out. The CSA of eMHC stained fibres were analysed 
(Figure 5.6.A-B). A significantly larger newly regenerating fibre CSA was recorded from muscle 
treated with AF-EV compared to those treated with the vehicle (n=5, p<0.001). Vehicle treated mice 
with CTX damaged muscles had an average eMHC stained fibre CSA of 484.51±68.27µm2 whereas AF-
EV treated Mice with CTX damaged muscles had an average eMHC stained fibre CSA of 
926.66±24.23µm2, 91.26% larger.  
Furthermore, analysis showed that AF-EV treatment had also brought levels of CD31+ vessels/fibre 
back to a level that was not significantly different to that of the non-damaged muscles, 1.31±0.07 
CD31+/fibre and 1.37±0.10 CD31+/fibre respectively (Figure 5.6.C-D). Also, AF-EV treatment in CTX 
damaged muscles had significantly higher level of CD31+/fibre than the vehicle treated CTX damaged 
muscles, 1.01±0.08 CD31+/fibre (n=5, p<0.05). 
On the other hand, counts of F4-80+ cells/mm2 showed no significant differences between the AF-EV 
and vehicle treated CTX damaged muscles, 3437±240.91 F4-80+ cells/mm2 and 3606.67±250.64 F4-
80+ cells/mm2 (Figure 5.6.E-F). However, a significant increase in F4-80+ cells were seen within CTX 
damaged muscles from that of the undamaged, 666.67±88.19 F4-80+ cells/mm2 (n=5, P<0.001). 
Further investigation into how AF-EV could enhance regeneration was carried out into the satellite 
cell and committed progenitor cell status. Levels of quiescent Pax7+/MyoD- cells did not differ 
between the vehicle treated, 0.56±0.29 cells/mm2, and AF-EV treated, 1.43±0.53 cells/mm2, CTX 
damaged muscles. On the other hand, the level of activated Pax7+/MyoD+ cells were significantly 
higher in the AF-EV treated, 1.15±0.27 cells/mm2, compared to the vehicle treated, 0.33±0.33 
cells/mm2 (n=5, p<0.05). However, committed Pax7-/MyoD+ cell levels did not differ between the 
vehicle and AF-EV treated CTX damaged groups of muscles, 0.22±0.22 cell/mm2 and 0.71±0.29 
cells/mm2. 
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Figure 5.6: Muscle regeneration following AF-EV treatment. (A) Embryonic Myosin heavy chain 
expression in damaged muscle (green). (B) Quantification of cross-sectional area of newly 
regenerated fibres. (C) CD31 staining for capillaries in regenerating muscle. (D) Quantification of 
CD31
+
 capillaries per fibre. (E) F4-80 staining for macrophages. (F) Damaged areas assessed for the 
number of positive F4-80 cells/mm
2
. Comparison of the number of Pax-7
+
/MyoD
- 
quiescent satellite 
cells (G), Pax-7+/MyoD+ activated satellite cells (H) and Pax-7-/MyoD+ muscle lineage committed 
progenitor cells (I) per mm
2
 between treated groups. Values are expressed as means ± SEM (n=5). (A) 
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Scale bar equal to 100µm. (C, E) Scale bar represent 50μm. p < 0.05 (*), p < 0.01 (**) or p < 0.001 
(***). 
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Comparison of AF-CM, AF-EV and Soluble Fraction in an Acute Damage Model  
Each of the fractions that make up the AF-CM may have different regenerative qualities following 
acute damage in vivo. Both the AF-EV and resultant soluble fraction were used as treatments along 
with the whole AF-CM. Treatments were compared to each other and a vehicle treated CTX damaged 
positive control. First we compared average CSA of eMHC stained fibres from across the total TA 
muscle section (Figure 5.7.A). A significant increase in CSA could be seen compared to the vehicle 
treated control (475.22±2.65µm2) with the AF-CM treatment (775.39±28.30µm2), AF-EV treatment 
(735.74±55.35µm2) and soluble fraction treatment (790.47±72.20µm2) (n=5, p<0.01, 0.05 and 0.01 
respectively). However, no significant different was detected between the AF-CM derived 
treatments. A more detailed inspection into the CSA of newly regenerating fibres within the 
superficial and deep area was also carried out to identify if the AF-CM and its derived fractions had 
differing effects on these areas (Figure 5.7.B-C). Within the superficial area AF-CM, AF-EV and the 
soluble fraction treatment led to a significantly larger average CSA in eMHC stained fibres compared 
to the vehicle treated control; 759.93±54.21µm2, 759.50±46.34µm2, 820.24±87.53µm2 and 
450.48±28.18µm2 respectively (n=5, p<0.05, 0.05 and 0.01). On the other hand, within the deep 
region of the TA muscle sections only the whole AF-CM treatment (789.41±38.39µm2) and the 
soluble fraction (763.15±60.92µm2) treatment led to a significantly larger CSA in eMHC stained fibres 
compared to the control, 498.19±25.35µm2 (n=5, p<0.05). The AF-EV fraction on the other hand, 
713.06±84.39µm2, did not show a significantly higher CSA compared to the control. Additionally, 
there were no significant differences in CSA between the AF-CM derived treatments in either of the 
superficial or deep regions of the muscle. 
Analysis into the number of CD31+ vessels/ fibre showed that only the whole AF-CM significantly 
increased the numbers to 1.36±0.20 CD31+/fibre from 0.75±0.07 CD31+/fibre in the control (n=5, 
p<0.05). Whole AF-CM treatment also showed significantly higher levels of CD31+ vessels/fibre 
compared to the soluble fraction treated group, 0.79±0.08 CD31+/fibre (n=5, p<0.05). However, 
neither AF-EV treatment (1.07±0.10 CD31+/fibre) nor the soluble fraction treatment led to a 
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significant increase in CD31+ vessels/fibre from the control. Moreover, when profiling Pax7/MyoD 
expression of cells within the sections, only AF-EV (3.52±1.00 cells/mm2) and treatment with the 
soluble fraction (4.92±1.03 cells/mm2) led to a significantly larger number of Pax7+/MyoD+ cells 
compared to the vehicle treated CTX control, 0.97±0.59 cells/mm2 (n=5, p<0.05). No other significant 
effect from the control was seen with other treatments or within that counted for Pax7+/MyoD- or 
Pax7-/MyoD+ expression. 
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Figure 5.7 
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Figure 5.7: Comparison between whole AF-CM, AF-EV and soluble fraction treatment in a model of 
CTX damage. (A) Quantification of cross-sectional area of newly regenerated fibres across the total 
TA muscle sections. (B) Quantification of cross-sectional area of newly regenerated fibres in the 
superficial region of the TA muscle sections. (C) Quantification of cross-sectional area of newly 
regenerated fibres in the deep region of the TA muscle sections. (D) Comparison of the number of 
CD31
+
 capillaries per fibre. (E) comparison of the number of Pax-7+/MyoD- quiescent satellite cells, 
Pax-7
+
/MyoD
+
 activated satellite cells and Pax-7
-
/MyoD
+
 muscle lineage committed progenitor cells 
per mm
2
. Values are expressed as means ± SEM (n=5). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Discussion 
Histological analysis of CTX damaged TA muscles from mice treated with or without AF-CM or its 
resulting fractions were carried out. Results showed that although the CTX damage model presented 
with regenerating fibres, muscles also showed widespread macrophage infiltration. In comparison to 
those untreated damaged muscles, muscles treated with the AF-CM displayed newly regenerating 
fibres of dramatically larger cross sectional areas. Furthermore, the number of active muscle 
precursors was noticeably higher within those treated with AF-CM. Regarding inspection of the 
vasculature within damaged muscles; the treatment of AF-CM had not only increased the number of 
blood vessels within a given damaged area but had also increased the number of blood vessels per 
muscle fibre. Interestingly, the AF-CM treatment was suggested to have increased the total number 
of macrophages within the damaged muscle. Upon replacement of AF-CM treatment with its 
resulting AF-EV fraction, damaged muscles still showed similar regenerative characteristics to its 
originating AF-CM. However, following comparison between AF-EV and the AF-CM soluble fraction, it 
was evident that treatment would benefit from the mixture of the two fractions because each was 
not as potent under the measures tested. It was therefore concluded that the whole AF-CM may be 
the more beneficial for use as a regenerative therapeutic and could not be replaced entirely by one 
of its fractions. 
Widespread Inflammation and Tissue Damage Following Cardiotoxin Injection  
Initially, mice were either treated with vehicle or whole AF-CM just prior to CTX induced TA muscle 
damage. Histological analysis of sections taken from the TA muscles, were stained using H&E 
techniques. Images provided the location of direct damage as indicated by the alteration in colour 
from the normal bright pink colouration towards a darker purplish colouration. This change in 
colouration can be explained by the reduction in cytoplasmic surface area, which would usually stain 
pink due to Eosin in the staining process staining the eosinophilic proteins within the cytoplasm of 
cells and fibres. Furthermore, an increase in the number of smaller cellular structures, most likely to 
be made up of infiltrating inflammatory cells, is apparent and provides an increase in the number of 
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purple haematoxylin stained nuclei within the region. In addition to this change in colouration within 
the predicted damaged region, the presence of centrally located nuclei within small fibres provides a 
tell-tale sign of regeneration and in this case, as a consequence of damage. Centralisation of the 
nucleus within early myotubes and also immature myofibres results from the microtubule network 
driving, along with its regulator Cdc42, the nuclei towards the nuclear envelope of other nuclei within 
the myotube (Roman and Gomes, 2017). The microtubule network organising centre is located at the 
nuclear envelope in differentiating myoblasts and myotubes, as opposed to the cytoplasm, in which 
it would normally be located in the majority of other cell types (Roman and Gomes, 2017). Another 
reason for the central location of the nucleus stems from the lack of organisation of neuro muscular 
junctions yet to be established during regeneration, a key aspect of a mature functioning myofibre. 
Further analysis into the status of the muscle sections and the damaged now regenerating areas was 
taken from acid phosphatase staining. No significant differences in acid phosphatase staining were 
established between the vehicle and AF-CM treated mice that had been affected with CTX. There was 
however a clear difference between those affected with CTX and those that were not. The strong 
presence of staining within the damaged regions suggests the presence of a large infiltration of 
inflammatory cells, thought to be macrophages, as well as the prolific inflammatory status of the 
tissue. The current inflammatory status could be attributed to previous necrotic events and or 
infiltration of inflammatory cells. 
AF-CM Treatment Accelerated Newly Regenerating Fibre Growth 
Although the presence of centrally located nuclei indicates regenerating myofibres, the presence of 
eMHC can be used to identify newly regenerating myofibres. It was noted that some larger fibres 
contained centrally located nuclei and yet lacked notable levels of eMHC. As the myofibres mature 
the expression of eMHC is replaced by a mature form of MHC however the presence of centrally 
located nuclei must still exist for some time after this switch until true maturation is reached. 
Analysis into the deep, superficial and the total area of the eMHC stained fibres unveiled that AF-CM 
treatment had led to a significantly larger CSA compared to the CTX damage control. The larger CSA 
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in AF-CM treated muscles therefore suggests that the AF-CM had accelerated the regenerative 
process and therefore sped up the maturation of the newly regenerating fibres towards a larger fibre 
of healthy status. Furthermore, because AF-CM increased the CSA of newly regenerating fibres of 
both the deep and superficial region of muscle it is suggested that acceleration of skeletal muscle 
fibres due to AF-CM treatment is not notably affected by metabolic state. Similar results would 
suggest that AF-EV contained at least some of the AF-CMs regenerative effects. The results showed 
that AF-EV treatment led to significantly larger newly regenerating fibre CSAs. This therefore 
suggested that the binding of the AF-EVs or indeed the effects of their cargo led to acceleration in 
the development of newly regenerating fibres.  
Increased Numbers of Macrophages in AF-CM Treated Muscles 
As substantiated by the acid phosphatase staining, a large infiltration of macrophages can be seen 
within the muscles of those damaged with CTX. This was even more exaggerated within those 
originally treated with AF-CM. In contrast to the AF-CM, the level of F4-80 cells in AF-EV treated 
muscles were shown to not change and once again suggests that the soluble fraction has an 
important part to play in altering the level of macrophages and therefore the inflammatory state of 
the tissue. Furthermore, it has been previously been shown that MSC-EVs have lower levels of 
cytokines such as IL-6 (Nakamura et al., 2015). It was also found within a model of necrotising 
enterocolitis that treatment with AFSCs increased the levels of COX2, known to be involved in 
inflammatory signalling (Zani et al., 2014). Increases in COX2 activity was believed to aid the 
enhancement of gut stem cell proliferation and therefore replace intestinal cells lost due to 
widespread necrosis. Classically pro-inflammatory cytokines or induced signalling may also exist in or 
be promoted by the AF-CM in the same manner. It is proposed that a spike in these cytokines due to 
AF-CM could induce a larger M1 macrophage response and therefore facilitates the clearing of debris 
more efficiently thus clearing the way for M2 cells to accelerate regeneration (Arnold et al., 2007). 
Due to the time-span in which the muscles were collected it could be hypothesised that many of the 
macrophages seen to be stained were M2 macrophages and therefore classically anti-inflammatory. 
 Chapter 5 
Page | 166  
 
Levels of M1 macrophages are known to spike within the first 48h followed by their replacement by 
M2 cells as the spike diminishes (Villalta et al., 2009, Arnold et al., 2007, Perdiguero et al., 2011, 
Perdiguero et al., 2012). However, although both M1 and M2 macrophages have differing ratios of 
classically M1 or M2 surface markers they still both retain positivity for these markers regardless 
(Daigneault et al., 2010, Chanput et al., 2013, Akagawa, 2002, Verreck et al., 2006). Staining of 
muscle sections for an M2 marker, such as Mannose receptor, would therefore stain most if not all 
macrophages because most macrophages would retain this marker even in an M1 state, just at lower 
levels. Therefore clarification as to whether the AF-CM altered macrophage polarisation is difficult 
histologically and therefore requires isolation of macrophages from the muscle, which could be 
analysed for the ratio of M1/ M2 marker expression using flow cytometry.  
AF-CM Treatment Increased the Number of Committed Muscle Progenitor Cells 
To understand how the AF-CM potentiates the acceleration of the myofibre regeneration, it was also 
necessary to ascertain if the satellite cell activity had been altered. No significant difference between 
the numbers of quiescent or active satellite cells could be seen. On the other hand, there was a 
significantly higher level of committed progenitor cells. The muscles were collected 5 days after 
injury which would suggest that the majority of satellite cell activation had already taken place and 
had already begun to commit to myogenic differentiation. AF-CM could therefore have already led to 
increased satellite cell activation in the initial stages of damage providing more active cells for 
commitment. However, this cannot be confirmed with this data. On the other hand, a higher number 
of committed myoblasts would provide a greater number of cells to fuse together to form myotubes 
and thus accelerate myotube/fibre formation.  
It was however interesting to note that the AF-EV treatment unlike the whole AF-CM led to 
significantly more activated Pax7+/MyoD+ cells within the damaged region compared to the vehicle 
treated damaged muscles. No differences were seen however in the committed Pax7-/MyoD+ cell 
population, unlike that seen with AF-CM treatment. These results suggest that paracrine factors 
within the soluble fraction of the AF-CM are overriding that of the AF-EV thus driving increased levels 
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of committed cells. On the other hand, the combined effects of the soluble fraction and AF-EV might 
be required for increasing the level of the committed cell population. 
The use of bone marrow derived MSCs in previous research on C2C12 cells showed that the MSC-CM 
caused increased proliferation and differentiation as indicated by the increased cell numbers and 
then increased expression of MyoD1 and Myogenin (Nakamura et al., 2015). This effect could 
therefore also be caused by the AF-CM treatment. Additionally it is widely accepted that the use of 
an MSC secretome as a therapeutic would most probably have a large short term effect as opposed 
to lasting over the time of a week (Balbi et al.). The majority of EVs or solubilised proteins would 
already be intercepted and therefore have produced an effect within the first 24 hours. This suggests 
that because the AF-CM treatment took place once and on the first day of damage, its effects are 
most likely to have increased the proliferation and therefore the numbers of active satellite cells. 
This, as discussed, would provide a larger number of committed cells as seen after 5 days in these 
results. 
AF-CM Increased the Number of blood Vessels within the Regenerating Tissue 
Damage within muscle usually leads to the activation of an angiogenic programme to provide enough 
nutrients and oxygen to the regenerating area. An increase in the number of fibres within a given 
area can be accounted for by the increase in small regenerating fibres and therefore an ability to fit 
more fibres in the area of damage. Each fibre is dependent on the local capillary network for its 
supply of nutrients. In an undamaged muscle, around 500 capillaries infiltrate the TA within a mm2 
area and each fibre was shown to have about 1 capillary within its immediate vicinity as evidenced by 
the data in Figure 3D-E. It was however clear that although the angiogenic programme pursued 
following damage increased the number of what was believed to be capillaries within the given 
damaged area, the number of these vessels/ fibre diminished. Furthermore, AF-EV treatment 
instigated increased vascularisation, bringing about levels of CD31+ vessels significantly higher than 
found in the damaged control and to a level that was comparable to the non-damaged control. 
Similarly to what was seen with the whole AF-CM, this increase in vascularisation can be suggested as 
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being a major factor contributing to the enlarged regenerating fibres because of an increased supply 
of blood, nutrients and oxygen. 
It has been shown previously that treatment with AFSC, other MSCs and their EV content promotes 
angiogenesis (Rahbarghazi et al., 2013, Gnecchi et al., 2016, Balbi et al., Lee et al., 2009, Lee et al., 
2012a). An increase in both the level of CD31+ vessels in the given area as well as per fibre due to AF-
CM treatment is believed to provide further nutrients and oxygen to those newly regenerating fibres. 
This improved vascularisation is suggested to be due to the AF-CM treatment and that it has at least 
in part accelerated fibre regeneration. The metabolism of regenerating fibres throughout the muscle, 
both within the deep and superficial area, would be hypothesised as being more similar than those of 
mature fibres within the two differing regions. The need for oxygen and nutrients at this stage of 
regeneration would therefore also be similar and accounts for newly regenerating fibres in both the 
deep and superficial region having been similarly positively affected by the AF-CM. Furthermore, a 
higher level of oxygen would maintain the oxidative metabolism of differentiating myoblasts thus 
accounting for higher levels of committed Pax 7-/MyoD+ cells discussed previously (Koopman et al., 
2014, Folmes et al., 2011, Zhang et al., 2011, Zhang et al., 2012). 
Both AF-EV and the Soluble Fraction are Important for Improved Regeneration 
To further provide evidence that the soluble fraction has a key role to play in the regenerative 
actions of the AF-CM, mice were treated with either the whole AF-CM or one of the two fractions, 
AF-EV or the soluble fraction. All three AF-CM based treatments resulted in larger newly regenerating 
fibre CSAs across the total damaged region suggesting that key components required for this 
accelerated increase in CSA is shared by both fractions. This result was mirrored in the superficial 
region. However, in the deep region only the AF-CM and soluble fraction provided significant 
increases in CSA. Increases in superficial fibre size but not deep fibre size with the AF-EV fraction 
suggests that the AF-EV is lacking a component of the soluble fraction that is able to utilise signalling 
found mainly in superficial fibres. The superficial region of a healthy muscle is documented as 
consisting of mainly glycolytic type IIB MHC containing  fast twitch fibres as opposed to the deep 
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region which consists mainly of oxidative fast twitch fibres containing type IIA MHC (Omairi et al., 
2017). If the soluble fraction and therefore the AF-CM contain more paracrine factors that aid 
regeneration via metabolic pathways compared to the AF-EV they may be more suited to 
regenerating the deep portion of the muscle. The AF-EV on the other hand could be hypothesised to 
not contain these unknown factors and can only improve regeneration significantly in the glycolytic 
superficial region which is not as dependent on oxidative metabolism. Only AF-CM treatment created 
a significantly larger vascularisation compared to the damaged control and further evidences its role 
through the enhancement of oxidative metabolism. The variation between experiments when 
looking at treatment of the mice with fractions of the AF-CM solidifies the idea that the fractions 
alone do not provide a reliable therapeutic effect. Therefore a combination of the fractions, such as 
that found in the whole AF-CM, would be suggested as being the most reliable route for therapeutic 
treatment with a mind to accelerate regeneration following necrotic damage.  
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6. Chapter 6 
Establishment of an NEC Intestinal Organoid Model to 
Test the Regenerative Capability of AFSC CM 
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Introduction 
Due to advances in healthcare more pre-term born infants are surviving to full term. However, 
because more infants are initially surviving premature birth with under-developed respiratory, 
immune and cardiovascular systems, the level of those being affected by NEC is increasing. There is 
around a 35% mortality rate in those affected. The need to identify a treatment for NEC other than 
just surgical resection of the affected gut, which can lead to long term health problems for the child if 
they do survive, is becoming ever more important. The use of AF, subsequently AFSCs and their 
paracrine factors has been previously suggested as a potential therapy for NEC (Zani et al., 2014). 
However, an AF-CM that is created in such a way that is suitable for future clinical use had not been 
tested. The AF-CM used here, as discussed therefore needed a model of NEC to test its regenerative 
capabilities and ability to inhibit any pathological affects associated with the environment of the gut 
in NEC patients. However, the production and use of an in-vivo rodent model by others that mimics 
NEC leads to animals presenting with an extremely severe condition that is often perceived as being 
too harsh to allow in the UK. Therefore the use of 3D intestinal organoids treated with either LPS or 
TNF-α, acting as inflammatory stimuli, was believed to be the next best option. 
NEC Background 
Although the causes are complex, the main reason for its onset is believed to be due to a lack of 
respiratory, intestinal and immune system development (Sharma and Hudak, 2013). Often an 
underdeveloped respiratory system causes onset of ischemia upon birth. Aggressive feeding leads to 
an increased demand for blood flow to the intestine, however the need for oxygen in the rest of the 
body reduces the oxygen levels available in the intestine, which is relatively less important than that 
of other organs such as the heart (Sharma and Hudak, 2013). As a consequence the gut becomes 
hypoxic and homeostasis of cell turnover compromised. Increased stasis eventually leads to microbial 
dysbiosis and the normal cross-talk between the intestinal epithelium and microflora is disrupted 
(Emami et al., 2009). High levels of LPS derived from the gram-negative bacterial colonisation is 
believed to induce a leaky intestine making the infant vulnerable to sepsis (Guo et al., 2013). An 
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elevated level of cytokines and inflammatory signalling not only leads to widespread apoptosis and 
necrosis but also triggers the infiltration of innate immune cells such as macrophages. Such cytokines 
include IL-6 and TNF-α (Sharma and Hudak, 2013, Zani et al., 2014, McElroy et al., 2011). Overzealous 
macrophages due to an immature immune system hyper-respond to the inflammation. LPS and 
presence of bacteria further exacerbate the pro-inflammation within the gut and therefore the cycle 
of inflammation and cell death is intensified.  
Cell Types of the Intestine and Their Role in NEC 
Severe NEC affected intestines present with extreme sloughing of the epithelial layer and therefore a 
loss of villi architecture (Koike et al., 2017). To some extent the severity of NEC has been postulated 
as being due to reduced gastric motility, which in itself is caused by a number of factors (Koike et al., 
2017). The intestinal epithelial layer is composed of a number of cell types. One is the Goblet cell, 
which produces mucus through the production of a range of Mucins, including Mucin-2. Mucus 
production in the gut serves not only as a primary barrier to protect from excessive sloughing, but 
also acts to prevent over colonisation by bacteria, prevents direct bacteria contact with the epithelia 
and also aids the motility of food through the intestine. High levels of inflammatory factors, in 
particular TNF-α have been shown to deplete the level of mucus production within the intestine and 
have therefore been hypothesised as playing a key role in the induction of NEC (Ahn et al., 2005, 
McElroy et al., 2011).   
Furthermore, stresses imposed on the intestine leading to NEC have a profound effect on the local 
stem cells. Although a reserve population of Bmi1 expressing stem cells have been found to exist, 
and rapidly proliferate to replace those lost due to stress, overwhelming, continuous and excessive 
inflammation is thought to exhaust the stem cell population (Yan et al., 2012, Tian et al., 2011, Zhu et 
al., 2013). Reduced stem cell levels due to exhaustion and cell death dramatically decreases the 
ability of the intestine to replace lost epithelia.  
Interplay between the resident stem cell population and Paneth cells provide signalling for the stem 
cells to proliferate and retain a healthy population of multipotent stem cells. Short range Wnt 
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signalling from the Paneth cells is detected by the adjacent stem cells thus retaining stem cells in 
their proliferative and progenitor state (Sato et al., 2011). MyD88 signalling and its downstream 
effects, presumably including NF-κB, following TLR activation triggers the production of multiple anti-
bacterial factors by the Paneth cell, such as Reg-IIIγ (Vaishnava et al., 2008). Reduced Paneth cell 
numbers and their juxtacrine signalling, negatively impacts not only on the stem cell pool but also the 
hosts defences. 
Gut motility is also regulated by mesenteric neuronal stimulation. Enteroendocrine cells within the 
villi secrete a range of hormones and paracrine factors that not only communicate with the local 
nervous system but also help to regulate normal cell homeostasis (Moran et al., 2008, Bohórquez et 
al., 2015). An important secreted peptide of the enteroendocrine cells is Chromogrannin-A (ChA). 
ChA is also a pre-cursor to a number of other secreted proteins required for signalling such as 
vasostatin and chromostatin (D'amico et al., 2014, Rumio et al., 2012, Eissa et al., 2018). Increases in 
ChA in patients and models of IBD and colitis are believed to have an immuno-regulatory role (Eissa 
et al., 2018). Interestingly, although ChA has a low affinity for Ca2+, it has a high capacity to do so 
(Eissa et al., 2018). The ability to mop up extracellular Ca2+ has been suggested to play a key role in 
regulating the functionality of smooth muscle contractions around the gut as well as that required 
for T-cell inflammatory responses (Eissa et al., 2018). Oral administration of vasostatin, the N-
terminal derivative of ChA, in mouse models of dextran sodium salt (DSS)-induced colitis was shown 
to inhibit the production of inflammatory cytokines and chemokines whilst also maintaining tight 
junction permeability (Rumio et al., 2012).  
Disadvantages of In Vivo NEC Models 
Rats induced to NEC through gavage-feeding with hyperosmolar formula, hypoxia and oral 
administration of LPS had been shown to have under a 20% survival at 7 days, all of which had died 
before 15 days (Zani et al., 2014). Due to the extremely high mortality rate of the in-vivo models, 
studies require large numbers of animals to ensure that they are statistically powerful enough even if 
animals die prior to experimental endpoints. It is therefore beneficial to have a model which retains 
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many of the cell types important within the intestine, in particular the epithelial layer of the villi and 
its crypts thus retaining an ability to undergo high levels of inflammation and cell death but also 
capable of regenerating. 
Intestinal Organoids 
With the knowledge that the local stem cell population within the crypts of the intestine were 
capable of differentiating into most of the varying cell types within the villi the idea of reconstituting 
this same system in culture was tested (Sato et al., 2009). Two approaches to creating mini intestinal 
organoids have been established. The first utilises the ability of the Lgr5+ stem cells to reconstitute 
the cell niche within a 3D matrix, such as Matrigel, whilst supplementing cultures with essential 
growth factors such as EGF, Noggin, and R-spondin (Sato et al., 2009). This approach either uses 
sorted and isolated Lgr5+ stem cells or develops organoids from primary isolation of intestinal crypts 
containing these stem cells without the need of sorting. On the other hand, iPSCs have also been 
shown to be effective at providing a source of intestinal like stem cell that can also reconstitute the 
cells found naturally in-vivo. iPSCs can be directed towards an endodermal lineage with Activin and 
then subsequently hindgut maturation with FGF-4 and Wnt3A (Spence et al., 2010, Date and Sato, 
2015). Interestingly, the mesenchymal cells are also capitulated simultaneously, of which cells attach 
to the budding epithelia monolayer that forms from the developing spheroids. This additional 
mesenchymal layer provides a further intestinal niche and is thought to provide paracrine factors 
such as R-spondin and Wnt proteins thus promoting stem cell self-renewal (Date and Sato, 2015, 
Spence et al., 2010). Furthermore, iPSC derived intestinal organoids are believed to resemble foetal 
epithelium as opposed to the adult like epithelium created through the first method discussed (Date 
and Sato, 2015). In common with both systems is the ability of intestinal organoids to produce crypt 
like structures with villus architecture and a simple but enclosed lumen.  
Intestinal Organoids for Models of NEC 
The ability to create intestinal organoid systems replicating the environment of the intestine in-vivo 
meant that additional factors could be added to culture to create models of pathology or organoids. 
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Furthermore, stem cells used to create organoids could be isolated from transgenic mice to create 
transgenic organoids. In addition to this, the self-replicating ability of organoids decreases animal 
usage. Taking what was known about the pathology surrounding NEC, the use of LPS or hypoxia had 
been used to replicate the NEC condition in organoids (Chen et al., 2012, Neal et al., 2012, Egan et 
al., 2015). Significantly smaller organoids were found to develop under hypoxic conditions compared 
to those cultured under normoxia (Chen et al., 2012) Furthermore, the use of E.coli LPS and 
subsequent TLR-4 signalling was also separately shown to induce significant increases in CC3 and 
decreases in PCNA suggestive of increased apoptosis and decreased proliferation (Neal et al., 2012). 
The use of organoids to model NEC allows the testing of AF-CM, by-passing to a certain extent the 
need to use the harsh as well as still developing in-vivo models. We wanted to first replicate what has 
been shown by other work, such as that produced by Neal et al, that shows LPS mimicking an NEC 
like cell death in organoids following LPS exposure (Neal et al., 2012). Furthermore, the use of TNF-α 
was also hoped to bring about a similar response. It was also hoped that differences in stress 
associated protein synthesis and autophagy signalling could be identified following stimulation of 
organoids along with AF-CM bringing about a reversal in this signalling back to that seen in 
unstimulated control organoids.  
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Results 
LPS and TNF-α Stimulation of Organoids 
Previous studies show the effectiveness of AFSCs to hinder the damage caused by, as well as 
extending life-span of those affected by the pre-term neonatal disease NEC (Zani et al., 2014). The 
potential of the AF-CM to treat NEC was also tested (Zani et al., 2014). An in-vitro 3D mouse model of 
the intestine was established and introduced to acute levels of inflammatory stimuli in a bid to mimic 
the cellular environment seen in NEC. Intestinal organoids from 6 week old mice had a lumen, villus 
domain and crypts all characteristic of an intestine in-vivo (Figure 6.1.A). Organoids were cultured 
with media containing either 10ng/ml TNF-α or 10μg/ml E.coli LPS from 30 minutes to 2 hours and 
differences in selected gene expression compared (Figure 6.1.B-E). Following treatment of organoids 
with TNF-α from 30 minutes to 2 hours, organoids showed a significantly elevated level of TNF-α 
gene expression compared to both the non-treated control and other tested conditions (n=3, 
P<0.01). After 1 hour of TNF-α treatment organoids had 12.6 times the TNF-α level compared to the 
control and over twice the level seen at 30 minute and 2 hour exposures. TNF-α gene expression did 
not significantly differ from the control between 30 minutes to 2 hours. On the other hand, 
treatment of organoids with LPS showed no significant alterations in TNF-α gene expression at 30 
minute and 1 hour exposures. However, after 2 hours of LPS treatment organoids showed 
significantly reduced levels of TNF-α gene expression compared to all other treatments and in 
particular 69.7% less expression compared to the non-treated control organoids (n=3, p<0.05).  
In the case of TGF-β gene expression, neither the TNF-α treatment or LPS treatment at any exposure 
tested showed any significant changes from the control. Furthermore, none of the treatments 
showed any significant differences in TGF-β gene expression between the different exposure timings. 
Next expression of Mucin-2 was examined. After 30 minutes exposure to TNF-α organoids showed 
significantly higher levels of Mucin-2 expression compared to that of the non-treated control (n=3, 
p<0.05). Mucin-2 gene expression levels were 36% higher after 1h exposure to TNF-α compared to 
the untreated control. Furthermore, Mucin-2 expression after 30 minutes exposure of TNF-α was 
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significantly higher than that seen after 2 hours, which was 45% lower than that at 30 minutes (n=3, 
p<0.05). However, treatment of organoids with LPS showed no significant change in Mucin-2 
expression compared to any other treatment or length of LPS exposure. 
To understand whether LPS or TNF-α had induced apoptosis, organoids were exposed to varying 
concentrations of LPS at 10μg/ml, 50μg/ml and 100μg/ml LPS or 20ng/ml TNF-α for 2 hours (Figure 
6.1.E). The level of cleaved- caspase-3 (CC3) protein, associated with apoptosis, was measured. The 
lowest concentration of LPS used (10μg/ml) which has previously been shown to induce cell death in 
the organoids produced no significant changes in the level of CC3 compared to the non-treated 
control or other treatment groups (Egan et al., 2015). However stimulation with 50μg/ml LPS led to 
significantly higher levels of CC3 compared to both the untreated control and those treated with 
10μg/ml LPS but also those treated with TNF-α (n=3/ p<0.05). Levels of CC3 after 50μg/ml LPS 
treatment were 4.8 times higher than that of the untreated control and 10μg/ml LPS treated 
organoids and 6.4 times higher than those treated with TNF-α. Additionally, treatment with 
100μg/ml LPS significantly increased CC3 protein expression compared to that of the control, 
10μg/ml LPS treated and TNF-α treated (n=3, p<0.01). CC3 levels after 100μg/ml LPS treatment were 
2.5 times more than the non-treated and 10μg/ml LPS treated organoids and 3.3 times higher than 
the TNF-α treated organoids. Treatment with 20ng/ml TNF-α did not lead to significant changes in 
CC3 levels compared to the untreated control. 
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Figure 6.1: Organoids stimulated with E. coli LPS or TNF-α for up to 2 hours and at different 
concentration. (A) Organoids derived from the small intestine of C57BL/6 mice 3 days after harvest. 
Images a) and b) were taken at different focal points to visualise the depth of the organoids 3D 
morphology. (A) Scale bar representative of 100μm.Gene expression values of TNF-α (B), TGF-β (C) 
and Mucin-2 (D) in organoids stimulated with 10ng/ml TNF-α (TNF) or 10μg/ml LPS for either 30 
minutes, 1 hour or 2 hours. (E) Protein expression of cleaved caspase-3 (CC3) in organoids stimulated 
with either 10μg/ml, 50μg/ml or 100μg/ml LPS for 2 hours. Arrows indicate crypt domains forming 
with the organoids Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 
0.001 (***).  
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Histological analysis of organoids treated with the varying concentrations of LPS for 2 hours was also 
carried out because of the increased CC3 seen at this time-point (Figure 6.2.A-F). Non-treated 
organoids and organoids treated with 10μg/ml, 50μg/ml and 100μg/ml LPS were stained for the 
proliferation marker Ki-67 along with the transmembrane adhesion molecule E-cadherin and nucleic 
marker stain DAPI. Statistical analysis showed the extent of co-localisation between the Ki-67 stain 
and DAPI staining. A significant increase of 42% in co-localisation was seen following the 10μg/ml LPS 
treatment compared to the non-treated control (n=4, p<0.05). This increase was also significantly 
higher than that seen following treatment with 100μg/ml LPS; 82.0% higher than the 100μg/ml 
treatment (n=4, p<0.05). No difference was seen between those treated with 50μg/ml and the other 
groups. Relative intensity of E-cadherin was analysed between groups. However, no differences 
between LPS treatments of the non-treated control were seen.  
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Figure 6.2 
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Figure 6.2: Immuno-fluorescent analysis of organoids stimulated with E.coli LPS 2 hours. Organoids 
stimulated with (A) PBS, (B) 10μg/ml, (C) 50μg/ml or (D) 100μg/ml LPS for 2 hours, sectioned and 
stained for DAPI (magenta/ blue) Ki-67 (green) and E-cadherin (red). (E) Statistical co-localisation of 
Ki-67 and the nucleus (DAPI) using Pearson's’ R values from stained samples. (F) Comparison of E-
cadherin intensity within the cellular membrane of stained organoids. (D) Scale bar is representative 
of 500μM. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Following short term exposure of organoids to LPS and TNF-α, organoids were exposed to 10μg/ml 
LPS or 10ng/ml TNF-α for 48 hours (Figure 6.3.A-D). Gene expressions of key proteins associated with 
the cells that make up the organoids were measured. Mucin-2, as previously discussed plays a key 
role in Goblet cell function. LPS significantly increased levels of Mucin-2 expression from the non-
treated control and also led to significantly higher levels compared to the TNF-α treated organoids 
(n=4, p<0.05).  LPS treatment after 48 hours led to 50.5% more Mucin-2 expression than the 
untreated control, whilst the TNF-α treatment led to levels 49.0% of that produced with the LPS 
treatment. TNF-α treatment produced no significant alteration in Mucin-2 expression compared to 
the non-treated control. 
Gene expression of Lysozyme-1, a protein encoded and secreted by Paneth cells, was analysed. LPS 
significantly increased Lysozyme expression by 50.0% from the non-treated control (n=4, p<0.01). 
Furthermore, the expression of Lysozyme following LPS treatment was 26.3% higher than that 
produced by the TNF-α treatment (n=4, p<0.05). TNF-α treatment produced no significant alteration 
in Lysozyme-1 expression compared to the non-treated control. 
The gene expression of Lgr5, a marker of intestinal stem cells and a receptor known to promote Wnt 
signalling was also analysed. Stimulation of the organoids with LPS led to significantly increased 
levels of Lgr5 gene expression compared to the non-treated control by 22% (n=4, p<0.05). Treatment 
with TNF-α also led to a significantly higher level of Lgr5 gene expression but by 26% compared to 
the non-treated control (n=4, p<0.01). On the other hand, there were no significant differences in 
Lgr5 expression between the LPS and TNF-α treated organoids. 
Finally, the gene expression of ChA, a frequently used marker of enteroendocrine cells of the 
intestine, was analysed.   No significant differences were seen between the non-treated control 
organoids and those treated with LPS for ChA expression. On the other hand, the TNF-α treatment 
significantly increased expression levels of ChA by 35.4% from the non-treated control (n=4, p<0.05). 
No significant differences were seen between the LPS and TNF-α treatment. Overall, it was shown 
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that differing concentrations of LPS and TNF-α could modulate the gene expression of organoids over 
differing time-points as well as altering levels of the apoptotic marker CC3.  
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Figure 6.3: Expression of genes commonly expressed in intestinal cells within organoids following 
stimulation of organoids with 10μg/ml E. coli LPS or 10ng/ml TNF-α for 48 hours. Gene expression 
of (A) Mucin-2, (B) Lysozyme-1, (C) Lgr5 and (D) Chromogranin-A. Values are expressed as means ± 
SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Gene Expression after Acute Stimulation and AF-CM Treatment 
After establishing how short exposures to LPS and TNF-α affected the organoids, organoids 
exposures to 10ng/ml TNF-α were repeated for 30 minutes and 1 hour. However, organoids were 
also treated with AF-CM for 24 hours before and the time during this TNF-α exposure. Gene 
expression of organoids was analysed and compared between the groups (Figure 6.4.A-E). TNF-α 
stimulation for 30 minutes on its own did not significantly alter the levels of TNF-α gene expression 
from the control (PBS treatment). TNF-α stimulation for 30 minutes along with AF-CM treatment also 
showed no significant difference from the control or from the TNF-α stimulation for 30 minutes 
alone. On the other hand, both organoid groups stimulated with TNF-α for 1 hour showed 
significantly higher levels of TNF-α gene expression compared to the control as well as those treated 
with TNF-α for 30 minutes, with or without AF-CM (n=3, p<0.001). The organoids stimulated with 
TNF-α for 1 hour without AF-CM treatment had gene expression levels 11.5, 6.6 and 5.7 times higher 
than that of the PBS controls, organoids stimulated with TNF-α alone for 30 minutes and organoids 
stimulated with TNF-α for 30 minutes and treated with AF-CM respectively. No significant difference 
between the 1 hour stimulated positive control and the 1 hour stimulated AF-CM treated organoids 
was seen with TNF-α gene expression. 
Analysis of TGF-β gene expression produced data with no significant differences between any of the 
treatment groups. No significant changes between groups were also seen with Lgr5 expression, 
Mucin-2 gene expression or the subsequently tested Lysozyme-1 expression. 
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Figure 6.4: Gene expression of organoids stimulated with 10ng/ml TNF-α for 0.5 hours or 1 hour 
with AF-CM treatment. Gene expression of (A) TNF-α, (B) TGF-β, (C) Lgr5, (D) Mucin-2 and (E) 
Lysozyme-1. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Comparison of AF-CM to AF-EV and AD-CM 
Next we examined the impact of AF-EV treatment on organoid gene expression and signalling 
following TNF-α stimulation. It was also important to ascertain whether CM produced from other 
stem cells, in particular adult derived stem cells, had the same potency as AF-CM in the way it 
affected organoids that were stimulated with TNF-α (Figure 6.5.A-D). Organoids were therefore 
stimulated with 10ng/ml TNF-α for 1 hour with or without treatments of AF-CM, AD-CM or AF-EV and 
compared to a non- TNF-α stimulated control. All groups of organoids stimulated with TNF-α 
presented with significantly elevated levels of TNF-α gene expression compared to the non-
stimulated control (n=3, p<0.01 and p<0.001). Levels of TNF-α gene expression in organoids 
stimulated with TNF-α with or without treatments were at least 5.5 times higher than that of the 
non-stimulated control. However, none of the CM treatments differed significantly between each 
other or the positive control.  Mucin-2 gene expression was also measured. Only AF-EV treatment of 
organoids stimulated with TNF-α significantly differed from the non-stimulated control (n=3, n<0.05). 
AF-EV treatment with TNF-α stimulation led to a 28% increase in Mucin-2 gene expression from the 
non-stimulated control. However, no significant differences in Mucin-2 gene expression were seen 
between the other groups.  
Due to previous results suggesting that AF-CM could alter NF-κB signalling, organoids were examined 
for NF-κB-p65. Nuclear intensity of p65 staining was measured and compared between the 
treatment groups discussed. Although p65 intensity did not significantly increased with TNF-α 
stimulation alone, all CM treatments significantly reduced nuclear intensity compared to that of the 
positive control (n=5, p<0.001 and 0.05). CM treatments did not show significant differences in p65 
nuclear intensity between each other however reduced levels to at least 23.4% of the positive 
control. Treatment with AF-EV did not significantly differ from the non-stimulated control whereas 
AD-CM and AF-CM showed significantly lower levels of p65 nuclear intensity compared to the non-
stimulated control (n=5, p<0.05). 
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Figure 6.5: Inflammation and NF-κB signalling in organoids stimulated with 10ng/ml TNF-α for 1 
hour with AF-CM, AD-CM or AF-EV treatment. Gene expression of (A) TNF-α and (B) Mucin-2. (C) 
Organoid stimulated with 10ng/ml TNF-α and stained for NF-κB-p65 ((p65) (green)) and DAPI 
(magenta) (D) Comparison of the level of NF-κB-p65 nuclear intensity between AF-CM, AD-CM and 
AF-EV as a treatment following TNF-α stimulation of organoids. (C) Scale bar is representative of 
500μM. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
  
 Chapter 6 
Page | 189  
 
Protein Expression after Acute LPS Stimulation and AF-CM Treatment 
Protein levels were measured after organoids were stimulated with 50µg/ml and 100µg/ml LPS for 2 
hours with or without AF-CM (Figure 6.6-8.). Organoids treated with 50µg/ml LPS with or without AF-
CM presented with significantly lower levels of CC3 compared to the unstimulated control (n=4, 
p<0.01).  Although organoids stimulated with 50µg/ml LPS without or with AF-CM did not differ 
between each other, treatments reduced CC3 protein levels by 57.2% and 51.7% from the 
unstimulated control. On the other hand treatment with 100µg/ml LPS without AF-CM treatment did 
lead to a significant increase in CC3 from the unstimulated control as well as being significantly 
higher than that of the 50µg/ml LPS treated organoid group (n=4, p<0.001). 100µg/ml LPS without 
AF-CM treatment in organoids showed 22.3% higher levels of CC3 compared to the unstimulated 
control and 66.7% higher levels compared to the 50µg/ml LPS without AF-CM treated organoids. 
Additionally, treatment of 100µg/ml LPS stimulated organoids with AF-CM led to a significantly 
reduced level of CC3 compared to the 100µg/ml LPS stimulated positive controls to one that was 
similar to the unstimulated control (n=4, p<0.05). AF-CM treatment of 100µg/ml LPS stimulated 
organoids reduced levels of CC3 by 42.3% compared to the positive control. 
Protein levels of E-cadherin did not significantly differ between organoids stimulated with or without 
50µg/ml LPS and the unstimulated control. However, stimulation with 100µg/ml LPS alone, organoids 
showed significantly elevated levels of E-cadherin compared to the unstimulated control (n=4, 
p<0.05). 100µg/ml LPS stimulated and increased E-cadherin levels from the unstimulated control by 
60.3%. Furthermore, treatment 100µg/ml LPS stimulated organoids with AF-CM showed levels of E-
cadherin similar and therefore not different to that of the unstimulated control but also not different 
to the positive control. 
Lysozyme-1 protein levels were shown to be significantly higher in those stimulated with 50µg/ml 
LPS alone compared to the unstimulated control, by 56.0% (n=4, p,0.05). Stimulation with LPS at 
50µg/ml also led to significantly higher levels of Lysozyme-1 compared to organoids stimulated with 
100µg/ml LPS with or without AF-CM treatment (n=4, p<0.01 and 0.05 respectively). However, 
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treatment of 50µg/ml LPS stimulated organoids with AF-CM led to significantly less Lysosyme-1 
protein levels compared to its positive control and to a level that did not significantly differ to the 
unstimulated control (n=4, p<0.01). AF-CM treatment had reduced levels to 26% of that seen in the 
50µg/ml LPS stimulated positive control. No significant change in Lysozyme-1 protein levels were 
seen following 100µg/ml LPS stimulation with or without AF-CM compared to the unstimulated 
control, neither were there differences between the 100µg/ml LPS stimulated groups. 
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Figure 6.6: Protein expression of organoids stimulated with either 50μg/ml or 100μg/ml E.coli LPS 
for 2 hours and treated with AF-CM. (A) Western blots of protein analysed. Protein expression of (B) 
cleaved Caspase-3 (CC3) (C) E-cadherin and (D) Lysozyme. Values are expressed as means ± SEM 
(n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Protein Synthesis Signalling after Acute LPS Stimulation 
Stress associated with NEC affects the function of the endoplasmic reticulum, in particular following 
maternal separation (Li et al., 2016). Any stress associated with the endoplasmic reticulum would 
potentially affect protein synthesis, thus potentially affecting autophagy related pathways. Key 
proteins involved in protein synthesis, as well as some known to cross talk with autophagy signalling, 
investigated (Figure 6.7.A-N). A summary of results can be found in Table 6.1. The size of a cells 
nucleolus, were often indicative of the level of rRNA and therefore mRNA translation, can be 
determined with the nucleoli marker Fibrillarin. Levels of Fibrillarin protein were also examined and 
the 50µg/ml LPs with AF-CM treatment led to a significant decrease from the positive control by 
52.6% (n=4, p<0.05).  Additionally, the 100µg/ml LPS alone showed significantly lower levels of 
Fibrillarin compared to the 50µg/ml LPS stimulation alone by 58.1% (n=4, p<0.05).  
No significant changes between groups were seen for the key protein synthesis regulating kinase 
AKT, its phosphorylated (pAKT) state levels or the calculated ratios from the two states.  Another 
regulator of many signalling pathways and in particular protein breakdown is FOXO3a.  pFOXO3a 
levels were shown to be significantly increased from the unstimulated control when organoids were 
stimulated with 50µg/ml LPS (n=4, p<0.05). Furthermore, this increase was shown to drive levels of 
FOXO3a significantly higher than its AF-CM treated counterpart but also of organoids stimulated with 
100µg/ml LPS with or without AF-CM treatment (n=4, p<0.01). 50µg/ml LPS alone increased FOXO3a 
levels up by 50.0% from the unstimulated control and were 62.8% higher than the 50µg/ml LPS AF-
CM treated organoids. Additionally, 50µg/ml LPS led to levels being 71.4% and higher than organoids 
stimulated with 100µg/ml LPS. The 50µg/ml LPS stimulated AF-CM treated organoids had levels of 
FOXO3a similar to that of the unstimulated control. No significant differences were however seen 
between the two 100µg/ml LPS stimulated groups of organoids or to the unstimulated control. On 
the other hand no differences were seen between any of the groups when looking at the levels of un-
phosphorylated FOXO3a. Upon calculating pFOXO3a/ FOXO3a ratios a significantly larger value 
compared to the unstimulated control was seen for the organoids stimulated with 50µg/ml LPS alone 
(n=4, p<0.05). This value was also significantly higher than that of 100µg/ml LPS stimulated organoids 
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without AF-CM treatment (n=4, p<0.05). Calculated ratios for 50µg/ml LPS stimulation were 81.5% 
and 93.7% larger than that of the unstimulated control and 100µg/ml LPS stimulated organoids 
without AF-CM treatment respectively. 
4EBP-1, which inhibits mRNA translation until it becomes phosphorylated, was also investigated.  
p4EBP-1 was significantly decreased from the control by 45.1% with 100µg/ml LPS alone (n=4, 
p<0.01). This increase was also significantly lower than those stimulated with the lower 
concentration of LPS and treated with AF-CM (n=4, p<0.01). Levels of 4EBP-1 were significantly 
decreased with 100µg/ml LPS alone by 84.6% from the control (n=4, p<0.05). Although the level 
achieved from 50µg/ml LPS stimulation alone did not differ from the control its levels were 
significantly higher than the other stimulated groups by at least 55.6% (n=4, p<0.05 and <0.001). On 
the other hand regarding the ratios of p4EBP-1/ 4EBP-1, none of the groups differed from each other 
or the control. 
Additionally, analysis of the protein synthesis regulator Eif2α and its phosphorylated state pEif2α 
showed no significant differences between the treatment groups or the control. However upon 
calculating the ratio between these two protein states, pEif2α/ Eif2α, it was found that organoids 
stimulated with 50µg/ml LPS alone were 12.2 times lower than and had significantly lower calculated 
ratios compared to the unstimulated control (n=4, p<0.05). No other calculated ratios showed any 
significant differences between groups.  
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Figure 6.7 
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Figure 6.7: Expression of protein synthesis signalling proteins in organoids stimulated with either 
50μg/ml or 100μg/ml E.coli LPS for 2 hours and treated with AF-CM. (A) Western blots of proteins 
analysed. Protein expression of (B) Fibrillarin. Protein expression of (C) pAkt, (D) Akt and (E) the levels 
of calculated pAkt/ Akt ratios. Protein expression of (F) pFoxo3a, (G) Foxo3a and (H) the levels of 
calculated pFoxo3a/ Foxo3a ratios. Protein expression of (I) p4EBP-1 and (J) 4EBP-1 and (K) the levels 
of calculated p-4EBP-1/ 4EBP-1 ratios. Protein expression of (L) pEif2α, (M) Eif2α and (N) the levels of 
calculated pEif2α / Eif2α  ratios. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 
(**) or p < 0.001 (***). 
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Autophagy Signalling after Acute LPS Stimulation 
Autophagy signalling was then analysed (Figure 6.8.A-D). p62, also known as sequestosome 1 
(SQSTM 1), is often used to gauge the degree of autophagy. None of the treatment groups tested 
significantly affected p62 levels. Autophagy signalling can often occur in response to stress as a 
mechanism to clear unwanted and damaged organelles (Nichenko et al., 2016, Garcia-Prat et al., 
2016). LC3BII/ LC3BII ratios showed no significant differences from the unstimulated control. On the 
other hand, AF-CM treatment of 50µg/ml LPS stimulated organoids had significantly higher LC3BII/ 
LC3BI compared to their positive control by 50% (n=4, p<0.05). Furthermore, AF-CM treated 50µg/ml 
LPS stimulated organoids presented with significantly higher values compared to the 50µg/ml LPS 
stimulated positive controls but did not significantly differ to their own positive control. Finally, 
C/EBP homologous protein (CHOP) was analysed. Levels of CHOP were significantly reduced from the 
control by at least 79.4% when organoids were stimulated with 100µg/ml LPS with or without AF-CM 
treatment (n=4, p<0.01). No difference in CHOP levels was found between the treatment groups. 
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Figure 6.8: Expression of autophagy signalling proteins in organoids stimulated with either 50μg/ml 
or 100μg/ml E.coli LPS for 2 hours and treated with AF-CM.  (A) Western blots of proteins analysed. 
Protein expression of (B) p62, (C) calculated ratios of LC3BII/ LC3BI and (D) CHOP. Values are 
expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Gene Expression after 24 hour Long Stimulation and AF-CM Treatment 
Organoids were then stimulated for 24 hours with one of two pro-inflammatory proteins, 10ng/ml 
TNF-α or 10µg/ml LPS and their gene expression levels examined after AF-CM treatments (figure 
6.9.A-G). A summary of results can be found in Table 6.1. First the gene expression of the 
inflammatory cytokine TNF-α was analysed. TNF-α stimulation with and without AF-CM treatment 
led to a significant increase in TNF-α gene expression compared to the non-stimulated, although 
differences between the two TNF-α stimulated groups was not (n=4, p<0.001). TNF-α stimulation 
with and without AF-CM treatment increased TNF-α gene expression by 88.1% and 84.3% 
respectively.  
TGF-β gene expression was next investigated and found that TNF-α stimulation significantly 
increased its expression by 35.5% compared to the control (n=4, p<0.001). AF-CM treatment of 
organoids stimulated with TNF-α increased its expression by another 8.3%, totalling 43.8% higher 
gene expression compared to the unstimulated control and 12.9% higher than that of the positive 
control. (n=4, p<0.05).  Although the LPS stimulation alone didn’t significantly alter TGF-β gene 
expression from the control, the AF-CM treated counterpart was significantly less than the 
unstimulated control and LPS stimulated control (n=4, p<0.01). AF-CM of LPS stimulated organoids 
reduced their TGF-β gene expression by 20.0% from the unstimulated control and 23.4% from the 
positive control. 
Angiogenesis associated genes related to the VEGF group of proteins were next analysed. Gene 
expression of VEGFA, which binds to both VEGFR1 and VEGFR2, was not altered in any of the tested 
groups. Furthermore, gene expression of VEGFB, known to bind only to VEGFR1, also was not 
changed by treatment. 
Analysis into the level of Lgr5 gene expression revealed that all treatment groups had significantly 
lower levels compared to the unstimulated control (n=4, p<0.001). At the very least, in the case of 
the TNF-α stimulated organoids without AF-CM treatment, Lgr5 expression levels were reduced by 
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19.0% from the control. However, no significant changes within and between the two TNF-α 
stimulated groups or   LPS stimulated groups were detected. 
In the case of the Goblet cell specific Mucin-2 gene expression, TNF-α stimulation reduced levels 
significantly from the unstimulated control by 25.2% (n=4, p<0.05 and <0.001). However, AF-CM 
treatment made no difference to its expression. AF-CM treatment of those stimulated with TNF-α 
had led to a significantly smaller level of Mucin-2 gene expression compared to its positive control 
(n=4, p<0.05). Addition of AF-CM treatment reduced the level from the unstimulated control by 
53.2%, which was 37.3% less than that of the organoids stimulated with TNF-α but without AF-CM 
treatment. Additionally, LPS stimulation significantly reduced Mucin-2 gene expression levels (n=4, 
p<0.001). However, AF-CM treatment did not bring gene expression back towards normal levels. The 
LPS stimulation had reduced expression levels by at least 48.6% in the case of the LPS stimulation 
alone. 
Finally, analysis of Lysozyme-1 gene expression was performed. TNF-α stimulated organoids showed 
significant reductions in gene expression compared to the control (n=4, p<0.01 and <0.001). 
However, AF-CM did not change expression from this level. Reductions from the unstimulated 
control with TNF-α stimulation was at least 23.6%. In addition, the LPS stimulation alone significantly 
reduced Lysozyme gene expression by 16.3% from the control (n=4, p<0.05). No significant 
differences between the two LPS stimulated groups were seen either however the organoids 
stimulated with TNF-α and had been treated with AF-CM presented with significantly lower levels of 
Lysozyme-1 expression compared to both LPS stimulated organoid groups by at least 18.5% (n=4, 
p<0.05 and <0.01). 
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Figure 6.9 
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Figure 6.9: Gene expression in organoids stimulated with either 10ng/ml TNF-α or 10μg/ml E.coli 
LPS for 24 hours and treated with AF-CM. Gene expression of (A) TNF-α, (B) TGF-β, (C) VEGFa189, 
(D) VEGFb, (E) LGR5, (F) Mucin-2 and (G) Lysozyme-1. Values are expressed as means ± SEM (n=4). p 
< 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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AF-CM Treatment of 48 hour LPS or TNF-α Stimulated Organoids 
Timings of organoid stimulation with a higher concentration of 50µg/ml LPS and 10ng/ml TNF-
stimulation were further increased to 48h to understand if protein levels could be further altered by 
the stimuli and whether AF-CM could inhibit these changes (Figure 6.10.A-D). A summary of results 
can be found in Table 6.1. In addition to protein levels, the level of TNF-α gene expression was 
measured to understand if these changes could be related to inflammatory signalling (Figure 6.10.E). 
Mucin-2 gene expression was also measured to provide a read-out of Goblet cell activity in the 
organoids after this longer stimulation period with or without AF-CM treatment (Figure 6.10.F). In 
relation to gene expression values organoids were stimulated with only TNF-α and the AF-CM 
treatment was compared to AD-CM and AF-EV to identify whether AF-CM provided a more potent 
effect that AF-AD and if AF-EV provided the effect of AF-CM if any.  
In the case of CC3 protein levels LPS stimulation with or without AF-CM treatment led no significant 
change from the unstimulated control.  However, E-cadherin was significantly reduced from both the 
control and LPS positive control with AF-CM treatment by 41.3% and 36% respectively (n=4, p<0.05). 
On the other hand, both LPS and TNF positive controls treatment did not differ in E-cadherin 
expression from the unstimulated control. Regarding CC3, stimulation with TNF-α alone prompted a 
significant increase in CC3 compared to the LPS stimulated organoids by at least 60.0% (n=4, p<0.01 
and <0.05). This increase was also shown to be significantly higher than that of the TNF-α stimulated 
AF-CM treated organoids, which although showed a similar level of CC3 to the unstimulated control 
was 60% less than the TNF-α stimulated groups CC3 level too (n=4, p<0.05). However, the AF-CM 
treated TNF-α stimulated organoids showed significantly higher levels of E-cadherin compared to the 
TNF-α stimulation alone by 40.6% (n=4, p<0.05). In relation to Lysozyme-1 protein levels, all groups 
of organoids showed significantly lower levels of protein compared to the unstimulated control (n=4, 
p<0.05, <0.01 and <0.001). LPS stimulation alone had reduced levels by 42.0% whilst the addition of 
AF-CM treatment had reduced levels by 43.0%. Moreover, TNF-α stimulation alone and with AF-CM 
treatment reduced Lysozyme-1 protein levels by 59.3% and 74.1% respectively.  
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Analysis of the TNF-α gene expression concluded that the organoids stimulated with TNF-α 
regardless of CM treatment showed significantly elevated expression (n=4, p<0.01 and <0.001). TNF-
α stimulation had increased TNF-α gene expression by at least 94%. Furthermore, only the organoid 
group treated with AF-CM showed significant increases in Mucin-2 expression from the AD-CM 
treated organoids (n=4, p<0.05). The data here showed a 41.0% increase from the unstimulated 
control. None of the other treatment groups differed significantly from each other or the 
unstimulated control. 
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Figure 6.10: Protein and gene expression of organoids stimulated with either 50μg/ml E.coli LPS or 
10ng/ml TNF-α for 48 hours and treated with AF-CM. (A) Western blots of proteins analysed. 
Protein expression of (B) cleaved Caspase-3 (CC3), (C) E-cadherin and (D) Lysozyme. Gene expression 
of (E) TNF-α and (F) Mucin-2. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) 
or p < 0.001 (***). 
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Protein Synthesis and Autophagy in 48 hour Stimulated Organoids 
Continuing from the 48 hour experiment described further western blots were carried out to analyse 
key autophagy and protein synthesis signalling pathway related proteins (Figure 6.11.A-N and 6.12.A-
E). A summary of results can be found in Table 6.1. Fibrillarin levels did not differ between the 
control and positive controls. However, the level of Fibrillarin was significantly lower in organoids 
stimulated with LPS and treated with AF-CM compared to LPS alone by 29.3% (n=4, p<0.05). Levels in 
organoids with TNF-α stimulation alone also had lower levels compared to the LPS AF-CM treated 
organoids by 12.2% (n=4, p<0.05). 
No significant differences were found between any of the tested groups of organoids when looking 
at levels of AKT, pAKT/ AKT, 4EBP-1, p4EBP-1/ 4EBP1, EIF2α, pEIF2α or pEIF2α/ EIF2α. 
On the other hand, LPS stimulation alone led to a significant decrease in the level of pAKT from the 
control by 72.7% (n=4, p<0.01). This reduction was also shown to be significantly less than that of 
organoids also stimulated with LPS but treated with AF-CM by 65.9%. The level of pAkt in LPS 
stimulated AF-CM treated organoids was not dissimilar to that of the unstimulated control.  
AF-CM treatment of LPS stimulated organoids showed a significant increase on FOXO3a from the 
unstimulated control by 86.2%, its corresponding positive control by 78.9% as well as that seen in the 
AF-CM treated organoids stimulated with TNF-α by 61% (n=4, p<0.001). Furthermore, the TNF-α 
stimulation alone significantly increased levels from the control by 82% (n=4, p<0.001). Treatment of 
the TNF-α stimulated organoids led to a significant decrease in FOXO3a by 48.9% to a level similar to 
that of the unstimulated control (n=4, p<0.05). Analysis of pFOXO3a showed no significant changes 
with LPS stimulation until AF-CM treatment was carried out, increasing levels by 23.8%, which was 
also significantly higher than those produced by organoids stimulated with TNF-α and treated with 
AF-CM by 68.5% (n=4, p<0.05). The addition of AF-CM treatment to LPS stimulated organoids and 
both TNF-α stimulated groups of organoids had significantly lower pFOXO3a/ FOXO3a ratios 
compared to the control (n=4, p<0.05). Those that did significantly differ from the unstimulated 
control were at least 85.2% lower but did not significantly differ from each other. AF-CM treated  
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Figure 6.11 
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Figure 6.11: Expression of protein synthesis signalling proteins in organoids stimulated with either 
50μg/ml E.coli LPS or 10ng/ml TNF-α for 48 hours and treated with AF-CM. (A) Western blots of 
proteins analysed. Protein expression of (B) Fibrillarin. Protein expression of (C) pAkt, (D) Akt and (E) 
the levels of calculated pAkt/ Akt ratios. Protein expression of (F) pFoxo3a, (G) Foxo3a and (H) the 
levels of calculated pFoxo3a/ Foxo3a ratios. Protein expression of (I) p4EBP-1 and (J) 4EBP-1 and (K) 
the levels of calculated p4EBP-1/ 4EBP-1 ratios. Protein expression of (L) pEif2α, (M) Eif2α and (N) 
the levels of calculated pEif2α / Eif2α ratios. Values are expressed as means ± SEM (n=4). p < 0.05 (*), 
p < 0.01 (**) or p < 0.001 (***). 
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organoids that had been stimulated with LPS had significantly higher levels of p4EBP1 compared to 
its positive control by 71.6% (n=4, p<0.05).  
Regarding autophagy (Figure 6.12.A-E), p62 protein levels showed significant increases from the 
control with AF-CM treatment in the LPS stimulated organoids (n=4, p<0.05). AF-CM treatment had 
increased levels from the norm following LPS stimulation by 55.1%. Calculated ratios for LC3BII/ 
LC3BI were significantly higher for organoids stimulated with TNF-α and treated with AF-CM 
compared to those stimulated with LPS and treated with AF-CM by 42.9% (n=4, p<0.05). No 
differences were observed between other treatment groups and the control. Levels of BIP were 
significantly decreased from the control by 78.0% with the TNF-α AF-CM treatment (n=4, p<0.05). 
However the level of BIP after this treatment did not differ from its positive control or that of the LPS 
stimulated organoids. On the other hand, the level of CHOP was significantly decreased by the LPS 
AF-CM treatment by 45.2% (n=4, p<0.05). TNF-α stimulation with or without AF-CM treatment also 
decreased levels of CHOP from the control by at least 69.0% (n=4, p<0.001). The TNF-α stimulation 
with or without AF-CM showed levels of CHOP significantly lower than that of the LPS stimulation 
alone by at least 56.7% (n=4, p<0.05). 
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Figure 6.12: Expression of autophagy signalling proteins in organoids stimulated with either 
50μg/ml E.coli LPS or 10ng/ml TNF-α for 48 hours and treated with AF-CM. (A) Western blots of 
proteins analysed. Protein expression of (B) p62, (C) calculated ratios of LC3BII/ LC3BI, (D) BIP and (E) 
CHOP. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Immuno-histological Analysis of 72 hour Stimulated Organoids 
In a bid to further mimic the inflammatory and damaging conditions found in NEC without the need 
to passage the organoids, the time frame for 50µg/ml LPS and 10ng/ml TNF-α stimulation was 
stretched to 72h. Once again stimulated organoids were also treated with or without AF-CM. Firstly 
immune-fluorescent analysis of the organoids was conducted and they were therefore stained for 
nucleic acid (DAPI), Lysozyme and E-cadherin (Figure 6.13.A-G).  
From the images it is apparent that lysozyme staining is restricted to the crypts of the organoids. As 
lysozyme is secreted by the Paneth cells, the densometric level of lysozyme per Paneth cell was 
calculated (Figure 6.13.F). The only treatment group to significantly differ from that of the 
unstimulated control were the 10ng/ml TNF-α stimulated AF-CM treated organoids, in which levels 
of Lysozyme/ Paneth cell were reduced by 60.3% (n=4, p<0.05). Furthermore, the TNF-α stimulated 
AF-CM treated levels were significantly lower than its positive control as well as the two LPS 
stimulated groups of organoids alone and with AF-CM treatment (n=4, p<0.01, <0.05 and <0.01).  
E-cadherin intensity was also analysed as a measure of barrier function, known to be affected in NEC 
(Guo et al., 2013, McElroy et al., 2011, Khailova et al., 2009). LPS stimulation showed no change in E-
cadherin intensity from the control. However stimulation with TNF-α alone led to a significant 
reduction in E-cadherin intensity (n=4, p<0.01). Levels following TNF-α stimulation were reduced by 
20.8% from the control. Furthermore, treatment of organoids that had been stimulated with TNF-α 
with AF-CM led to a significant increase in E-cadherin intensity from those not treated by 13.2% (n=4, 
p<0.05). AF-CM treatment therefore increased levels of E-cadherin intensity back to a level similar to 
that of the unstimulated. 
In addition to analysis of Lysozyme and E-cadherin, immunofluorescent analysis was carried out for 
Ki-67 to detect any changes in proliferation capacity (Figure 6.13.A-F). The only cells of the epithelial 
layer in the intestine that proliferate are the resident stem cells.  Statistical analysis of Ki-67 co-
localisation with the nucleus (DAPI stained nucleic acid) was performed (Figure 6.14.A-F).  Organoids 
stimulated with LPS with or without AF-CM showed no difference in co-localisation compared to the  
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Figure 6.13 
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Figure 6.13: Immuno-fluorescent analysis of organoids stimulated with either 50μg/ml E.coli LPS or 
10ng/ml TNF-α for 72 hours and treated with AF-CM. (A) Organoids sectioned and stained for DAPI 
(blue), Lysozyme (green), and E-cadherin (red). (B) Densiometric analysis of Lysozyme staining within 
Paneth cells. (C) Comparison of E-cadherin intensity within cellular membranes of stained organoids. 
(A) Scale bar representative of 500μm. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 
0.01 (**) or p < 0.001 (***). 
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unstimulated control. However, stimulation with TNF-α alone significantly reduced levels of Ki-67 co-
localisation from the unstimulated control and those stimulated with LPS (n=4, p<0.05 and <0.01). 
Levels of co-localisation following TNF-α stimulation alone had reduced by 7.5%, 8.6% and 11.9% 
from the unstimulated control, LPS positive control and those stimulated with LPS but treated with 
AF-CM respectively. AF-CM treatment of TNF-α stimulated organoids did not change levels of Ki-67 
co-localisation from the positive control and levels were significantly lower than that of the LPS 
stimulated organoids treated with AF-CM by 10.7% (n=4, p<0.01). 
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Figure 6.14 
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Figure 6.14: Immuno-fluorescent analysis of organoids stimulated with either 50μg/ml E.coli LPS or 
10ng/ml TNF-α for 72 hours and treated with AF-CM. (A) Organoids sectioned and stained for DAPI 
(blue) and Ki-67 (red). (B) Statistical co-localisation of Ki-67 and the nucleus (DAPI) using Pearson’s R 
values from stained samples. (A) Scale bar representative of 500μm. Values are expressed as means 
± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
  
 Chapter 6 
Page | 216  
 
Protein Translation of 72 hour Long Stimulated Organoids 
To assess any changes in protein synthesis that may have occurred with the increase in exposure 
time to the inflammatory stimuli the culture media or organoids was briefly labelled with puromycin. 
A summary of results can be found in Table 6.1. Puromycin is a structural analogue of aminoacyl-
transfer RNA. In the short time cells are introduced to puromycin, puromycin is incorporated via the 
peptide bonds into the lengthening peptide chains (Schmidt et al., 2009). This so-called SUnSET 
technique was carried out and normalised to the total protein content (Figure 6.15.A, C). Although 
LPS stimulation alone showed no change in puromycin incorporation, the level was significantly 
increased with AF-CM treatment both from the control and positive control (n=4, p<0.01 and <0.05). 
The AF-CM treatment of LPS stimulated organoids increased levels by 33.4% and 22.3% from the 
control and the positive control respectively. Those stimulated with TNF-α with or without treatment 
did not differ from the control. However AF-CM treated LPS stimulated organoids significantly higher 
puromycin incorporation levels compared to those stimulated with TNF-α alone by 32.6% (n=4, 
p<0.01). On the other hand, Fibrillarin and E-cadherin levels were not changed significantly between 
any of the treatment groups (Figure 6.15.D and G). 
Western blotting was also carried out for the apoptotic marker, CC3 and Paneth cell marker 
Lysozyme (figure 16.15.B, E-F). In relation to CC3, LPS stimulation with or without AF-CM treatment 
provided no change in CC3 levels. However, stimulation with TNF-α alone and with AF-CM did 
significantly increase levels of CC3 by at least 52.7% (n=4, p<0.01 and <0.05). Although the AF-CM did 
not bring levels back towards that of the unstimulated control. Levels of Lysozyme-1 were 
significantly increased by LPS alone by 43.3% from the control (n=4, p<0.05). Lysozyme-1 levels of 
those stimulated with LPS and treated with AF-CM along with both TNF-α stimulated group were 
shown to not-significantly differ from the control. 
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Figure 6.15 
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Figure 6.15: Protein expression of organoids stimulated with either 50μg/ml E.coli LPS or 10ng/ml 
TNF-α for 72 hours and treated with AF-CM. (A) Western blots of puromycin incorporated proteins 
and ponceau staining for total protein following 15 minutes of organoids being incubated in 
puromycin before lysis. (B) Western blots of proteins analysed. Analysis of (C) puromycin 
incorporated proteins normalised to total protein. (D) Protein expression of Fibrillarin. (E) Protein 
expression of cleaved Caspase-3 (CC3), (F) Lysozyme and (G) E-cadherin. Values are expressed as 
means ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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Autophagy Signalling in 72 hour Long Stimulated Organoids 
Finally, further Western blots were carried out on the organoids stimulated with LPS and TNF-α for 
key autophagy related proteins (Figure 6.16.A-F). Levels of p62, CHOP or calculated LC3BII/ LC3BI 
ratios did not significantly differ between any groups of treated organoids. LPS stimulation alone did 
not alter levels of BIP, however upon treatment with AF-CM levels significantly increased by 51.2% 
from the unstimulated control (n=4, p<0.05). Levels following the AF-CM were also significantly 
higher than that of the TNF-α stimulated organoids treated with AF-CM by 67.4% (n=4, p<0.01). 
Regarding LC3B-I, only stimulation with TNF-α alone increased levels significantly from the control by 
88.1%, but also those stimulated with LPS by at least 73.8% and those stimulated with TNF-α not 
treated with AF-CM by 52.9% (n=4, p<0.001, <0.01 and <0.05). TNF-α stimulation alone also 
significantly increased LC3B-II levels from the control and those stimulated with LPS but not the TNF-
α stimulated AF-CM treated organoids (n=4, p<0.05). Following TNF-α stimulation alone, levels of 
LC3B-II were 90.4% higher than the control and at least 79.7% higher than those stimulated with LPS.  
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Figure 6.16 
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Figure 6.16: Expression of autophagy signalling proteins in organoids stimulated with either 
50μg/ml E. coli LPS or 10ng/ml TNF-α for 72 hours and treated with AF-CM. (A) Western blots of 
proteins analysed. Protein expression of (B) p62, (C) BIP, (D) CHOP, (E) LC3BI, (F) LC3BII and (G) 
calculated ratios of LC3BII/ LC3BI. Values are expressed as means ± SEM (n=4). p < 0.05 (*), p < 0.01 
(**) or p < 0.001 (***). 
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To summarise the results a variety of 3D intestinal organoid based model were developed, which 
included stimulating organoids with either E. coli LPS or TNF-α at different concentrations for 
different lengths of time.  From these models an inflammatory related gene expression was shown to 
alter as well as the apoptotic protein marker CC3 and protein markers associated with cell types 
found within the intestine. Expression of selected genes did not significantly alter with AF-CM 
treatment compared to their positive controls at shorter time points such as 30 minute and 1 hour 
exposures to stimuli. However, on a protein level AF-CM was shown to inhibit certain changes from 
the control following stimulation alone after just 2 hours. Furthermore, after 24 hours TNF-α or LPS 
stimulation changes to specific genes tested were seen to alter, some of which were reversed by AF-
CM treatment. This result was further corroborated by changes to protein levels measured after 
extending the time for which organoids were stimulated with TNF-α or LPS. Some of the changes that 
occurred were of proteins associated with protein synthesis and autophagy. 
Time point Summary 
2 hours • Lower concentrations of LPS decrease apoptosis and increase 
proliferation 
• Alterations in signalling indicative of an initial pro-inflammatory 
response to LPS 
24 hours • TNF-α induced a large pro-inflammatory response in organoid 
gene expression. 
• TNF-α caused a reduction in Lysozyme and Mucin gene 
expression 
48 hours • LPS did not induce an increase in apoptosis 
• TNF-α increased the levels of apoptosis 
• LPS with AF-CM, TNF-α and TNF-α with AF-CM led to reduced 
levels of unfolded protein response proteins 
72 hours • AF-CM improved stem cell proliferation from the reduction 
following TNF-α stimulation. 
• Changes to barrier function unclear 
Table 6.1: A summary of the results seen in organoids stimulated with LPS or TNF-α for 2, 24, 48 or 
72 hours with and without AF-Cm treatment. 
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Discussion 
Intestinal organoids have been previously used to model NEC and it was therefore an aim to replicate 
these conditions so that the AF-CM could be tested on them (Neal et al., 2012, Hackam et al., 2013). 
Cultured organoids presented with the lumen, crypts and villous domains found in a normal intestine 
in-vivo. Stimulation of organoids with either E. coli LPS or TNF-α for varying amounts of time and at 
different concentration produced reactions that were revealing of an inflammatory response but also 
healthy homeostasis. Furthermore, the use of AF-CM as a treatment in a bid to inhibit the effects of 
TNF-α or LPS stimulation for 2 hours or less was seen to affect organoids on a post-translational level 
and was shown to reduce the level of apoptosis. Western blot results did not conclusively identify 
changes in protein synthesis or autophagy; however, changes to individual proteins within each of 
the pathways were seen. AF-CM was shown to not only bring some of these changes back to a level 
seen in the unstimulated control but also accentuated the response following stimulation.  
LPS and TNF-α Induced Cell Death and Inflammation in Organoids 
Organoids were stimulated with previously tested concentrations of E. coli LPS at 10µg/ml along with 
10ng/ml TNF-α for time points ranging from 30 minutes to 2 hours. Gene expression of TNF-α was 
increased with the TNF-α stimulation after 1 hour, decreased with LPS after 2 hours. The pattern of 
expression following TNF-α stimulation could be explained through the cyclical patterns of NF-κB 
signalling found previously in-vitro (Zeuner et al., 2016). As discussed, NF-κB signalling stimulated by 
TNF-α and TNFR interactions lead to NF-κB translocating into the nucleus thus acting as a 
transcription factor and promoting the expression of genes such as TNF-α. An increase in TNF-α 
expression and subsequent TNF-α release would further potentiate the signalling pathway. On the 
other hand LPS reduced TNF-α gene expression. It has been previously suggested that short term 
stimulation by LPS leading to increased TNF-α production is not controlled on the transcriptional 
level but instead post-transcriptionally (Gao et al., 2001). If true, increases in TNF-α due to post-
transcriptional regulation may in fact activate negative feedback mechanisms to inhibit TNF-α gene 
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expression. Inhibition of TNF-α gene expression has been previously postulated in murine 
macrophage cell lines as being due to TNF-α-inhibiting factor (TIF) repression of the TNF-α promotor 
(Baer et al., 1998). The repressive activity of TIF was also suggested as being activated by selective 
induction of the NF-κB p50 subunit following LPS stimulation.  
Mucin-2 gene expression at 30 minutes was increased prior to decreasing to the norm after 2 hours. 
This has been previously shown to increase in p14 and p28 mice ilium samples following TNF-α 
injections 8h before resection (McElroy et al., 2011). The reduced expression is suggested as being 
due to TNFR-2 dependent signalling as opposed to TNFR-1 dependent, which would otherwise cause 
apoptosis of mucin laden Goblet cells instead. Negative feedback mechanisms or even saturation of 
TNFR-2 by TNF-α would explain the fall towards the basal level seen in unstimulated organoids after 
30 minutes. 
Interestingly the use of 10µg/ml LPS, previously shown to induce apoptosis and cell death, did not 
increase levels of CC3, a marker suggestive of apoptosis (Neal et al., 2012). On the other hand, the 
higher concentrations of 50µg/ml and 100µg/ml LPS did increase CC3. The cells of the intestine 
within the villi and also the crypts are known to synergistically interact with the body’s microbiota 
(Rakoff-Nahoum et al., 2004, Shirkey et al., 2006, Vaishnava et al., 2008). This interplay is key to 
maintaining the normal homeostasis of cells in the intestine and the way they function such as their 
proliferation and secretion of substances into the lumen including Mucins and Lysozymes. This 
normal interaction inevitably leads to LPS contact and this bacterial polysaccharide has been 
suggested as being key to some of the functions such as proliferation and cell secretion (Vaishnava et 
al., 2008, Kuo et al., 2015, Shirkey et al., 2006, Rakoff-Nahoum et al., 2004). A low level of LPS 
exposure to the organoids, which have already been previously exposed to LPS naturally, would not 
significantly alter LPS related signalling. Which is why a higher level than what is usually used in other 
cell types that are not naturally associated with LPS must be used to induce a response in organoids. 
On the other hand, the exact mechanism by which LPS had been introduced to the organoids 
previously has not been documented and it is therefore presumed, and as carried out here, that LPS 
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was dosed in the culture media. Dosing of the Matrigel, as opposed to relying on diffusion of LPS 
from the media may have a more potent outcome on signalling and gene expression and in this case 
activation of apoptotic pathways leading to cleavage of caspase-3.  
A 10µg/ml LPS exposure unlike the other concentrations of LPS increased Ki-67 co-localisation (Figure 
6.2.A-E). This increase may be postulated to occur as a pathological response of the Lrg5+ or Bmi1+ 
stem cell population following inflammation as previously noted to occur for other stem cell 
populations such as skeletal muscle satellite cells previously discussed (Zhu et al., 2013, Tian et al., 
2011, Yan et al., 2012). On the other hand, due to a lack of an increase in the level of apoptosis at 
this concentration the 10µg/ml stimulation of organoids could be hypothesised as promoting a 
healthy environment and thus normal proliferation as opposed to inducing stress (Rakoff-Nahoum et 
al., 2004).  The lack of alteration in E-cadherin levels may also reflect a lack of pathology and stress 
(Figure 6.2.A-F). However, much of the research looking at changes to barrier function has tended to 
look at this measure after longer exposure periods to LPS (Rentea et al., 2017, Guo et al., 2013, 
Khailova et al., 2009). The 2 hour time point may therefore be too early to identify changes to E-
cadherin on a protein level. 
Additionally, after 48h of exposure to the same concentration of LPS, gene expression of Mucin-2, 
Lysozyme and Lgr5 was increased (figure 6.3.A-E). It is interesting to see that at this later time point 
the Mucin-2 expression is increased on a transcriptional level not seen previously at the lower time 
points tested. This extended exposure could have come about from a natural pathogenic or 
inflammatory response (Ahn et al., 2005).  In this hypothesis, the intestine would benefit from 
increases in antibacterial Mucin-2 and Lysozyme-1. Lysozyme-1 is known to directly kill bacteria 
through hydrolysis of bacterial wall components (Tanabe et al., 2005).The upregulation of Lgr5 is 
indicative of an increase in stem cell proliferation because of its role, although not well understood, 
in facilitating R-spondin induced Wnt signalling (Sato et al., 2009, Sato et al., 2011). This also, as 
discussed, would be beneficial to the intestine if an infection took place to counter an increase in cell 
loss. Furthermore, Lgr5 expression increase was seen after TNF-α stimulation, which can also be 
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explained as a consequence of the stem cell inflammatory response via the NF-κB pathway shared by 
LPS.   
AF-CM and AF-EV Organoids Treatment Acts Post-Transcriptionally 
Due to TNF-α inducing an inflammatory response in organoids treated for 1 hour as before indicated 
by TNF-α expression, organoids were stimulated with TNF-α for 1 hour and 30 minutes as a 
comparison with or without AF-CM treatment (Figure 6.4.A-D). However, the AF-CM treatment did 
not alter the increase in TNF-α level seen after 1 hour. The lack of response suggests that AF-CM was 
not acting on a transcriptional level and was therefore hypothesised to be more likely acting on a 
post-transcriptional level. Any gene expression changes subsequent to this would be likely detectable 
at later time points, hence the 24 hour time point used later. The lack of changes in the positive 
controls to other gene expression levels may reflect variability in the model at this lower time point.  
The fact that AF-CM, AD-CM and AF-EV treatments over the 1 hour stimulation interval with TNF-α 
did not alter the expression of genes tested from the positive control also reflects the potential 
mechanism of action of the AF-CM on the post-transcriptional level (Figure 6.5.A-B). Evidence for this 
is first highlighted with the immunofluorescent staining of NF-κB-p65 and analysis of its intensity 
within the nucleus insightful of nuclear translocation (Figure 6.5.C-D). All CM treatments reduced 
nuclear intensity from the positive control thus providing evidence, along with the previous data, 
that AF-CM was indeed acting on a post-transcriptional level and in particular through repression of 
the NF-κB pathway.  However, AF-CM treatment did not differ from AD-CM suggesting a similar 
ability to reduce NF-κB nuclear translocation in organoids. Similarly, AF-CM did not differ from its 
resultant AF-EV fraction suggesting that much of the ability of AF-CM to reduce NF-κB signalling is 
facilitated by its EV fraction.  
AF-CM Modulates Lysozyme Levels via NF-κB Signalling Pathways 
Although variability between assays utilising LPS for shorter exposure times was seen, in assays the 
AF-CM can be seen further to affect protein levels compared to a positive control (Figure 6.6.A-D). 
Western blot analysis of CC3 revealed significant reductions in CC3 from those stimulated with 
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100µg/ml LPS. Lysozyme levels were significantly increased with the 50µg/ml LPS control and 
reversed with AF-CM back to a level similar to that of the control. This result along with the previous 
results is indicative of an increase in the inflammatory response instigated through LPS signalling. 
However it has been previously suggested that changes to the level of Lysozyme due to LPS 
stimulation is independent of TLR-4 signalling (Tanabe et al., 2005). The LPS used in this study is 
ultra-pure and therefore believed to be unable to stimulate other pathways other than through TLR-
4. On the other hand, it may also be beneficial for the model to use standard LPS, which may 
potentiate more signalling pathways and exacerbated changes to Lysozyme levels. However, it is also 
likely that the effects of LPS on other cell types within the model lead to paracrine signalling which 
activates the increase in Lysozyme within Paneth cells indirectly. The drop in apoptosis at the 
50µg/ml concentration would also match the increase in proliferation of the resident stem cells. 
Looking at the previous p65 staining it is therefore proposed that this reversal in lysozyme level is 
modulated with AF-CM via repression of NF-κB signalling.   
Longer Exposures to LPS or TNF-α in Organoids Mimic NEC 
Comparison between CC3 levels seen after this 2 hour time point and that seen at 48 hour (Figure 
10B) and 72 hour (Figure 6.15.D) showed further variation with those stimulated with 50μg/ml LPS. 
Although not all results were significant, CC3 levels at 2 hour and 48 hours were lower than the 
control. On the other hand, exposure for 72 hours showed an increase (not significant). The results 
further suggested that 50μg/ml LPS stimulation of organoids over a short period of time up to at 
least 48 hours is beneficial for the organoids, potentially having a role in homeostatic regulation. 
However, increases in stimulation time leads to increases in apoptosis. This increase suggests that 
the extended exposure to the LPS may become disadvantageous and thus increases apoptosis. In 
order to take advantage of this outcome, organoids in future could be stimulated for longer time-
points in an attempt to induce further and significant increases apoptosis. A limiting factor that led to 
the original choice of time points included the need to passage the organoids after 6 days post 
passaging. Organoids become extremely large with detrimental intraluminal deposits of dead cells 
 Chapter 6 
Page | 228  
 
and debris. Passaging and mechanically breaking up the organoids during an exposure time point 
would allow LPS to access the intraluminal side of the organoids, which could potentiate a differing 
effect. On the other hand, exposure of organoids intra-luminally to LPS and also TNF-α may be more 
representative of the gut being over-run by pathogenic bacteria. However, previous research 
suggests that introduction of Gram-negative derived LPS within the organoid lumen mimics normal 
intestinal colonisation, whereas introduction of this LPS basally promotes an outcome similar to ‘life-
threatening septicaemia’ (Karve et al., 2017). It must however be noted that the source of  the LPS 
used was not specified in previous studies and the variation in responses to LPS derived from 
different species of bacterium can lead to differing responses with respect to NF-κB signalling as 
discussed previously.  
An increase in exposure to TNF-α for 24 and 48 hours can be thought of as promoting an 
inflammatory response as suggested by TNF-α gene expression levels. This data along with the 
increased TGF-β mimics what is seen in the gut of human inflammatory bowel disease (IBD) (Ihara et 
al., 2017). However, it has also been hypothesised that elevated levels of TGF-β in a variety of 
inflammatory gut conditions is simply part of a response by the epithelium and the stromal tissue to 
reduce inflammation (Ihara et al., 2017). It is therefore suggested that the significant further increase 
in TGF-β with AF-CM treatment following LPS stimulation is anti-inflammatory and beneficial longer 
term, although TNF-α gene expression levels with AF-CM treatment had not changed yet from the 
positive control. Interestingly, the TNF-α and LPS reduced Lysozyme-1 and Mucin-2 gene expression. 
This reduction is also believed to be representative of what is seen in inflammatory bowel disease. 
Following the initial increases in Mucin expression as inflammatory response through NF-κB 
signalling, TNF-α has also been shown to induce JNK signalling (Ahn et al., 2005). The activation of 
JNK is thought to act as a negative feedback response and therefore provides an explanation for 
reduced Mucin-2 levels following extended stimulation, which would reduce the level of protection 
from pathogenic bacteria in the gut. Reversal of this reduction was not seen with AF-CM treatment 
suggesting that the AF-CM could not directly inhibit the JNK signalling. Use of AF-CM may therefore 
be questionable if it still represses NF-κB signalling, which could potentiate further a reduction in 
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Mucin-2 expression. This may also help to explain why there was a significant decrease in E-cadherin 
from the LPS control, which did not differ from the unstimulated control, when AF-CM was used as 
treatment. This decrease is a concern because it may have a detrimental effect on barrier function 
and therefore increased permeability to further LPS or bacterial aggravation. It would therefore be of 
interest to look at the level of CD14 in the organoids. CD14 co-localises with TLR-4 to mediate some 
of the LPS effects in particular tight junction permeability (Guo et al., 2013). However, the level of 
CD14 expression also relies on the LPS and TLR-4 interactions and downstream signalling via NF-κB. 
The lack of reduced E-cadherin following LPS stimulation alone could stem from LPS stimulation not 
being for long enough to increase levels of CD14 at the membrane of cells, which is suggested to be a 
key driver in reducing barrier integrity (Guo et al., 2013). Although the study looking at the effects of 
LPS on intestinal tight junctions were carried out in mainly Caco-2 cells, TLR-4 was also only shown to 
increase at the membrane following 4 days of LPS stimulation (Guo et al., 2013). 
AF-CM did not Conclusively Alter Autophagy Signalling 
Reduced Fibrillarin and pFOXO-3a/ FOXO-3a protein levels with AF-CM treatment following LPS 
stimulation for 48 hours would suggest that the AF-CM has reduced the level of mRNA translation. A 
bypass in the protein synthesis signalling pathway due to introduction of miRNA may explain the lack 
of change seen with AKT, EIF2α, 4EBP1 and their respective phosphorylated levels.  This result along 
with the increase in the key autophagy regulator p-62 and decrease in BIP and CHOP, suggesting a 
lack of autophagy, questions whether mRNA is being deleted prior to translation. miRNA found in 
MSC-CM, as has been recorded in various studies, would reduce mRNA levels and translation (Mead 
and Tomarev, 2017, Mellows et al., 2017, Thomou et al., 2017). It has already been shown that rRNA 
levels and effects of miRNA are linked through chromatin binding of Argonaute-2 along with DICER 
interactions (Atwood et al., 2016). Reduced mRNA would decrease the need for translational 
machinery and therefore rRNA, potentially leading to reduced rRNA production and as a result a 
smaller nucleolus, as represented here by the level of Fibrillarin. Interestingly, the AF-CM treatment 
of organoids stimulated for 72 hours with LPS led to an increase in protein translation as shown by 
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puromycin incorporation. However, puromycin incorporated bands of protein are all of low 
molecular weight. A longer puromycin incubation period for the organoids may lead to larger 
proteins incorporating puromycin. Furthermore, the results suggest puromycin incorporation levels 
are not correlated to the Fibrillarin because levels of Fibrillarin do not significantly differ.  
Intriguingly, the pattern portrayed by p62 and CHOP levels and those significantly seen to change 
with BIP suggest that the AF-CM treatment of LPS stimulated organoids have higher levels of 
autophagy or unfolded protein response signalling. Although this does not translate into changes 
between the ratio of LC3BII/ LC3BI, the autophagic signalling through BIP, CHOP and p62 along with 
simultaneous increases in protein synthesis (puromycin data) can be explained through the recycling 
of unwanted proteins through autophagy thus providing amino acids for protein synthesis. This has 
also been shown previously by others who showed a transient increase in protein translation along 
with autophagy whilst the proteolysis as a whole remained high in skeletal muscle of spinal cord 
injury patients (S. et al.). 
AF-CM Decreased the Levels of Lysozyme per Paneth Cell 
Immuno-histological analysis 72 hour stimulated organoids showed that there was less lysozyme/ 
Paneth cell in TNF-α stimulated organoids treated with AF-CM. This is interesting because there was 
actually no decrease in the total lysozyme following western blot analysis. On the other hand, 
organoids stimulated with TNF-α were also shown to contain more CC3, presumably showing 
increased apoptosis. It is therefore suggested that the TNF-α is causing an inflammatory response 
and therefore cell death. The AF-CM may be as discussed modulating NF-κB signalling thus leading to 
reduced lysozyme. Yet with an increase in cellular apoptosis, a reduced number of Paneth cells and 
total lysozyme level would be expected. The reduced proliferation as demarked by the reduced Ki-67 
staining in TNF-α stimulated organoids may suggest a reduced stem cell population and a capability 
of organoids to produce Paneth cells or any other cell for that matter. Although AF-CM had not 
altered total lysozyme levels it had inhibited the reduction of E-Cadherin intensity following TNF-α 
stimulation following histological analysis. However, western blot analysis showed E-cadherin levels 
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did not change with any treatment. This variation in results probably stems from the number of 
organoids being analysed within each analysis. Measuring E-cadherin intensity is not carried out on 
every one of the hundreds of organoids present within the Matrigel. On the other hand, western blot 
analysis is carried out on all organoids in each well tested and could be perceived as being more 
reliable due to the higher power of the study.  
To conclude, further studies need to be carried out on the organoids using different LPS and or TNF-α 
stimulation parameters. The use of LPS and TNF- α had caused organoids to alter expression of key 
genes and proteins thought to be involved in the stress of NEC, however further experimentation 
would be required to establish a reliable and predictable model. On the other hand, AF-CM also 
altered levels following stimulation and was thought to be due to post-transcriptional modification of 
signalling pathways at least partly related to NF-κB. 
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The general aim of this project was to create and characterise an AFSC derived CM that could be 
translated into a clinically compliant therapeutic for NEC. Currently, treatment of NEC concentrates 
on managing the symptoms through the use of antibiotics, reduced enteral feeding and in more 
severe cases surgery to remove affected portions of the bowel (Sharma and Hudak, 2013, Zani and 
Pierro, 2015). However, much of this treatment either leads to long term intestinal problems such as 
short bowel syndrome or does not directly aid recovery through the enticement of regeneration. It 
had been previously shown that treatment of NEC rodent models with AFSCs had extended lifespan 
and activated regenerative programmes (Zani et al., 2014). However, many of these positive 
outcomes were evident in the absence of AFSC engraftment, as had also been shown in other studies 
using different MSCs for a multitude of pathologies (Zani et al., 2014, Gnecchi et al., 2006, Gnecchi et 
al., 2005, Gnecchi et al., 2016). It was therefore hypothesised that the regenerative effects seen 
following MSC therapy were in fact largely due to paracrine secretions. 
 In order to translate the AFSC paracrine factors into a clinically compliant therapy, AF-CM was 
collected so that it was free of exogenous molecules. AFSCs surface expression was characterised to 
ensure that AF-CM was collected from AFSCs that expressed generally accepted MSC markers. 
Furthermore, their differentiation potential was tested. AF-CM was then investigated to understand 
if it contained EVs, and if so their sizes to understand what type of EV existed in the AF-CM. 
Additionally an extensive characterisation of the protein and RNA content in the AF-EV and soluble 
fraction was carried out. To test whether AF-CM could influence the activity of non-autologous cells, 
various cell types were treated with AF-CM to test their effect on proliferation and migration, the 
ability of AF-CM to protect from senescence and finally its ability to dampen inflammatory signalling. 
Once the AF-CM had been shown to alter cellular properties in-vitro, its ability to increase 
regeneration in an established model of acute damage was tested. Finally, to understand whether 
any regenerative traits could be translated into treatment of NEC, an attempt to create an intestinal 
organoid model of NEC was carried out. The model was used to test the efficacy of AF-CM to 
attenuate disease associated features. 
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The data presented provides evidence that the AFSCs used to create AF-CM expressed MSC surface 
markers but was also capable of differentiating into chondrogenic, osteogenic and angiogenic cell 
types thus proving them to be MSCs. Investigation of the AF-CM revealed that it contained small EVs 
typical in size to exosomes (Thery et al., 2002b, Thery et al., 2006, Lötvall et al., 2014). 
Characterisation of the AF-CM cargo showed a diverse assortment of proteins both in the soluble 
fraction and the AF-EV. Of particular interest was the fact that RNA within the AF-EV fraction was 
made up almost entirely of miRNA, contrary to previous reports stating the presence of mRNA also 
within MSC derived EVs (Valadi et al., 2007, Eirin et al., 2014). Not only did AF-CM support 
proliferation and migration capacity of non-autologous stem cells, it protected IMR90 cells from H2O2 
induced senescence. In addition, AF-CM was shown to reduce NF-κB activity and nuclear 
translocation which may also explain its ability to reduce the levels of the pro-inflammatory marker 
(CD80) on THP-1 macrophages. Thereafter we showed that AF-CM could accelerate the regeneration 
of skeletal muscle in vivo following acute damage to skeletal muscle induced by CTX. Comparison of 
AF-CM and its derivative fractions, AF-EV and soluble fraction, revealed that although much of the 
activity was shown to derive from the AF-EV, it was believed that in general the use of a whole AF-
CM with both fractions present would be more beneficial to producing a regenerative response.  
Finally, we attempted to replicate an NEC mimicking intestinal organoid model, as previously carried 
out by others. However we were unable to reproduce published findings.  Nevertheless we found 
that the AF-CM was capable of altering organoid signalling post-transcriptionally.    
AF-CM Molecular Content Modulates Cellular Activity Beneficial to Regeneration in Vitro 
In vitro results showed that AF-CM increased the capacity of non-autologous stem cell proliferation 
and migration. With mass spectrometry analysis and miRNA arrays it was possible to speculate how 
the AF-CM was able to potentiate these effects. Proteins such as the heat shock family of proteins 
(HSPs) and HMGB1 known to have ‘alarmin’ functionality is proposed to be at least partly responsible 
for these attributes. Alarmins have been discussed as providing a forewarning like signal to the cell of 
interest (Bianchi, 2007). Although these proteins have been recorded as having inflammatory 
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functions, their presence prior to stress caused by pathology initiates a minor stress response in cells 
to brace them for more extreme stressors (Mollica et al., 2007, Bianchi, 2007, Beninson et al., 2014). 
Low levels of inflammatory stimuli are known to increase cellular proliferation and migration (Prisco 
et al., 2016, Barreca et al., 2017, Widera et al., 2006). Regarding the HSPs they are believed to 
mediate their effects by binding to two main types of receptor, TLRs and scavenger receptors, in 
particular TLR4, TLR2 and CD91 have been identified (Barreca et al., 2017).It has further been found 
that downstream of this binding, signalling pathways including PI3K/ AKT and NF-κB were activated 
leading to upregulation of MMPs such as MMP9, in this example from T cell EVs (Barreca et al., 
2017). The upregulation of these signalling pathways was shown to increase in mesangioblast 
migration (Barreca et al., 2017).  
In addition to HSPs, HMGB1 was also found in the AF-CM, which has been previously shown to 
increase both migration and proliferation (Palumbo et al., 2004, Limana et al., 2005). The increase in 
proliferation, as well as inhibition of apoptosis, was proposed to be facilitated by HMGB1 binding to 
RAGE/TLR4 as opposed to RAGE on its own (X. et al., 2014). Once again, the effects of this binding 
were found to be PI3K/ AKT mediated (X. et al., 2014). Although we have not specifically looked at 
PI3K/ AKT activity following AF-CM treatment within these in vitro assays, it can be speculated that 
AF-CM alters PI3K/ AKT signalling to bring about increased proliferation and migration following 
HMGB1 and HSP binding to receptors such as TLR4 and RAGE. Along with the evidence that AF-CM 
reduces NF-κB activity in cells stimulated with pro-inflammatory molecules such as TNF-α and LPS, 
and the knowledge that these alarmins also increase NF-κB activity, it can also be hypothesised that 
AF-CM treatment may initiate this signalling as well as the PI3K/ AKT pathway to upregulate the 
proliferation and migration seen.  
Additionally, insignificant NF-κB signalling stimulating negative feedback responses and preparing the 
cell for further more extreme insult may explain the protection afforded by AF-CM to the IMR-90 
cells stressed with H2O2 thus preventing senescence. It would however be of interest to understand 
whether the AF-CM is protecting cells from senescence via an alarmin like system. T72 AF-CM was 
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shown to increase NF-κB activity on its own without inflammatory stimulation, whereas the T24 AF-
CM did not. On the other hand, T72 AF-CM afforded greater protection from senescence.   The T24 
AF-CM is therefore hypothesised as having the optimum level of alarmin molecules without causing a 
net pro-inflammatory response in target cells. Levels are believed to cause an anti-inflammatory 
response whilst also increasing migration and proliferation capacity and affording protection from 
senescence. A senescent state is often taken on by a cell as opposed to apoptosis, so it could be 
possible that AF-CM is instead pushing cells towards an apoptotic fate instead. Future work could 
involve analysing with a flow cytometer to not only establish the level of p53 and p21, as markers of 
senescence, but also perform a cell count to establish if cell death is increased compared to that of 
stressed cell without AF-CM treatment. 
With regard to AF-EV miRNA content, some of the top 50 compiled miRNAs found to be present have 
been previously shown to be pro-survival, pro-migratory and capable of increasing proliferation. 
Examples included miR3196, miR125b-5p, miR1273-3p, miR762, miR3960, miR24-3p and miR382 (Liu 
et al., 2016, Yu et al., 2017, Xu et al., 2016, Xia et al., 2015, Seok et al., 2014, Niu et al., 2016). 
Induction of pro-survival signalling from a regenerative context would often be depicted as being a 
positive feature of miRNA. However, as discussed causing cells to survive instead of undergoing 
apoptosis may instead drive them into senescence. A senescent state is counterintuitive for 
regeneration because of the increased basal levels of inflammatory factors produced in such cells as 
well as them being unable to divide and replace lost tissue. It can therefore be speculated that if AF-
CM is indeed preventing senescence it could be due to its protein content as opposed to miRNA 
content. The in vitro results also show no significant differences between the use of AF-CM and AF-
EV. miRNA will only survive within the protective environment of the EVs without the need of the 
RISC proteins (not found in the soluble fraction). If the miRNA afforded protection from senescence it 
would be expected that the AF-EV would protect cells from senescence more so than the whole AF-
CM either due to miRNA alone or synergistic effects of protein and miRNA. This is not the case and so 
the transfer of protein within the soluble fraction with AF-EV or AF-EV alone is believed to support 
the anti-senescent effect.  
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Interestingly, AF-CM reduced NF-κB activity and nuclear translocation in addition to reducing the 
level of CD80 in M1 macrophages. AF-EV contained Let7b, a miRNA known to target mRNA of 
proteins involved in the inflammatory response (Teng et al., 2013, Ti et al., 2015). In particular, let7b 
has been shown to target and reduce the level of TLR4 (Teng et al., 2013). TLR4 is upregulated 
following reception of an inflammatory stimulus such as LPS (Wan et al., 2016). Targeting of TLR4 by 
let7b would reduce the level of surface TLR4 capable of binding LPS and therefore reduce 
downstream Nf-κB signalling, as also hypothesised by others to occur following MSC-EV treatment (Ti 
et al., 2015). Let7b within AF-CM is therefore believed to be at least partly responsible for the 
reduced inflammatory state of THP-1 macrophages and reduced NF-κB activity seen in the U251 cells. 
The data here also presents a possible role for AFSCs within the AF. It is believed that the level of NF-
κB activity regulates the switch to induce labor in the pregnant mother (Lee et al., 2012b, Lim et al., 
2012, Kim et al., 2015) . It is therefore suggested that AFSCs play a role in stifling the level of NF-κB 
activity in order to inhibit pre-term labor as well as reducing harmful pro-inflammatory cytokines for 
the foetus. Stress during the pregnancy would be hypothesised to induce AFSCs into secreting anti-
inflammatory factors such as those characterised in the AF-CM. 
The ability of the different cells used to take up AF-EVs was postulated to be mainly through active 
endocytic processes. From results showing the size of AF-EVs as well as the proteins present, it was 
suggested that the majority of AF-EVs were exosomes. Macro-pinocytosis has been suggested as 
being the most efficient mechanism of exosome uptake (Nakase et al., 2015). Efficiency of this 
uptake was found to be enhanced with stimulation of EGF receptors (Nakase et al., 2015). It may be 
beneficial to test if AF-CM treatment with EGF increases AF-EV uptake by cells and enables lower 
concentrations of AF-CM to be used both for research and clinically. A more efficient uptake of AF-EV 
with AF-CM treatment would reduce the volume required for therapy and lower costs for both the 
manufacturer and potentially the subsequent consumer. 
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Whole AF-CM provides a More Effective Regenerative Therapy in Vivo than AF-EV Alone 
Similarly to results seen in vitro, the effects of AF-EV were seen to vary in comparison to the use of 
whole AF-CM in vivo. In vitro results showed no difference between AF-CM and AF-EV in reducing the 
level of senescence. However, AF-EV was shown to be more effective at reducing NF-κB nuclear 
translocation although levels of expression, as judged by luciferase levels, were found to be reduced 
similarly by AF-CM. On the other hand, due to the AF-EV not effecting the regeneration of damaged 
muscle equally between the deep and superficial regions it was concluded that the use of AF-CM and 
not AF-EV alone was more beneficial. It is believed that although the majority of AF-CM actions are 
potentiated by AF-EV cargo, the secretome within the soluble fraction is also important and could act 
synergistically or control cellular events that the AF-EV could not.  One aspect of the accelerated 
regeneration, as indicated by the larger fibre CSA in AF-CM treated mice, was the increased level of 
active resident stem cells. As discussed, activation of stem cells is often preceded by inflammatory 
stimulation. Some of the proteins as well as miRNA within the AF-CM, including the HSPs, HMGB1, 
miR3960 and miR24-3p (discussed previously) could potentiate this effect and activate satellite cells. 
Furthermore, the increases in proliferation and migration could be afforded to these cells by the AF-
CM via mechanisms discussed previously. This would therefore increase the number of satellite cells 
capable of fusing, leading to larger fibres but also increase the speed in which they migrate to the 
area of damage, further accelerating regeneration. Although some of these proteins are present 
within the AF-EV only, it is also important to note that some were present in both, whilst others only 
in the soluble fraction. Although the exact mechanism of action of all proteins present in the AF-CM 
are not known, it can be speculated that at least some in each fraction are important for this 
increased satellite cell activity leading to increased fibre size in both the superficial and deep regions 
of muscle.  
Another aspect of regeneration measured was the blood vessel density of damaged muscles. miRNA 
within the AF-EV, such as miR382 and let7b, has been suggested to be pro-angiogenic (Seok et al., 
2014). It is therefore suggested that miRNA such as these are at least partly responsible for the 
increased angiogenesis in vivo. However, varying effects were seen with AF-EV treatment on vessel 
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density, whilst treatment with the whole AF-CM consistently led to increases in blood vessel per 
fibre. Other cargo within the AF-CM is therefore believed to increase angiogenesis within the muscle, 
including the proteins. However the ability of AF-CM to modulate NF-κB activity in vitro is believed to 
provide a means to bringing about normal homeostatic regulation of NF-κB levels so that signalling 
persists to enhance proangiogenic events such as the increased endothelial proliferation and 
migration, but not excessively which would have otherwise led to higher levels of pro-inflammation. 
Although not a great deal of change was seen with regard to F4/80+ cell levels within the muscle 
sections, thought to be indicative of macrophages, the data recorded in vitro suggests that their 
inflammatory activity could have been altered by the AF-CM. Although the level of F4/80+ cells 
increased with AF-CM treatment, the levels following AF-EV treatment did not. This contrasts the in 
vitro data suggesting that the AF-EV contained the majority of anti-inflammatory molecules and once 
again highlights the importance of using both the soluble and AF-EV fraction together to harness the 
effects of both miRNA and protein. However, the in vitro data does provide more evidence, along 
with the time in which muscles were collected, that the increase in F4/80+ cells seen is likely due to 
increases in anti-inflammatory M2 macrophages. The in vitro data also suggests that although AF-CM 
was not enough to bring CD-80 levels in THP-1 cells down to a level seen in M2 macrophages and 
therefore prevent or reverse M1 polarisation, it may be enough to ease the transition of the M1 
phase in the muscle towards the M2 phase. Further experiments are required as discussed later to 
establish this in vivo. 
Effect of AF-CM on LPS and TNF-α Stimulated Intestinal Organoids 
Although the intestinal organoid model used in this work did not provide predictable outputs for 
analysis, a number of hypothesises can be proposed regarding the ability of AF-CM to alter organoid 
signalling and therefore potentially in NEC patients. From our findings it was recognised that AF-CM 
post-transcriptionally regulates cells including that of the organoids. Furthermore, the post-
transcriptional regulation was comparatively similar to what was seen in previous in vitro studies 
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where NF-κB activity was modified. In addition, the ability of AF-CM to reduce NF-κB activity along 
with reduced apoptosis can be explained by some of the identified AF-CM cargo.  
Arguably the most important finding into the study of AF-CM effects on the organoids was the ability 
of AF-CM to reduce NF-κB nuclear translocation. This was similar to that found within the in vitro 
U251 cell assays. Comparison between the preliminary in vitro assays and those conducted in 
organoids would suggest that the same mechanisms of action exist following AF-CM treatment. 
These mechanisms of action as discussed may include the transfer of miRNA such as let7b thus 
leading to reduced levels of TLR4 but also Nf-κB signalling. It was previously shown in rat models of 
NEC that AFSCs increased the level of COX-2 within the intestine thus bringing about enhanced 
survival and repair (Zani et al., 2014). The increase in COX-2 might explain the reduction in NF-κB 
signalling seen here in these results because contrary to its classical pro-inflammatory activity COX-2 
also negatively regulates NF-κB expression, which was shown to be decreased in the U251 cells, as 
indicated by luciferase activity (Poligone and Baldwin, 2001). Activity of COX-2 is also known to be 
controlled by prostaglandins, in particular cyclopentenone prostaglandins such as PGJ2 (Poligone and 
Baldwin, 2001). Therefore it may be of interest to identify whether AF-CM contains lipid based 
signalling molecules, such as PGJ2 that could affect COX-2 signalling and subsequent NF-κB activity.  
Furthermore, the ability of AF-CM to reduce the level of CD-80 in M1 THP-1 cells suggests that AF-CM 
could reduce the activity of M1 macrophages within an in vivo NEC setting. If proved capable of doing 
so, a reduced M1 pro-inflammatory response would help bring the overactive inflammatory state of 
these macrophages towards that seen normally. A reduced pro-inflammatory state would be 
suggested to reduce the level of cytokine induced necrosis but also stabilise the homeostasis of cell 
turn over. 
Interestingly although NF-κB activity was altered, the level of stem cell proliferation within the 
organoids did not mirror that seen in previous in vitro assays. No change in E-cadherin levels were 
seen, even though components within the AF-CM such as let7b and miR125b, known to reduce tight 
junction permeability and increase intestinal barrier function were present (Liu et al., 2018, Martinez 
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et al., 2017). The previous research showed that let7b prevented intestinal barrier dysfunction by 
targeting p38 MAPK leading to reduced PTEN expression and therefore increased AKT and occludin 
levels within NCM460 cells (Liu et al., 2018). Occludin has been shown to regulate the flux of 
macromolecules across the intestinal epithelial barrier (Al-Sadi et al., 2011). Additionally, miR125b-
5p has been shown to regulate the expression of the tight junction related gene cingulin (Martinez et 
al., 2017). An increase in cingulin expression was found in IBS-D samples. Increases in cingulin 
corresponded with decreases in miR125b-5b and may reflect the body’s response to try and increase 
cingulin levels to aid barrier function (Martinez et al., 2017). It could therefore be speculated that AF-
CM, containing miR125b, in this instance would hinder this response and potentially reduce tight 
junction functionality. On the other hand, the levels of cingulin may reflect hyperactivity and 
dysregulation of homeostasis due to the disease. Introduction of miR125 with the AF-CM would be 
hypothesised to bring about a reduction in cingulin and normalise its homeostatic levels. Contrary to 
the lack of activity seen, reduced apoptosis following AF-CM treatment of organoids stimulated with 
high concentrations of LPS suggest that its cargo has a protective effect. This data is evidenced by the 
protection it afforded from senescence in vitro in IMR90 cells but also the cargo it was found to 
contain discussed previously. Further investigation towards making the organoid model more 
representative of NEC is required. It is clear that LPS and TNF-α activity from these results does not 
mirror that seen by others and may derive from variable diffusion rates of stimulants but also AF-CM 
cargo through the Matrigel (Neal et al., 2012).  
On the other hand, in vitro results as well as those seen within the acute damage in vivo model 
suggest that the AF-CM possess molecules beneficial to NEC intestinal regeneration such as increased 
proliferation, protection from stressors and anti-inflammatory actions. The increased in vivo 
angiogenesis seen in our results suggest that AF-CM could produce similar results within an in vivo 
NEC setting. Increased vasculature would improve the all-important oxygen supply to the tissues and 
coupled with the NF-κB modulating activity of AF-CM reduce inflammation and cell death. The AF-CM 
created here has been proven to improve the activity of cells in favour of regeneration. Under the 
conditions it was created, it provides a clinically relevant source of paracrine factors that could be 
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used in the future therapeutically. With regard to NEC, the AF-CM here has the potential to be used 
as a therapeutic because of its ability to also improve regeneration in an acute damage setting in 
vivo. 
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Main Study Limitations 
In summary, although the work carried out showed that AF-CM reduced the amount of NF-κB 
signalling, protected from senescence and increased migration and proliferation capacity, the exact 
mechanism by which it did so was not conclusive and only speculated surrounding the known 
functions of some of the cargo identified within the AF-CM and AF-EV. However, due to the vast 
array of protein and miRNA species identified, which all had both varying but also shared functions, 
not any single molecule can be identified as being the only effector within the AF-CM.  Furthermore, 
comparison to an AF-CM created from adherent cells as opposed to the stressful conditions used 
here should be carried out. Additionally, the anti-inflammatory effects, suggested in the U251 and 
THP-1 macrophages, were established only in vitro. Studies on how the AF-CM effects macrophage 
polarisation and activity should be further investigated in vivo. Arguably the main limitation of the 
study was the ability to recreate a reproducible model of NEC within intestinal organoids. It is 
therefore of interest to study how experimental variation affects the organoid model in order to 
better mimic NEC and therefore obtain an experimentally viable model to test the regenerative 
ability of AF-CM against NEC. 
Future Work 
Establishing the Anti-inflammatory Properties of AF-CM Further 
In order to understand how AF-CM affects macrophage activity in vivo, the macrophages first need to 
be isolated from the tissue of interest for characterisation. In contrast, the tissue containing the 
macrophage population could be processed for protein or gene expression analysis. Isolation of 
macrophages from the tissue can be then be analysed for M1 and M2 markers. Flow cytometry can 
be carried out to measure levels of Ly6C, CD80 (or CD86) as well as Arginase and CD206 for M1 and 
M2 marker levels respectively. Furthermore, ELISA assays should be carried out for known pro-
inflammatory (TNF-α and IL-6) and anti-inflammatory cytokines (IL-10 and CCL2/MCP-1) in the CM 
produced from either differentiated and polarised THP-1 cells or primary cell cultures of isolated 
macrophages. However isolation of macrophages from tissue can prove problematic because of the 
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time it takes to breakdown surrounding tissue thus affecting macrophage viability but also the 
tendency of isolation reagents to activate damage signalling within tissues. For example, collagenase 
is often used to dissociate muscle fibres enabling satellite cells to be studied (Otto et al., 2011). 
However, activation of satellite cells on the muscle fibres enabling migration studies would also lead 
to chemokine responses from fibres and satellite cell alike and potentially affect the polarisation of 
macrophages. A simpler but less targeted way of studying the macrophage activity within the 
diseased tissue would be to dissociate the tissue as a whole and perform qPCR on genes known to be 
involved in inflammation (TNF-α, IL-6, IL-10and IL-1β) to get a profile of the inflammatory state 
throughout the whole tissue. 
Establishing the Active molecules within AF-CM 
To establish whether the miRNA species or protein species are more important for the AF-CM effect 
on proliferation, migration, senescence and NF-κB activity either of them should be deleted from the 
CM prior to treatment. Removing miRNA can be carried out by first solubilising the miRNA with 
detergent thus disrupting AF-EV membranes. Secondly RNase added to the AF-CM would destroy all 
miRNA within the AF-CM. Alternatively, the AF-CM can be heated to 80ᵒC for at least 5 minutes to 
irreversibly denature the protein present but without significantly damaging the miRNA integrity 
(Matsuura et al., 2015, Jung et al., 2010). If the effects of AF-CM are inhibited completely by the heat 
treatment it is likely that the protein is the more significant effector and vice versa. Although it is 
likely that a mixture of the AF-CM components have pivotal roles for promoting the effects seen in 
vitro, selective miRNAs can be knocked down in the AF-CM. By treating the AFSCs during AF-CM 
collection with siRNA species selective to let7b for example would reduce the level of let7b being 
packaged into the AF-EV. Reduced activity following treatment with the let7b deprived AF-CM would 
suggest that let7b is responsible for the improved activity seen previously without the knockdown. 
However, siRNAs are known to have issues with bio-stability, delivery and specificity leading to off 
target effects particularly in vivo (Elmén et al., 2005).  It has been shown that providing the siRNA 
with a phosphorothioate backbone dramatically increases it’s targeting efficiency and improves 
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stability within serum thus creating a locked nucleic acid modified oligonucleotide (LNA) (Elmén et 
al., 2005, Elmén et al., 2008). LNA mediated silencing of miR122 has also been shown in vivo, also 
presenting the first report of antagonism in primates (Elmén et al., 2008). This technology could 
therefore also be used to silence specific miRNA being packaged within the AF-CM but also to 
knockdown its systemic effects in vivo, for example within the CTX model. Similarly, a new specific 
targeting method for protein knockdown within a cell has been developed, without the need of 
modifying the genome and miRNA, called Trim-Away (Clift et al., 2017). Trim-Away utilises the body’s 
natural antibody bound bacterial targeting system, which specifically uses the protein Trim21 (Clift et 
al., 2017). Trim-21 auto-ubiquitinates upon binding to the bound antibody and targets it for 
proteasomal degradation (Clift et al., 2017). By introducing an antibody specific to the protein of 
interest along with exogenous Trim protein, the protein of interest is rapidly targeted and destroyed 
even in non-dividing cells (Clift et al., 2017). This technique could therefore be used to knockdown 
proteins such as HMGB1 within the AFSCs thus reducing transfer into the AF-CM or used directly in 
recipient target cells. 
Comparison of AF-CM to AF-CM Collected from Non-Stressed Adherent AFSCs 
AF-CM created in a similar fashion to that produced and used previously as a therapeutic in a rat 
model of NEC should be compared in its make-up to the AF-CM used throughout this project (Zani et 
al., 2014). AF-CM created under non-stressful conditions should be collected as previously carried 
out over 30 hours in α-mem from adherent AFSCs. The resulting adherent AF-CM (A-AF-CM) should 
be characterised for the number of EVs contained within it because as discussed it is thought that 
stress induces stem cells to secrete higher concentrations of exosomes. Furthermore, the protein 
and RNA content of the A-AF-CM should be characterised and compared to the AF-CM as carried out 
here in this project. Additionally, investigation into the A-AF-CM regenerative potential both in vitro 
and in vivo, as completed here in this project, could be carried out alongside the AF-CM for 
comparison. 
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Increasing the Reproducibility of the Organoid NEC Model 
A number of potential faults in the way organoids were treated in order to mimic NEC were 
identified. Investigations into whether these necessary modifications better mimic and create a 
reproducible model are therefore required.  The first step to take would be to stimulate organoids 
with LPS or TNF-α that has been mixed within the Matrigel itself. This would have to be done either 
during a mechanical passage or simply dissolving the current Matrigel that organoids reside in and 
re-suspending them in the new treated Matrigel. However, it must be noted that introducing the 
stimulants to Matrigel after mechanical passaging will allow them to interact directly with the intra-
luminal side of the organoid. Secondly, investigation into the differences in effect between ultra-pure 
LPS (TLR4 specific) used here and the standard LPS (capable of binding TLR4/2) should be carried out. 
The dual stimulation of TLR4 and TLR2 may potentiate a more pathogenic response compared to 
TLR4 alone. Another variable that could be tested is the use of LPS and TNF-α stimulation 
simultaneously as opposed to their individual use throughout this study. The combined action of LPS 
and TNF-α through their separate receptors may lead to significantly more pro-inflammatory 
signalling and reliable cell death. Additionally, LPS and TNF-α are not the only factors that contribute 
to NEC. The culture of organoids under hypoxic conditions (1% or 5% O2) as opposed to normoxia 
(20% O2, 5% CO2) would be expected to increase further damage to the organoids and mimic the 
cellular environment of intestinal cells in NEC (Jun et al., 2014). This can be carried out in 
combination with LPS or TNF-α stimulation or independently to understand its effects on cell death. 
Cell death analysis can be carried out as done previously via western blotting and densiometric 
analysis of CC3 stained protein bands. 
Testing the Ability of AF-CM as a Therapeutic for NEC in Vivo 
To truly test the ability of AF-CM as a potential therapeutic for NEC it must be tested in an in vivo 
NEC model. As discussed, a number of model variations exist that use mainly either mouse of rat 
models (Zani et al., 2016, Zani et al., 2014). The ability to replicate these experimental models as 
carried out by others would also enable the investigation into the surrounding tissues of the 
intestinal epithelium such as the mesenteric nervous system but also the innate immune systems 
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response to determine if the damage here can also be alleviated (Zani et al., 2014, Zani et al., 2016). 
Once the efficacy of the AF-CM has been established in vivo, its safety and toxicology should also be 
assessed prior to any use in humans.  Control animals treated with AF-CM alone will also provide 
data suggesting whether the AF-CM can be classed as safe at this stage and understand if it has no 
adverse effects such as an unwanted inflammatory reaction. Data on how the AF-CM is metabolised 
and it’s safe to toxic levels must be established to understand the safest and most optimum dosing 
regimen. Clinical research using AF-CM must ensure that the AF-CM is created using good 
manufacturing practice (GMP) guidelines such as its manufacture in a GMP approved lab. Potentially, 
its use in healthy human volunteers would be carried out with the scaled-up dosing regimens to 
establish further AF-CM safety and dosage. Finally, a phase 1/2 clinical trial surrounding the use of 
AF-CM as a therapeutic for NEC in patients would help show whether AF-CM actually increases 
survival rate of patients with NEC and arguably more importantly, if it increases the quality of life 
following survival due to increased regeneration of the gut therefore reducing the need for surgery. 
Further phase 3 and 4 clinical trials would test the use of AF-CM in hundreds to thousands of patients 
over a number of years to further establish the long-term outcome of the treatment, adverse effects 
and safety. 
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8. Appendix I 
Primary antibodies: 
Antibody Working 
Dilution 
Source Supplier Catalogue 
Number 
4EBP1 1:1000 Rabbit Cell signalling 9452 
Akt 1:1000 Rabbit Cell signalling 9272 
BiP (C50B12) 1:1000 Rabbit Cell signalling 3177 
CD-31 1:200 Rat BioRad MCA2388 
CHOP 1:1000 Rabbit Cell signalling 5554 
Cleaved Caspase-3 
(D175) 
1:1000 Rabbit Cell signalling 9664 
E-cadherin 1:200 Mouse BD Transduction 610182 
eIF2α  1:1000 Rabbit Cell signalling 9722 
Embryonic MHC3   1:200 Mouse Santa Cruz  SC-53091 
F4/80  1:200 Rat BioRad MCA497R 
Fibrillarin 1:2000 Rabbit Abcam Ab5821 
FoxO3a (D19A7) 1:1000 Rabbit Cell signalling 12829 
GAPDH 1:1000 Mouse Millipore MAB374 
Ki-67 1:400 Rabbit Cell signalling 9129 
LC3B 1:1000 Rabbit Cell signalling 2775 
Lysozyme-C 1:200 Goat Santa Cruz Sc-27958 
Mannose  1:200 Rabbit Abcam Ab64693 
Mucin-2 (H-300) 1:200 Rabbit Santa Cruz Sc-15334 
MyoD 1:200 Rabbit Santa Cruz Sc-760 
p-4EBP1 
(Thr37/46)(236B4) 
1:1000 Rabbit Cell signalling 2855 
P62/ SQSTM1 1:1000 Rabbit Sigma P0067 
p-Akt (ser473) 1:1000 Rabbit Cell signalling 4060 
Pax-7 1:1 Goat DSHB  
p-eIF2α 1:1000 Rabbit Abcam Ab32157 
p-FoxO3a (ser253) 1:1000 Rabbit Cell signalling 13129 
Puromycin 1:1000 Mouse Millipore MABE343 
α-Tubulin 1:1000 Mouse Cell signalling 3873 
β-actin 1:1000 Rabbit Cell signalling 4970 
Table 8.1: Primary antibodies 
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Secondary antibodies: 
Antibody Working 
Dilution 
Source Supplier Catalogue Number 
Alexa fluor 488 
anti-goat 
1:200 Donkey Molecular probes A11055 
Alexa fluor 488 
anti-mouse 
1:200 Goat Invitrogen A11029 
Alexa fluor 488 
anti-mouse 
1:200 Goat Invitrogen A11032 
Alexa fluor 488 
anti-rabbit 
1:200 Goat Invitrogen A11034 
Alexa fluor 488 
anti-Rat 
1:200 Goat Molecular Probes A21212 
Alexa fluor 594 
anti-rabbit 
1:200 Goat Invitrogen A11037 
HRP conjugated 
ant- Mouse 
1:10000 Rabbit Dako P0260 
HRP conjugated 
ant- Rat 
1:5000 Goat R and D Systems HAF 005 
HRP conjugated 
ant-goat 
1:5000 Rabbit Dako P0160 
HRP conjugated 
ant-Rabbit 
1:5000 Goat Invitrogen 65-6120 
Table 8.2: Secondary antibodies 
Microbeads 
Antibody Working 
Dilution 
Source Supplier Catalogue Number 
CD117 Microbead 
Kit - Human 
100 μL/ 108 cells clone AC126 Miltenyi Biotec 130-091-332 
Table 8.3: Microbeads 
Flow cytometry antibodies 
Antibody Working 
Dilution 
Source Supplier Catalogue 
Number 
CD-105 1:200 Mouse Millipore CS208 
CD-117/APC 1:200 Mouse R&D Biosystems FAB332A-025 
CD34/FITC 1:200 Mouse Millipore CBL555F 
CD-44/Alexa fluor 
647 
1:200 Mouse Millipore CS208200 
CD-45/FITC 1:200 Mouse Biolegend 304105 
CD-73/ PE  1:200 Mouse Biolegend 344004 
CD-80 1:200 Mouse Biolegend 305207 
CD-90/ PE 1:200 Mouse Biolegend 328107 
Table 8.4: Flow cytometry antibodies 
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9. Appendix II 
RT-qPCR Primers 
Primer Forward 3' Reverse 5' 
m LGR5  ATT CGG TGC ATT TAG CTT GG CGA ACA CCT GCG TGA ATA TG 
m Mucin-2  CCG ACT TCA ACC CAA GTG AT GAG CAA GGG ACT CTG GTC TG 
m Lysozyme-1 GTC ACA CTT CCT CGC TTT CC TGG CTT TGC TGA CTG ACA AG 
m Chromogrannin-A  AAG GTG ATG AAG TGC GTC CT GGT GTC GCA GGA TAG AGA GG 
m TNFα  CAG GCG GTG CCT ATG TCT C CGA TCA CCC CGA AGT TCA GTA 
G 
m TGFβ  CTT CAA TAC GTC AGA CAT TCG 
GG 
GTA ACG CCA GGA ATT GTT GCT 
A 
Table 9.1: RT-qPCR primers 
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10. Appendix III 
Solutions 
1X PBS 
One PBS (Oxoid) tablet was dissolved in Ultrapure H2O (80ml) and pH adjusted to 7.4 with HCl (1M) 
prior to making up to 100ml with ultrapure H2O and autoclaving.  
Permeabilisation buffer 
Sucrose (20.54g), HEPES (0.952g), NaCl (0.584g), MgCl2 (0.260g), sodium azide (0.1g) and Triton-X-100 
(1ml) were made up to 200ml with dH2O. 
Wash Buffer 
Foetal bovine serum (FBS – 25ml), sodium azide (200mg) and Triton X-100 (250µl) were dissolved in 
1X PBS and made up to a final volume of 500ml. 
DAPI fluorescent stain 
DAPI (7.5μl) were mixed in Dako Fluorescent mounting medium (15ml). 
4% Paraformaldehyde (PFA) in PBS 
PFA powder (20g) was dissolved in 1X PBS (480ml) by heating to 65ᵒC and made up to 500ml with 1X 
PBS.  
Lysis Buffer 
EDTA (1mM), EGTA (5mM), Triton-X 100 (0.5%), Tris-HCl (50mM, pH 7), 2-mercaptoethanol (2%), 4% 
SDS, Urea (4M) made up in ultrapure water. 
1x Running Buffer 
Ultrapure dH2O (950ml) and of 20X NuPAGE running buffer (Novex, Life Technologies - 50ml) were 
mixed. Antioxidant (0.5ml) was added to 200ml of 1X running buffer mix. 
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Transfer Buffer 
Methanol (30ml), 20X NuPAGE transfer buffer (Novex, Life Technologies - 15ml) and antioxidant 
(0.3ml), were mixed and made up to 300ml with Ultrapure H2O. 
PBS-T 
Tween-20 (250µl, 0.05%) was dissolved in 1X PBS (500ml). 
Blocking buffer 
Microbiological grade bovine serum albumin (2.5g, 5%) was mixed in PBS-T (30ml) and made up to a 
final volume of 50ml. 
Reducing sample treatment buffer (6X RSTB) 
Sodium dodecyl sulfate (SDS – 12g) was dissolved in a mix of β-mercaptoethanol (30ml), Glycerol 
(30ml), Tris-HCl (0.5M, pH 6.8) and ultrapure H2O (10ml). 
Freezing Media stock 
FBS and DMSO solution were mixed 90/10 % by volume. 
Alizarin Red S working solution 
Alizarin Red S (1mg/ml) was made up in ultrapure H2O and adjusted to pH 5.5 using ammonium 
hydroxide. 
Oil Red O stock and working solution 
For stock Oil Red O (3mg/ml) was dissolved in 99% isopropanol. For a working solution, Oil Red O 
stock was mixed with ultrapure H2O: 60/40 % by volume and allowed to sit for 10 minutes before 
filtering through a 0.2µm filter. Stable for up to 2 hours.   
Alcian Blue working solution 
Alcian blue (0.1mg/ml) was made up in ethanol (98-100%) and acetic acid (98-100%) mixed 60/40% 
by volume. Stable for up to a year. De-staining solution was the same without the addition of Alcian 
blue. 
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Acid phosphatase staining solution 
Sodium acetate (0.2M): anhydrous sodium acetate (1.64g, MW82) or sodium acetate trihydrate 
(mw136, 2.72g) was made up to 100ml with dH2O. 
Acetic Acid: glacial acetic acid (1.2ml) was made up to 100ml with dH2O. 
Acetate buffer: sodium acetate (35.2ml) and acetic acid (14.8ml) was made up to 100ml with dH2O. 
Solution A:  Pararsaniline Hydrochloride (40mg) was dissolved in HCl (1ml, 2M).  
Solution B: Sodium nitrite (40mg) was dissolved in dH2O (1ml). 
Solutions A and B were mixed 50/50 % by volume and left for 1-2 minutes until a pale straw colour 
formed. 
Naphthol AS-BI phosphate solution: of Naphthol AS-BI phosphate (25mg) was dissolved in DMSO (10 
drops). 
Working stain: All the Naphthol AS-BI phosphate solution, dH2O (30ml), Acetate buffer (12.5ml, 0.1M, 
pH 5.0) and HPR (2ml) were mixed and pH adjusted to 5.0 using  NaOH (1M). 
Senescence Fixative (0.2% Glutaraldehyde, 2% PFA/PBS) 
Glutaraldehyde stock solution (25%), PFA/PBS (4%) and dH2O were mixed at 0.8/50/49.2 % by 
volume. 
Senescence staining solution 
Sodium Phosphate pH 6.0; Potassium Ferricyanide Stock (3.29g/100ml, 100μM); Potassium 
Ferrocyanide Stock (4.22g/100ml, 100μM); NaCl stock (14.6g/100ml, 2.5M); MgCl2 stock 
(20.3g/100ml, 1M); X-gal (50mg/ml); dH2O 
For Sodium Phosphate two solutions were made up: NaH2PO4 (1.370g/100ml, 0.1M) and Na2HPO4 
(1.779g/100ml, 0.1M). Na2HPO4 added to NaH2PO4 (80ml) until the pH=6 before making up to 100ml 
with dH2O. 
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For 20ml of stain: 
Sodium phosphate (pH6, 4ml), Potassium Ferricyanide (1ml), Potassium Ferrocyanide (1ml), NaCl 
(2.4ml, 2.5M), MgCl2 (40μl, 1M), dH2O (10.56ml) and X-gal (1ml) were mixed. 
Citrate Buffer (0.01M) 
Citrate Buffer 0.01M: 9ml solution A, 41ml Solution B and 450ml H2O) 
▪ Solution A (21.01g/L Citric acid 0.1M in H2O) 
▪ Solution B (29.41g/L Sodium citrate 0.1M in H2O) 
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Chemicals 
Substance Supplier Catalogue number 
2-mercaptoethanol Sigma-Aldrich 63689 
Alcian Blue Sigma-Aldrich A-3157 
Alizarin Red Sigma-Aldrich A5533 
Ammonium hydroxide Sigma-Aldrich 221228-M 
Anhydrous sodium acetate Sigma-Aldrich W302406 
BSA Fisher scientific BP9700-100 
Citric acid Sigma-Aldrich C0759 
DMSO AnalaR 103234L 
EDTA Fisher scientific 10618973 
EGTA Tocris 28071G 
Glacial acetic acid Fisher scientific 10050000 
Glutaraldehyde Millipore MERCK 1.04239.0250 
Glycerol Sigma-Aldrich G6279 
HCL Sigma-Aldrich W530574 
HEPES powder Fisher scientific BP410-500 
Isopentane Acros organics 126470010 
Isopropanol Fisher Scientific BP2618-212 
Methanol Fisher Scientific M/4056/17 
MgCl2 Sigma-Aldrich M2670-500 
N-acetylcysteine Enzo Lifesciences ALX-105-005-G005 
NaCl Sigma-Aldrich 71382 
Naphthol AS BIphosphate Acros organics 1919-91-1 
Oil Red O Sigma-Aldrich O0625 
Pararsaniline HCl Acros organics 270100050 
PBS tablets Oxoid BR0014G 
PFA Fisher Scientific P/0840/53 
Potassium ferricyanide Acros organics 223111000 
Potassium ferrocyanide Acros organics 424130025 
SDS Fisher Scientific S/5200/53 
Sodium Azide Acros organics 190381000 
Sodium citrate BDH 30128 
Sodium nitrite Fisher Chemical S/5640/62 
Sodium phosphate Fisher scientific BP330-500 
Sucrose Fisher Chemical S/8560/53 
Trypan blue Gibco 11538886 
Urea AnalaR 102908D 
Valproic acid Sigma-Aldrich P4543-25G 
X-gal VWR 0428-16 
Xylene Fisher Scientific X/0250/17 
Table 10.1: Chemicals 
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Materials and reagents: 
Substance Supplier Catalogue number 
1x Passive lysis buffer Promega E153A 
AdDMEM F12 Invitrogen 12634010 
Agarose Sigma-Aldrich A4679 
Amersham ECL Prime  Western 
Blotting Detection Reagent 
GE Healthcare RPN2232 
B27 supplement Invitrogen 17504-044 
Cell recovery solution Corning 354253 
Cell Titer 96 Non-radioactive 
Cell Proliferation Assay 
Sarsted G4002 
Chang B/C Irvine scientific T101-019 
CT99021 Selleckchem S2924 
DAPI Molecular probes D-1306 
DC BioRad protein assay BioRad 5000112 
DMEM 4.5g/l glucose Gibco 10741574 
DPX mounting media Fisher Scientific D/5319/05 
E.coli LPS Invivogen Tlrl-eklps 
Eosin Sigma-Aldrich 318906-500ml 
FBS Gibco 10270-106 
FcR Blocking reagent Miltenyi Biotec 130-059-901 
Glutamax Gibco 11574466 
Growth factor reduced, Phenol 
red free Matrigel 
Corning 356231 
h-rR-spondin PeproTech 120-38 
Hydro mounting media Agar scientific R1356 
L-glutamine Gibco 11539876 
LPS-SM Ultrapure InvivoGen Tlrl-smlps 
Luciferase Assay System Promega E1500 
MACS Multistand Miltenyi Biotec 130-042-303 
Mayers Haematoxylin Sigma-Aldrich MHS16-500ml 
Mesenpro RSTM Gibco 10212293 
MiniMACS Separator Miltenyi Biotec 130-042-102 
m-rEGF R&D systems 2028-EG-200 
m-rNoggin PeproTech 250-38 
MS MACS Column Miltenyi Biotec 130-042-201 
N2 supplement Invitrogen 17502-048 
Naja pallida CTX Latoxan L8102 
Penicillin/streptomycin Gibco 11568876 
PKH26 Sigma P9691 
Protease Inhibitor Cocktail Set 1 Calbiochem 539131 
Recombinant Human TNF-α  PeproTech 300 01A 
SilverXpress silver staining kit Invitrogen LC6100 
Solubilization Solution/Stop Mix  Promega G401A 
Stem XVivo Adipogenic 
supplement  
R&D systems 13472505 
Stem XVivo chondrogenic 
supplement 
R&D systems 13462505 
Stem XVivo osteogenic 
supplement  
R&D systems 13482505 
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Stem XVivo 
osteogenic/adipogenic base 
media 
R&D systems 13412515 
Triton X-100 Fisher scientific  T/3751/08 
TrpLE Select Gibco 12093745 
Ultra-pure E.coli LPS Invivogen Tlrl-peklps 
α-MEM Gibco 12509069 
Phorbel-12-myristate-13-
acetate  
Sigma P8139-1MG 
Gibco RPMI 1640 Medium 
(ATCC modification) 
Gibco 11504566 
Recombinant Human IFN-y Biolegend 713906 
Recombinant Human IL-4  Biolegend 714904 
Recombinat Human IL-13  
 
Biolegend 571102 
Recombinant Human TNF-α Peprotech 300-01A 
Table 10.2: Materials and reagents 
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